id	sid	tid	token	lemma	pos
aiua-9892	1	1	stesura	stesura	PROPN
aiua-9892	1	2	seveso	seveso	PROPN
aiua-9892	1	3	393archivio	393archivio	PROPN
aiua-9892	1	4	italiano	italiano	NOUN
aiua-9892	1	5	di	di	X
aiua-9892	1	6	urologia	urologia	PROPN
aiua-9892	1	7	e	e	PROPN
aiua-9892	1	8	andrologia	andrologia	NOUN
aiua-9892	1	9	2021	2021	NUM
aiua-9892	1	10	;	;	PUNCT
aiua-9892	1	11	93	93	NUM
aiua-9892	1	12	,	,	PUNCT
aiua-9892	1	13	4	4	NUM
aiua-9892	1	14	original	original	ADJ
aiua-9892	1	15	paper	paper	NOUN
aiua-9892	1	16	no	no	DET
aiua-9892	1	17	conflict	conflict	NOUN
aiua-9892	1	18	of	of	ADP
aiua-9892	1	19	interest	interest	NOUN
aiua-9892	1	20	declared	declare	VERB
aiua-9892	1	21	.	.	PUNCT
aiua-9892	2	1	since	since	SCONJ
aiua-9892	2	2	1941	1941	NUM
aiua-9892	2	3	,	,	PUNCT
aiua-9892	2	4	when	when	SCONJ
aiua-9892	2	5	charles	charles	PROPN
aiua-9892	2	6	huggins	huggins	PROPN
aiua-9892	2	7	and	and	CCONJ
aiua-9892	2	8	colleagues	colleague	NOUN
aiua-9892	2	9	uncovered	uncover	VERB
aiua-9892	2	10	the	the	DET
aiua-9892	2	11	hormonal	hormonal	ADJ
aiua-9892	2	12	dependence	dependence	NOUN
aiua-9892	2	13	of	of	ADP
aiua-9892	2	14	metastatic	metastatic	ADJ
aiua-9892	2	15	prostate	prostate	NOUN
aiua-9892	2	16	cancer	cancer	NOUN
aiua-9892	2	17	,	,	PUNCT
aiua-9892	2	18	androgen	androgen	NOUN
aiua-9892	2	19	deprivation	deprivation	NOUN
aiua-9892	2	20	therapy	therapy	NOUN
aiua-9892	2	21	has	have	AUX
aiua-9892	2	22	been	be	AUX
aiua-9892	2	23	the	the	DET
aiua-9892	2	24	therapeutical	therapeutical	ADJ
aiua-9892	2	25	mainstay	mainstay	NOUN
aiua-9892	2	26	for	for	ADP
aiua-9892	2	27	metastatic	metastatic	ADJ
aiua-9892	2	28	prostate	prostate	NOUN
aiua-9892	2	29	cancer	cancer	NOUN
aiua-9892	2	30	.	.	PUNCT
aiua-9892	3	1	after	after	ADP
aiua-9892	3	2	decades	decade	NOUN
aiua-9892	3	3	of	of	ADP
aiua-9892	3	4	absent	absent	ADJ
aiua-9892	3	5	novelties	novelty	NOUN
aiua-9892	3	6	,	,	PUNCT
aiua-9892	3	7	we	we	PRON
aiua-9892	3	8	assisted	assist	VERB
aiua-9892	3	9	to	to	ADP
aiua-9892	3	10	the	the	DET
aiua-9892	3	11	introduction	introduction	NOUN
aiua-9892	3	12	of	of	ADP
aiua-9892	3	13	novel	novel	ADJ
aiua-9892	3	14	hormonal	hormonal	ADJ
aiua-9892	3	15	agents	agent	NOUN
aiua-9892	3	16	for	for	ADP
aiua-9892	3	17	the	the	DET
aiua-9892	3	18	treatment	treatment	NOUN
aiua-9892	3	19	of	of	ADP
aiua-9892	3	20	castration	castration	NOUN
aiua-9892	3	21	-	-	PUNCT
aiua-9892	3	22	resistant	resistant	ADJ
aiua-9892	3	23	metastatic	metastatic	ADJ
aiua-9892	3	24	prostate	prostate	NOUN
aiua-9892	3	25	cancer	cancer	NOUN
aiua-9892	3	26	.	.	PUNCT
aiua-9892	4	1	abiraterone	abiraterone	NOUN
aiua-9892	4	2	and	and	CCONJ
aiua-9892	4	3	enzalutamide	enzalutamide	NOUN
aiua-9892	4	4	were	be	AUX
aiua-9892	4	5	the	the	DET
aiua-9892	4	6	first	first	ADJ
aiua-9892	4	7	two	two	NUM
aiua-9892	4	8	novel	novel	ADJ
aiua-9892	4	9	hormonal	hormonal	ADJ
aiua-9892	4	10	agents	agent	NOUN
aiua-9892	4	11	approved	approve	VERB
aiua-9892	4	12	for	for	ADP
aiua-9892	4	13	the	the	DET
aiua-9892	4	14	treatment	treatment	NOUN
aiua-9892	4	15	of	of	ADP
aiua-9892	4	16	metastatic	metastatic	ADJ
aiua-9892	4	17	prostate	prostate	NOUN
aiua-9892	4	18	cancer	cancer	NOUN
aiua-9892	4	19	and	and	CCONJ
aiua-9892	4	20	are	be	AUX
aiua-9892	4	21	now	now	ADV
aiua-9892	4	22	widely	widely	ADV
aiua-9892	4	23	used	use	VERB
aiua-9892	4	24	.	.	PUNCT
aiua-9892	5	1	abiraterone	abiraterone	NOUN
aiua-9892	5	2	is	be	AUX
aiua-9892	5	3	an	an	DET
aiua-9892	5	4	inhibitor	inhibitor	NOUN
aiua-9892	5	5	of	of	ADP
aiua-9892	5	6	cyp17a1	cyp17a1	NOUN
aiua-9892	5	7	,	,	PUNCT
aiua-9892	5	8	an	an	DET
aiua-9892	5	9	enzyme	enzyme	NOUN
aiua-9892	5	10	essential	essential	ADJ
aiua-9892	5	11	in	in	ADP
aiua-9892	5	12	the	the	DET
aiua-9892	5	13	process	process	NOUN
aiua-9892	5	14	of	of	ADP
aiua-9892	5	15	androgen	androgen	NOUN
aiua-9892	5	16	synthesis	synthesis	NOUN
aiua-9892	5	17	.	.	PUNCT
aiua-9892	6	1	enzalutamide	enzalutamide	ADV
aiua-9892	6	2	competitively	competitively	ADV
aiua-9892	6	3	inhibits	inhibit	VERB
aiua-9892	6	4	androgen	androgen	NOUN
aiua-9892	6	5	binding	bind	VERB
aiua-9892	6	6	to	to	ADP
aiua-9892	6	7	the	the	DET
aiua-9892	6	8	androgen	androgen	NOUN
aiua-9892	6	9	receptor	receptor	NOUN
aiua-9892	6	10	(	(	PUNCT
aiua-9892	6	11	ar	ar	NOUN
aiua-9892	6	12	)	)	PUNCT
aiua-9892	6	13	,	,	PUNCT
aiua-9892	6	14	nuclear	nuclear	ADJ
aiua-9892	6	15	translocation	translocation	NOUN
aiua-9892	6	16	of	of	ADP
aiua-9892	6	17	the	the	DET
aiua-9892	6	18	ar	ar	PROPN
aiua-9892	6	19	,	,	PUNCT
aiua-9892	6	20	dna	dna	NOUN
aiua-9892	6	21	binding	bind	VERB
aiua-9892	6	22	and	and	CCONJ
aiua-9892	6	23	coactivator	coactivator	NOUN
aiua-9892	6	24	recruitment	recruitment	NOUN
aiua-9892	6	25	.	.	PUNCT
aiua-9892	7	1	both	both	DET
aiua-9892	7	2	abiraterone	abiraterone	NOUN
aiua-9892	7	3	and	and	CCONJ
aiua-9892	7	4	enzalutamide	enzalutamide	ADV
aiua-9892	7	5	are	be	AUX
aiua-9892	7	6	first	first	ADJ
aiua-9892	7	7	line	line	NOUN
aiua-9892	7	8	treatments	treatment	NOUN
aiua-9892	7	9	for	for	ADP
aiua-9892	7	10	metastatic	metastatic	ADJ
aiua-9892	7	11	castrationresistant	castrationresistant	NOUN
aiua-9892	7	12	prostate	prostate	NOUN
aiua-9892	7	13	cancer	cancer	NOUN
aiua-9892	7	14	(	(	PUNCT
aiua-9892	7	15	mcrpc	mcrpc	NOUN
aiua-9892	7	16	)	)	PUNCT
aiua-9892	7	17	,	,	PUNCT
aiua-9892	7	18	but	but	CCONJ
aiua-9892	7	19	there	there	PRON
aiua-9892	7	20	is	be	VERB
aiua-9892	7	21	a	a	DET
aiua-9892	7	22	lack	lack	NOUN
aiua-9892	7	23	of	of	ADP
aiua-9892	7	24	quality	quality	NOUN
aiua-9892	7	25	evidence	evidence	NOUN
aiua-9892	7	26	regarding	regard	VERB
aiua-9892	7	27	which	which	PRON
aiua-9892	7	28	is	be	AUX
aiua-9892	7	29	associated	associate	VERB
aiua-9892	7	30	with	with	ADP
aiua-9892	7	31	better	well	ADJ
aiua-9892	7	32	outcomes	outcome	NOUN
aiua-9892	7	33	and	and	CCONJ
aiua-9892	7	34	who	who	PRON
aiua-9892	7	35	would	would	AUX
aiua-9892	7	36	benefit	benefit	VERB
aiua-9892	7	37	the	the	DET
aiua-9892	7	38	most	most	ADJ
aiua-9892	7	39	with	with	ADP
aiua-9892	7	40	one	one	NUM
aiua-9892	7	41	or	or	CCONJ
aiua-9892	7	42	another	another	PRON
aiua-9892	7	43	of	of	ADP
aiua-9892	7	44	these	these	DET
aiua-9892	7	45	drugs	drug	NOUN
aiua-9892	7	46	.	.	PUNCT
aiua-9892	8	1	our	our	PRON
aiua-9892	8	2	propose	propose	PROPN
aiua-9892	8	3	was	be	AUX
aiua-9892	8	4	to	to	PART
aiua-9892	8	5	evaluate	evaluate	VERB
aiua-9892	8	6	the	the	DET
aiua-9892	8	7	clinical	clinical	ADJ
aiua-9892	8	8	outcomes	outcome	NOUN
aiua-9892	8	9	of	of	ADP
aiua-9892	8	10	patients	patient	NOUN
aiua-9892	8	11	submitted	submit	VERB
aiua-9892	8	12	to	to	ADP
aiua-9892	8	13	either	either	PRON
aiua-9892	8	14	abiraterone	abiraterone	NOUN
aiua-9892	8	15	or	or	CCONJ
aiua-9892	8	16	enzalutamide	enzalutamide	NOUN
aiua-9892	8	17	for	for	ADP
aiua-9892	8	18	castration	castration	NOUN
aiua-9892	8	19	-	-	PUNCT
aiua-9892	8	20	resistant	resistant	ADJ
aiua-9892	8	21	metastatic	metastatic	ADJ
aiua-9892	8	22	prostate	prostate	NOUN
aiua-9892	8	23	cancer	cancer	NOUN
aiua-9892	8	24	in	in	ADP
aiua-9892	8	25	our	our	PRON
aiua-9892	8	26	center	center	NOUN
aiua-9892	8	27	.	.	PUNCT
aiua-9892	9	1	patients	patient	NOUN
aiua-9892	9	2	and	and	CCONJ
aiua-9892	9	3	methods	method	NOUN
aiua-9892	9	4	patients	patient	NOUN
aiua-9892	9	5	eligible	eligible	ADJ
aiua-9892	9	6	for	for	ADP
aiua-9892	9	7	this	this	DET
aiua-9892	9	8	study	study	NOUN
aiua-9892	9	9	had	have	VERB
aiua-9892	9	10	a	a	DET
aiua-9892	9	11	diagnosis	diagnosis	NOUN
aiua-9892	9	12	of	of	ADP
aiua-9892	9	13	metastatic	metastatic	ADJ
aiua-9892	9	14	castration	castration	NOUN
aiua-9892	9	15	-	-	PUNCT
aiua-9892	9	16	resistant	resistant	ADJ
aiua-9892	9	17	prostate	prostate	NOUN
aiua-9892	9	18	cancer	cancer	NOUN
aiua-9892	9	19	defined	define	VERB
aiua-9892	9	20	as	as	ADP
aiua-9892	9	21	castrate	castrate	NOUN
aiua-9892	9	22	serum	serum	NOUN
aiua-9892	9	23	testosterone	testosterone	NOUN
aiua-9892	9	24	<	<	X
aiua-9892	9	25	50	50	NUM
aiua-9892	9	26	ng	ng	PROPN
aiua-9892	9	27	/	/	SYM
aiua-9892	9	28	ml	ml	NOUN
aiua-9892	9	29	and	and	CCONJ
aiua-9892	9	30	biochemical	biochemical	ADJ
aiua-9892	9	31	progression	progression	NOUN
aiua-9892	9	32	(	(	PUNCT
aiua-9892	9	33	three	three	NUM
aiua-9892	9	34	consecutives	consecutive	NOUN
aiua-9892	9	35	rises	rise	VERB
aiua-9892	9	36	in	in	ADP
aiua-9892	9	37	prostatic	prostatic	ADJ
aiua-9892	9	38	specific	specific	ADJ
aiua-9892	9	39	antigen	antigen	NOUN
aiua-9892	9	40	(	(	PUNCT
aiua-9892	9	41	psa	psa	NOUN
aiua-9892	9	42	)	)	PUNCT
aiua-9892	9	43	at	at	ADV
aiua-9892	9	44	least	least	ADV
aiua-9892	9	45	one	one	NUM
aiua-9892	9	46	week	week	NOUN
aiua-9892	9	47	apart	apart	ADV
aiua-9892	9	48	resulting	result	VERB
aiua-9892	9	49	in	in	ADP
aiua-9892	9	50	two	two	NUM
aiua-9892	9	51	50	50	NUM
aiua-9892	9	52	%	%	NOUN
aiua-9892	9	53	increases	increase	NOUN
aiua-9892	9	54	over	over	ADP
aiua-9892	9	55	the	the	DET
aiua-9892	9	56	nadir	nadir	NOUN
aiua-9892	9	57	,	,	PUNCT
aiua-9892	9	58	and	and	CCONJ
aiua-9892	9	59	a	a	DET
aiua-9892	9	60	psa	psa	NOUN
aiua-9892	9	61	>	>	X
aiua-9892	9	62	2	2	NUM
aiua-9892	9	63	ng	ng	PROPN
aiua-9892	9	64	/	/	SYM
aiua-9892	9	65	ml	ml	NOUN
aiua-9892	9	66	)	)	PUNCT
aiua-9892	9	67	or	or	CCONJ
aiua-9892	9	68	radiological	radiological	ADJ
aiua-9892	9	69	progression	progression	NOUN
aiua-9892	9	70	(	(	PUNCT
aiua-9892	9	71	appearance	appearance	NOUN
aiua-9892	9	72	of	of	ADP
aiua-9892	9	73	new	new	ADJ
aiua-9892	9	74	lesions	lesion	NOUN
aiua-9892	9	75	:	:	PUNCT
aiua-9892	9	76	either	either	CCONJ
aiua-9892	9	77	two	two	NUM
aiua-9892	9	78	or	or	CCONJ
aiua-9892	9	79	more	more	ADJ
aiua-9892	9	80	new	new	ADJ
aiua-9892	9	81	bone	bone	NOUN
aiua-9892	9	82	lesions	lesion	NOUN
aiua-9892	9	83	or	or	CCONJ
aiua-9892	9	84	a	a	DET
aiua-9892	9	85	soft	soft	ADJ
aiua-9892	9	86	lesion	lesion	NOUN
aiua-9892	9	87	using	use	VERB
aiua-9892	9	88	response	response	NOUN
aiua-9892	9	89	evaluation	evaluation	NOUN
aiua-9892	9	90	criteria	criterion	NOUN
aiua-9892	9	91	in	in	ADP
aiua-9892	9	92	solid	solid	ADJ
aiua-9892	9	93	tumours	tumour	NOUN
aiua-9892	9	94	(	(	PUNCT
aiua-9892	9	95	recist	recist	NOUN
aiua-9892	9	96	)	)	PUNCT
aiua-9892	9	97	)	)	PUNCT
aiua-9892	9	98	and	and	CCONJ
aiua-9892	9	99	initiated	initiate	VERB
aiua-9892	9	100	treatment	treatment	NOUN
aiua-9892	9	101	with	with	ADP
aiua-9892	9	102	either	either	CCONJ
aiua-9892	9	103	abiraterone	abiraterone	NOUN
aiua-9892	9	104	or	or	CCONJ
aiua-9892	9	105	enzalutamide	enzalutamide	ADV
aiua-9892	9	106	between	between	ADP
aiua-9892	9	107	january	january	PROPN
aiua-9892	9	108	1	1	NUM
aiua-9892	9	109	,	,	PUNCT
aiua-9892	9	110	2016	2016	NUM
aiua-9892	9	111	and	and	CCONJ
aiua-9892	9	112	december	december	PROPN
aiua-9892	9	113	31	31	NUM
aiua-9892	9	114	,	,	PUNCT
aiua-9892	9	115	2019	2019	NUM
aiua-9892	9	116	.	.	PUNCT
aiua-9892	10	1	follow	follow	VERB
aiua-9892	10	2	-	-	PUNCT
aiua-9892	10	3	up	up	NOUN
aiua-9892	10	4	extended	extend	VERB
aiua-9892	10	5	from	from	ADP
aiua-9892	10	6	january	january	PROPN
aiua-9892	10	7	1	1	NUM
aiua-9892	10	8	,	,	PUNCT
aiua-9892	10	9	2016	2016	NUM
aiua-9892	10	10	until	until	ADP
aiua-9892	10	11	december	december	PROPN
aiua-9892	10	12	31	31	NUM
aiua-9892	10	13	,	,	PUNCT
aiua-9892	10	14	2020	2020	NUM
aiua-9892	10	15	.	.	PUNCT
aiua-9892	11	1	in	in	ADP
aiua-9892	11	2	2019	2019	NUM
aiua-9892	11	3	,	,	PUNCT
aiua-9892	11	4	we	we	PRON
aiua-9892	11	5	treated	treat	VERB
aiua-9892	11	6	358	358	NUM
aiua-9892	11	7	patients	patient	NOUN
aiua-9892	11	8	diagnosed	diagnose	VERB
aiua-9892	11	9	with	with	ADP
aiua-9892	11	10	prostate	prostate	NOUN
aiua-9892	11	11	cancer	cancer	NOUN
aiua-9892	11	12	,	,	PUNCT
aiua-9892	11	13	representing	represent	VERB
aiua-9892	11	14	roughly	roughly	ADV
aiua-9892	11	15	5.5	5.5	NUM
aiua-9892	11	16	%	%	NOUN
aiua-9892	11	17	cases	case	NOUN
aiua-9892	11	18	nationwide	nationwide	ADJ
aiua-9892	11	19	.	.	PUNCT
aiua-9892	12	1	individual	individual	ADJ
aiua-9892	12	2	clinical	clinical	ADJ
aiua-9892	12	3	cases	case	NOUN
aiua-9892	12	4	were	be	AUX
aiua-9892	12	5	discussed	discuss	VERB
aiua-9892	12	6	in	in	ADP
aiua-9892	12	7	bi	bi	ADJ
aiua-9892	12	8	-	-	ADJ
aiua-9892	12	9	weekly	weekly	ADJ
aiua-9892	12	10	oncourology	oncourology	NOUN
aiua-9892	12	11	meetings	meeting	NOUN
aiua-9892	12	12	.	.	PUNCT
aiua-9892	13	1	patients	patient	NOUN
aiua-9892	13	2	with	with	ADP
aiua-9892	13	3	clinical	clinical	ADJ
aiua-9892	13	4	criteria	criterion	NOUN
aiua-9892	13	5	of	of	ADP
aiua-9892	13	6	poor	poor	ADJ
aiua-9892	13	7	prognosis	prognosis	NOUN
aiua-9892	13	8	(	(	PUNCT
aiua-9892	13	9	symptoms	symptom	NOUN
aiua-9892	13	10	,	,	PUNCT
aiua-9892	13	11	short	short	ADJ
aiua-9892	13	12	period	period	NOUN
aiua-9892	13	13	of	of	ADP
aiua-9892	13	14	response	response	NOUN
aiua-9892	13	15	under	under	ADP
aiua-9892	13	16	introduction	introduction	NOUN
aiua-9892	13	17	:	:	PUNCT
aiua-9892	13	18	prostate	prostate	NOUN
aiua-9892	13	19	cancer	cancer	NOUN
aiua-9892	13	20	is	be	AUX
aiua-9892	13	21	the	the	DET
aiua-9892	13	22	most	most	ADV
aiua-9892	13	23	common	common	ADJ
aiua-9892	13	24	cancer	cancer	NOUN
aiua-9892	13	25	in	in	ADP
aiua-9892	13	26	men	man	NOUN
aiua-9892	13	27	,	,	PUNCT
aiua-9892	13	28	accounting	account	VERB
aiua-9892	13	29	for	for	ADP
aiua-9892	13	30	15	15	NUM
aiua-9892	13	31	%	%	NOUN
aiua-9892	13	32	of	of	ADP
aiua-9892	13	33	all	all	DET
aiua-9892	13	34	diagnosed	diagnose	VERB
aiua-9892	13	35	cancers	cancer	NOUN
aiua-9892	13	36	and	and	CCONJ
aiua-9892	13	37	is	be	AUX
aiua-9892	13	38	the	the	DET
aiua-9892	13	39	sixth	sixth	ADJ
aiua-9892	13	40	leading	lead	VERB
aiua-9892	13	41	cause	cause	NOUN
aiua-9892	13	42	of	of	ADP
aiua-9892	13	43	cancerrelated	cancerrelate	VERB
aiua-9892	13	44	deaths	death	NOUN
aiua-9892	13	45	amongst	amongst	ADP
aiua-9892	13	46	men	man	NOUN
aiua-9892	13	47	worldwide	worldwide	ADV
aiua-9892	13	48	.	.	PUNCT
aiua-9892	14	1	abiraterone	abiraterone	NOUN
aiua-9892	14	2	and	and	CCONJ
aiua-9892	14	3	enzalutamide	enzalutamide	NOUN
aiua-9892	14	4	were	be	AUX
aiua-9892	14	5	the	the	DET
aiua-9892	14	6	first	first	ADJ
aiua-9892	14	7	two	two	NUM
aiua-9892	14	8	novel	novel	ADJ
aiua-9892	14	9	hormonal	hormonal	ADJ
aiua-9892	14	10	agents	agent	NOUN
aiua-9892	14	11	approved	approve	VERB
aiua-9892	14	12	for	for	ADP
aiua-9892	14	13	the	the	DET
aiua-9892	14	14	treatment	treatment	NOUN
aiua-9892	14	15	of	of	ADP
aiua-9892	14	16	metastatic	metastatic	ADJ
aiua-9892	14	17	prostate	prostate	NOUN
aiua-9892	14	18	cancer	cancer	NOUN
aiua-9892	14	19	but	but	CCONJ
aiua-9892	14	20	there	there	PRON
aiua-9892	14	21	is	be	VERB
aiua-9892	14	22	a	a	DET
aiua-9892	14	23	lack	lack	NOUN
aiua-9892	14	24	of	of	ADP
aiua-9892	14	25	quality	quality	NOUN
aiua-9892	14	26	evidence	evidence	NOUN
aiua-9892	14	27	regarding	regard	VERB
aiua-9892	14	28	which	which	PRON
aiua-9892	14	29	is	be	AUX
aiua-9892	14	30	associated	associate	VERB
aiua-9892	14	31	with	with	ADP
aiua-9892	14	32	better	well	ADJ
aiua-9892	14	33	outcomes	outcome	NOUN
aiua-9892	14	34	and	and	CCONJ
aiua-9892	14	35	who	who	PRON
aiua-9892	14	36	would	would	AUX
aiua-9892	14	37	benefit	benefit	VERB
aiua-9892	14	38	the	the	DET
aiua-9892	14	39	most	most	ADJ
aiua-9892	14	40	with	with	ADP
aiua-9892	14	41	one	one	NUM
aiua-9892	14	42	or	or	CCONJ
aiua-9892	14	43	another	another	PRON
aiua-9892	14	44	of	of	ADP
aiua-9892	14	45	these	these	DET
aiua-9892	14	46	drugs	drug	NOUN
aiua-9892	14	47	.	.	PUNCT
aiua-9892	15	1	objective	objective	NOUN
aiua-9892	15	2	:	:	PUNCT
aiua-9892	15	3	to	to	PART
aiua-9892	15	4	evaluate	evaluate	VERB
aiua-9892	15	5	the	the	DET
aiua-9892	15	6	clinical	clinical	ADJ
aiua-9892	15	7	outcomes	outcome	NOUN
aiua-9892	15	8	of	of	ADP
aiua-9892	15	9	real	real	ADJ
aiua-9892	15	10	-	-	PUNCT
aiua-9892	15	11	world	world	NOUN
aiua-9892	15	12	patients	patient	NOUN
aiua-9892	15	13	submitted	submit	VERB
aiua-9892	15	14	to	to	ADP
aiua-9892	15	15	treatment	treatment	NOUN
aiua-9892	15	16	with	with	ADP
aiua-9892	15	17	novel	novel	ADJ
aiua-9892	15	18	hormonal	hormonal	ADJ
aiua-9892	15	19	agents	agent	NOUN
aiua-9892	15	20	,	,	PUNCT
aiua-9892	15	21	enzalutamide	enzalutamide	ADV
aiua-9892	15	22	and	and	CCONJ
aiua-9892	15	23	abiraterone	abiraterone	NOUN
aiua-9892	15	24	,	,	PUNCT
aiua-9892	15	25	for	for	ADP
aiua-9892	15	26	castration	castration	NOUN
aiua-9892	15	27	resistant	resistant	ADJ
aiua-9892	15	28	metastatic	metastatic	ADJ
aiua-9892	15	29	prostate	prostate	NOUN
aiua-9892	15	30	cancer	cancer	NOUN
aiua-9892	15	31	in	in	ADP
aiua-9892	15	32	an	an	DET
aiua-9892	15	33	academic	academic	ADJ
aiua-9892	15	34	center	center	NOUN
aiua-9892	15	35	.	.	PUNCT
aiua-9892	16	1	patients	patient	NOUN
aiua-9892	16	2	and	and	CCONJ
aiua-9892	16	3	methods	method	NOUN
aiua-9892	16	4	:	:	PUNCT
aiua-9892	16	5	we	we	PRON
aiua-9892	16	6	retrospectively	retrospectively	ADV
aiua-9892	16	7	reviewed	review	VERB
aiua-9892	16	8	patients	patient	NOUN
aiua-9892	16	9	treated	treat	VERB
aiua-9892	16	10	for	for	ADP
aiua-9892	16	11	castration	castration	NOUN
aiua-9892	16	12	-	-	PUNCT
aiua-9892	16	13	resistant	resistant	ADJ
aiua-9892	16	14	prostate	prostate	NOUN
aiua-9892	16	15	cancer	cancer	NOUN
aiua-9892	16	16	with	with	ADP
aiua-9892	16	17	either	either	CCONJ
aiua-9892	16	18	abiraterone	abiraterone	NOUN
aiua-9892	16	19	or	or	CCONJ
aiua-9892	16	20	enzulatamide	enzulatamide	VERB
aiua-9892	16	21	between	between	ADP
aiua-9892	16	22	january	january	PROPN
aiua-9892	16	23	1	1	NUM
aiua-9892	16	24	,	,	PUNCT
aiua-9892	16	25	2016	2016	NUM
aiua-9892	16	26	and	and	CCONJ
aiua-9892	16	27	december	december	PROPN
aiua-9892	16	28	31	31	NUM
aiua-9892	16	29	,	,	PUNCT
aiua-9892	16	30	2019	2019	NUM
aiua-9892	16	31	.	.	PUNCT
aiua-9892	17	1	the	the	DET
aiua-9892	17	2	primary	primary	ADJ
aiua-9892	17	3	endpoints	endpoint	NOUN
aiua-9892	17	4	were	be	AUX
aiua-9892	17	5	biochemical	biochemical	ADJ
aiua-9892	17	6	response	response	NOUN
aiua-9892	17	7	,	,	PUNCT
aiua-9892	17	8	biochemical	biochemical	ADJ
aiua-9892	17	9	progression	progression	NOUN
aiua-9892	17	10	,	,	PUNCT
aiua-9892	17	11	radiological	radiological	ADJ
aiua-9892	17	12	progression	progression	NOUN
aiua-9892	17	13	,	,	PUNCT
aiua-9892	17	14	clinical	clinical	ADJ
aiua-9892	17	15	deterioration	deterioration	NOUN
aiua-9892	17	16	(	(	PUNCT
aiua-9892	17	17	attributed	attribute	VERB
aiua-9892	17	18	to	to	ADP
aiua-9892	17	19	disease	disease	NOUN
aiua-9892	17	20	progression	progression	NOUN
aiua-9892	17	21	)	)	PUNCT
aiua-9892	17	22	and	and	CCONJ
aiua-9892	17	23	death	death	NOUN
aiua-9892	17	24	.	.	PUNCT
aiua-9892	18	1	results	result	NOUN
aiua-9892	18	2	:	:	PUNCT
aiua-9892	18	3	enzalutamide	enzalutamide	ADV
aiua-9892	18	4	had	have	AUX
aiua-9892	18	5	a	a	DET
aiua-9892	18	6	higher	high	ADJ
aiua-9892	18	7	biochemical	biochemical	ADJ
aiua-9892	18	8	response	response	NOUN
aiua-9892	18	9	rate	rate	NOUN
aiua-9892	18	10	than	than	ADP
aiua-9892	18	11	abiraterone	abiraterone	NOUN
aiua-9892	18	12	in	in	ADP
aiua-9892	18	13	patients	patient	NOUN
aiua-9892	18	14	with	with	ADP
aiua-9892	18	15	mcrpc	mcrpc	PROPN
aiua-9892	18	16	(	(	PUNCT
aiua-9892	18	17	77.1	77.1	NUM
aiua-9892	18	18	%	%	NOUN
aiua-9892	18	19	vs	vs	ADP
aiua-9892	18	20	58.1	58.1	NUM
aiua-9892	18	21	%	%	NOUN
aiua-9892	18	22	,	,	PUNCT
aiua-9892	18	23	p	p	X
aiua-9892	18	24	=	=	PROPN
aiua-9892	18	25	0.016	0.016	NUM
aiua-9892	18	26	)	)	PUNCT
aiua-9892	18	27	.	.	PUNCT
aiua-9892	19	1	achieving	achieve	VERB
aiua-9892	19	2	a	a	DET
aiua-9892	19	3	biochemical	biochemical	ADJ
aiua-9892	19	4	response	response	NOUN
aiua-9892	19	5	was	be	AUX
aiua-9892	19	6	associated	associate	VERB
aiua-9892	19	7	with	with	ADP
aiua-9892	19	8	a	a	DET
aiua-9892	19	9	lower	low	ADJ
aiua-9892	19	10	risk	risk	NOUN
aiua-9892	19	11	of	of	ADP
aiua-9892	19	12	biochemical	biochemical	ADJ
aiua-9892	19	13	progression	progression	NOUN
aiua-9892	19	14	(	(	PUNCT
aiua-9892	19	15	or	or	CCONJ
aiua-9892	19	16	:	:	PUNCT
aiua-9892	19	17	0.248	0.248	NUM
aiua-9892	19	18	,	,	PUNCT
aiua-9892	19	19	p	p	X
aiua-9892	19	20	=	=	NOUN
aiua-9892	19	21	0.017	0.017	NUM
aiua-9892	19	22	)	)	PUNCT
aiua-9892	19	23	and	and	CCONJ
aiua-9892	19	24	death	death	NOUN
aiua-9892	19	25	(	(	PUNCT
aiua-9892	19	26	or	or	CCONJ
aiua-9892	19	27	:	:	PUNCT
aiua-9892	19	28	0.302	0.302	NUM
aiua-9892	19	29	,	,	PUNCT
aiua-9892	19	30	p	p	X
aiua-9892	19	31	=	=	NOUN
aiua-9892	19	32	0.038	0.038	NUM
aiua-9892	19	33	)	)	PUNCT
aiua-9892	19	34	.	.	PUNCT
aiua-9892	20	1	conclusions	conclusion	NOUN
aiua-9892	20	2	:	:	PUNCT
aiua-9892	20	3	enzalutamide	enzalutamide	PROPN
aiua-9892	20	4	conferred	confer	VERB
aiua-9892	20	5	higher	high	ADJ
aiua-9892	20	6	biochemical	biochemical	ADJ
aiua-9892	20	7	response	response	NOUN
aiua-9892	20	8	rate	rate	NOUN
aiua-9892	20	9	than	than	ADP
aiua-9892	20	10	abiraterone	abiraterone	NOUN
aiua-9892	20	11	in	in	ADP
aiua-9892	20	12	patients	patient	NOUN
aiua-9892	20	13	with	with	ADP
aiua-9892	20	14	mcrpc	mcrpc	NOUN
aiua-9892	20	15	.	.	PUNCT
aiua-9892	21	1	despite	despite	SCONJ
aiua-9892	21	2	the	the	DET
aiua-9892	21	3	trend	trend	NOUN
aiua-9892	21	4	to	to	ADP
aiua-9892	21	5	better	well	ADJ
aiua-9892	21	6	performance	performance	NOUN
aiua-9892	21	7	of	of	ADP
aiua-9892	21	8	other	other	ADJ
aiua-9892	21	9	endpoints	endpoint	NOUN
aiua-9892	21	10	in	in	ADP
aiua-9892	21	11	the	the	DET
aiua-9892	21	12	enzalutamide	enzalutamide	ADJ
aiua-9892	21	13	group	group	NOUN
aiua-9892	21	14	,	,	PUNCT
aiua-9892	21	15	it	it	PRON
aiua-9892	21	16	did	do	AUX
aiua-9892	21	17	not	not	PART
aiua-9892	21	18	achieve	achieve	VERB
aiua-9892	21	19	statistical	statistical	ADJ
aiua-9892	21	20	significance	significance	NOUN
aiua-9892	21	21	.	.	PUNCT
aiua-9892	22	1	well	well	ADV
aiua-9892	22	2	-	-	PUNCT
aiua-9892	22	3	designed	design	VERB
aiua-9892	22	4	prospective	prospective	ADJ
aiua-9892	22	5	studies	study	NOUN
aiua-9892	22	6	are	be	AUX
aiua-9892	22	7	needed	need	VERB
aiua-9892	22	8	to	to	PART
aiua-9892	22	9	elucidate	elucidate	VERB
aiua-9892	22	10	the	the	DET
aiua-9892	22	11	comparative	comparative	ADJ
aiua-9892	22	12	efficacies	efficacy	NOUN
aiua-9892	22	13	of	of	ADP
aiua-9892	22	14	these	these	DET
aiua-9892	22	15	agents	agent	NOUN
aiua-9892	22	16	.	.	PUNCT
aiua-9892	23	1	key	key	ADJ
aiua-9892	23	2	words	word	NOUN
aiua-9892	23	3	:	:	PUNCT
aiua-9892	23	4	prostate	prostate	NOUN
aiua-9892	23	5	cancer	cancer	NOUN
aiua-9892	23	6	;	;	PUNCT
aiua-9892	23	7	abiraterone	abiraterone	NOUN
aiua-9892	23	8	;	;	PUNCT
aiua-9892	23	9	enzalutamide	enzalutamide	ADV
aiua-9892	23	10	;	;	PUNCT
aiua-9892	23	11	castration	castration	NOUN
aiua-9892	23	12	-	-	PUNCT
aiua-9892	23	13	resistant	resistant	ADJ
aiua-9892	23	14	.	.	PUNCT
aiua-9892	23	15	submitted	submit	VERB
aiua-9892	23	16	7	7	NUM
aiua-9892	23	17	june	june	PROPN
aiua-9892	23	18	2021	2021	NUM
aiua-9892	23	19	;	;	PUNCT
aiua-9892	23	20	accepted	accept	VERB
aiua-9892	23	21	15	15	NUM
aiua-9892	23	22	august	august	PROPN
aiua-9892	23	23	2021	2021	NUM
aiua-9892	23	24	introduction	introduction	NOUN
aiua-9892	23	25	prostate	prostate	NOUN
aiua-9892	23	26	cancer	cancer	NOUN
aiua-9892	23	27	is	be	AUX
aiua-9892	23	28	the	the	DET
aiua-9892	23	29	most	most	ADV
aiua-9892	23	30	common	common	ADJ
aiua-9892	23	31	cancer	cancer	NOUN
aiua-9892	23	32	in	in	ADP
aiua-9892	23	33	men	man	NOUN
aiua-9892	23	34	,	,	PUNCT
aiua-9892	23	35	accounting	account	VERB
aiua-9892	23	36	for	for	ADP
aiua-9892	23	37	15	15	NUM
aiua-9892	23	38	%	%	NOUN
aiua-9892	23	39	of	of	ADP
aiua-9892	23	40	all	all	DET
aiua-9892	23	41	diagnosed	diagnose	VERB
aiua-9892	23	42	cancers	cancer	NOUN
aiua-9892	23	43	and	and	CCONJ
aiua-9892	23	44	being	be	AUX
aiua-9892	23	45	the	the	DET
aiua-9892	23	46	sixth	sixth	ADJ
aiua-9892	23	47	leading	leading	ADJ
aiua-9892	23	48	cause	cause	NOUN
aiua-9892	23	49	of	of	ADP
aiua-9892	23	50	cancer	cancer	NOUN
aiua-9892	23	51	-	-	PUNCT
aiua-9892	23	52	related	relate	VERB
aiua-9892	23	53	deaths	death	NOUN
aiua-9892	23	54	amongst	amongst	ADP
aiua-9892	23	55	men	man	NOUN
aiua-9892	23	56	worldwide	worldwide	ADV
aiua-9892	23	57	.	.	PUNCT
aiua-9892	24	1	metastatic	metastatic	ADJ
aiua-9892	24	2	prostatic	prostatic	ADJ
aiua-9892	24	3	cancer	cancer	NOUN
aiua-9892	24	4	can	can	AUX
aiua-9892	24	5	be	be	AUX
aiua-9892	24	6	roughly	roughly	ADV
aiua-9892	24	7	divided	divide	VERB
aiua-9892	24	8	in	in	ADP
aiua-9892	24	9	two	two	NUM
aiua-9892	24	10	main	main	ADJ
aiua-9892	24	11	clinical	clinical	ADJ
aiua-9892	24	12	stages	stage	NOUN
aiua-9892	24	13	:	:	PUNCT
aiua-9892	24	14	hormone	hormone	NOUN
aiua-9892	24	15	-	-	PUNCT
aiua-9892	24	16	sensitive	sensitive	ADJ
aiua-9892	24	17	and	and	CCONJ
aiua-9892	24	18	castrationresistant	castrationresistant	ADJ
aiua-9892	24	19	prostate	prostate	NOUN
aiua-9892	24	20	cancer	cancer	NOUN
aiua-9892	24	21	.	.	PUNCT
aiua-9892	25	1	novel	novel	ADJ
aiua-9892	25	2	hormonal	hormonal	ADJ
aiua-9892	25	3	agents	agent	NOUN
aiua-9892	25	4	for	for	ADP
aiua-9892	25	5	metastatic	metastatic	ADJ
aiua-9892	25	6	castration	castration	NOUN
aiua-9892	25	7	-	-	PUNCT
aiua-9892	25	8	resistant	resistant	ADJ
aiua-9892	25	9	prostate	prostate	NOUN
aiua-9892	25	10	cancer	cancer	NOUN
aiua-9892	25	11	:	:	PUNCT
aiua-9892	25	12	comparing	compare	VERB
aiua-9892	25	13	outcomes	outcome	NOUN
aiua-9892	25	14	.	.	PUNCT
aiua-9892	26	1	a	a	DET
aiua-9892	26	2	single	single	ADJ
aiua-9892	26	3	-	-	PUNCT
aiua-9892	26	4	center	center	NOUN
aiua-9892	26	5	retrospective	retrospective	ADJ
aiua-9892	26	6	study	study	NOUN
aiua-9892	26	7	roberto	roberto	VERB
aiua-9892	26	8	saldanha	saldanha	NOUN
aiua-9892	26	9	jarimba	jarimba	PROPN
aiua-9892	26	10	1	1	NUM
aiua-9892	26	11	,	,	PUNCT
aiua-9892	26	12	miguel	miguel	PROPN
aiua-9892	26	13	nobre	nobre	PROPN
aiua-9892	26	14	eliseu	eliseu	PROPN
aiua-9892	26	15	1	1	NUM
aiua-9892	26	16	,	,	PUNCT
aiua-9892	26	17	joão	joão	PROPN
aiua-9892	26	18	pedroso	pedroso	PROPN
aiua-9892	26	19	lima	lima	PROPN
aiua-9892	26	20	1	1	NUM
aiua-9892	26	21	,	,	PUNCT
aiua-9892	26	22	vasco	vasco	PROPN
aiua-9892	26	23	quaresma	quaresma	PROPN
aiua-9892	26	24	1	1	NUM
aiua-9892	26	25	,	,	PUNCT
aiua-9892	26	26	pedro	pedro	PROPN
aiua-9892	26	27	moreira	moreira	PROPN
aiua-9892	26	28	1	1	NUM
aiua-9892	26	29	,	,	PUNCT
aiua-9892	26	30	pedro	pedro	PROPN
aiua-9892	26	31	coelho	coelho	PROPN
aiua-9892	26	32	nunes	nunes	PROPN
aiua-9892	26	33	1	1	NUM
aiua-9892	26	34	,	,	PUNCT
aiua-9892	26	35	2	2	NUM
aiua-9892	26	36	,	,	PUNCT
aiua-9892	26	37	edgar	edgar	NOUN
aiua-9892	26	38	tavares	tavare	NOUN
aiua-9892	26	39	da	da	PROPN
aiua-9892	26	40	silva	silva	PROPN
aiua-9892	26	41	1	1	NUM
aiua-9892	26	42	,	,	PUNCT
aiua-9892	26	43	2	2	NUM
aiua-9892	26	44	,	,	PUNCT
aiua-9892	26	45	arnaldo	arnaldo	PROPN
aiua-9892	26	46	josé	josé	PROPN
aiua-9892	26	47	figueiredo	figueiredo	PROPN
aiua-9892	26	48	1	1	NUM
aiua-9892	26	49	,	,	PUNCT
aiua-9892	26	50	2	2	NUM
aiua-9892	26	51	1	1	NUM
aiua-9892	26	52	urology	urology	NOUN
aiua-9892	26	53	and	and	CCONJ
aiua-9892	26	54	renal	renal	ADJ
aiua-9892	26	55	transplantation	transplantation	NOUN
aiua-9892	26	56	department	department	NOUN
aiua-9892	26	57	,	,	PUNCT
aiua-9892	26	58	centro	centro	PROPN
aiua-9892	26	59	hospitalar	hospitalar	PROPN
aiua-9892	26	60	e	e	PROPN
aiua-9892	26	61	universitário	universitário	PROPN
aiua-9892	26	62	de	de	X
aiua-9892	26	63	coimbra	coimbra	PROPN
aiua-9892	26	64	,	,	PUNCT
aiua-9892	26	65	coimbra	coimbra	PROPN
aiua-9892	26	66	,	,	PUNCT
aiua-9892	26	67	portugal	portugal	PROPN
aiua-9892	26	68	;	;	PUNCT
aiua-9892	26	69	2	2	NUM
aiua-9892	26	70	faculty	faculty	NOUN
aiua-9892	26	71	of	of	ADP
aiua-9892	26	72	medicine	medicine	NOUN
aiua-9892	26	73	,	,	PUNCT
aiua-9892	26	74	university	university	NOUN
aiua-9892	26	75	of	of	ADP
aiua-9892	26	76	coimbra	coimbra	PROPN
aiua-9892	26	77	,	,	PUNCT
aiua-9892	26	78	portugal	portugal	PROPN
aiua-9892	26	79	.	.	PUNCT
aiua-9892	27	1	doi	doi	PROPN
aiua-9892	27	2	:	:	PUNCT
aiua-9892	27	3	10.4081	10.4081	NUM
aiua-9892	27	4	/	/	SYM
aiua-9892	27	5	aiua.2021.4.393	aiua.2021.4.393	ADJ
aiua-9892	27	6	summary	summary	NOUN
aiua-9892	27	7	archivio	archivio	NOUN
aiua-9892	27	8	italiano	italiano	NOUN
aiua-9892	27	9	di	di	X
aiua-9892	27	10	urologia	urologia	PROPN
aiua-9892	27	11	e	e	PROPN
aiua-9892	27	12	andrologia	andrologia	NOUN
aiua-9892	27	13	2021	2021	NUM
aiua-9892	27	14	;	;	PUNCT
aiua-9892	27	15	93	93	NUM
aiua-9892	27	16	,	,	PUNCT
aiua-9892	27	17	4	4	NUM
aiua-9892	27	18	r.	r.	NOUN
aiua-9892	27	19	saldanha	saldanha	NOUN
aiua-9892	27	20	jarimba	jarimba	NOUN
aiua-9892	27	21	,	,	PUNCT
aiua-9892	27	22	m.	m.	NOUN
aiua-9892	27	23	nobre	nobre	PROPN
aiua-9892	27	24	eliseu	eliseu	PROPN
aiua-9892	27	25	,	,	PUNCT
aiua-9892	27	26	j.	j.	PROPN
aiua-9892	27	27	pedroso	pedroso	PROPN
aiua-9892	27	28	lima	lima	PROPN
aiua-9892	27	29	,	,	PUNCT
aiua-9892	27	30	et	et	PROPN
aiua-9892	27	31	al	al	PROPN
aiua-9892	27	32	.	.	PROPN
aiua-9892	27	33	394	394	NUM
aiua-9892	27	34	androgen	androgen	NOUN
aiua-9892	27	35	deprivation	deprivation	NOUN
aiua-9892	27	36	therapy	therapy	NOUN
aiua-9892	27	37	(	(	PUNCT
aiua-9892	27	38	adt	adt	NOUN
aiua-9892	27	39	)	)	PUNCT
aiua-9892	27	40	,	,	PUNCT
aiua-9892	27	41	high	high	ADJ
aiua-9892	27	42	metastatic	metastatic	ADJ
aiua-9892	27	43	burden	burden	NOUN
aiua-9892	27	44	,	,	PUNCT
aiua-9892	27	45	visceral	visceral	ADJ
aiua-9892	27	46	metastasis	metastasis	NOUN
aiua-9892	27	47	or	or	CCONJ
aiua-9892	27	48	poor	poor	ADJ
aiua-9892	27	49	prognostic	prognostic	ADJ
aiua-9892	27	50	genetic	genetic	ADJ
aiua-9892	27	51	mutations	mutation	NOUN
aiua-9892	27	52	)	)	PUNCT
aiua-9892	27	53	were	be	AUX
aiua-9892	27	54	treated	treat	VERB
aiua-9892	27	55	with	with	ADP
aiua-9892	27	56	taxane	taxane	NOUN
aiua-9892	27	57	-	-	PUNCT
aiua-9892	27	58	based	base	VERB
aiua-9892	27	59	chemotherapy	chemotherapy	NOUN
aiua-9892	27	60	.	.	PUNCT
aiua-9892	28	1	the	the	DET
aiua-9892	28	2	decision	decision	NOUN
aiua-9892	28	3	to	to	PART
aiua-9892	28	4	begin	begin	VERB
aiua-9892	28	5	treatment	treatment	NOUN
aiua-9892	28	6	with	with	ADP
aiua-9892	28	7	a	a	DET
aiua-9892	28	8	novel	novel	ADJ
aiua-9892	28	9	hormonal	hormonal	ADJ
aiua-9892	28	10	agent	agent	NOUN
aiua-9892	28	11	was	be	AUX
aiua-9892	28	12	taken	take	VERB
aiua-9892	28	13	either	either	CCONJ
aiua-9892	28	14	as	as	ADP
aiua-9892	28	15	first	first	ADJ
aiua-9892	28	16	line	line	NOUN
aiua-9892	28	17	therapy	therapy	NOUN
aiua-9892	28	18	in	in	ADP
aiua-9892	28	19	patients	patient	NOUN
aiua-9892	28	20	with	with	ADP
aiua-9892	28	21	less	less	ADV
aiua-9892	28	22	aggressive	aggressive	ADJ
aiua-9892	28	23	features	feature	NOUN
aiua-9892	28	24	(	(	PUNCT
aiua-9892	28	25	asymptomatic	asymptomatic	ADJ
aiua-9892	28	26	,	,	PUNCT
aiua-9892	28	27	durable	durable	ADJ
aiua-9892	28	28	response	response	NOUN
aiua-9892	28	29	under	under	ADP
aiua-9892	28	30	previous	previous	ADJ
aiua-9892	28	31	adt	adt	NOUN
aiua-9892	28	32	,	,	PUNCT
aiua-9892	28	33	low	low	ADJ
aiua-9892	28	34	metastatic	metastatic	ADJ
aiua-9892	28	35	burden	burden	NOUN
aiua-9892	28	36	and	and	CCONJ
aiua-9892	28	37	no	no	DET
aiua-9892	28	38	visceral	visceral	ADJ
aiua-9892	28	39	metastases	metastasis	NOUN
aiua-9892	28	40	)	)	PUNCT
aiua-9892	28	41	or	or	CCONJ
aiua-9892	28	42	as	as	ADP
aiua-9892	28	43	second	second	ADJ
aiua-9892	28	44	line	line	NOUN
aiua-9892	28	45	therapy	therapy	NOUN
aiua-9892	28	46	in	in	ADP
aiua-9892	28	47	patients	patient	NOUN
aiua-9892	28	48	that	that	PRON
aiua-9892	28	49	progressed	progress	VERB
aiua-9892	28	50	under	under	ADP
aiua-9892	28	51	first	first	ADJ
aiua-9892	28	52	line	line	NOUN
aiua-9892	28	53	therapy	therapy	NOUN
aiua-9892	28	54	with	with	ADP
aiua-9892	28	55	taxane	taxane	NOUN
aiua-9892	28	56	-	-	PUNCT
aiua-9892	28	57	based	base	VERB
aiua-9892	28	58	chemoterapy	chemoterapy	NOUN
aiua-9892	28	59	.	.	PUNCT
aiua-9892	29	1	in	in	ADP
aiua-9892	29	2	the	the	DET
aiua-9892	29	3	absence	absence	NOUN
aiua-9892	29	4	of	of	ADP
aiua-9892	29	5	contraindication	contraindication	NOUN
aiua-9892	29	6	for	for	ADP
aiua-9892	29	7	either	either	DET
aiua-9892	29	8	pharmaceutical	pharmaceutical	ADJ
aiua-9892	29	9	drugs	drug	NOUN
aiua-9892	29	10	,	,	PUNCT
aiua-9892	29	11	patients	patient	NOUN
aiua-9892	29	12	were	be	AUX
aiua-9892	29	13	sequentially	sequentially	ADV
aiua-9892	29	14	assigned	assign	VERB
aiua-9892	29	15	to	to	ADP
aiua-9892	29	16	either	either	CCONJ
aiua-9892	29	17	enzalutamide	enzalutamide	ADJ
aiua-9892	29	18	or	or	CCONJ
aiua-9892	29	19	abiraterone	abiraterone	NOUN
aiua-9892	29	20	group	group	NOUN
aiua-9892	29	21	.	.	PUNCT
aiua-9892	30	1	the	the	DET
aiua-9892	30	2	database	database	NOUN
aiua-9892	30	3	used	use	VERB
aiua-9892	30	4	was	be	AUX
aiua-9892	30	5	anonymized	anonymize	VERB
aiua-9892	30	6	and	and	CCONJ
aiua-9892	30	7	unstructured	unstructured	ADJ
aiua-9892	30	8	.	.	PUNCT
aiua-9892	31	1	data	datum	NOUN
aiua-9892	31	2	were	be	AUX
aiua-9892	31	3	originally	originally	ADV
aiua-9892	31	4	extracted	extract	VERB
aiua-9892	31	5	from	from	ADP
aiua-9892	31	6	electronic	electronic	ADJ
aiua-9892	31	7	medical	medical	ADJ
aiua-9892	31	8	records	record	NOUN
aiua-9892	31	9	.	.	PUNCT
aiua-9892	32	1	demographic	demographic	ADJ
aiua-9892	32	2	and	and	CCONJ
aiua-9892	32	3	clinicopathological	clinicopathological	ADJ
aiua-9892	32	4	features	feature	NOUN
aiua-9892	32	5	(	(	PUNCT
aiua-9892	32	6	international	international	ADJ
aiua-9892	32	7	society	society	NOUN
aiua-9892	32	8	of	of	ADP
aiua-9892	32	9	urological	urological	ADJ
aiua-9892	32	10	pathology	pathology	NOUN
aiua-9892	32	11	(	(	PUNCT
aiua-9892	32	12	isup	isup	NOUN
aiua-9892	32	13	)	)	PUNCT
aiua-9892	32	14	score	score	NOUN
aiua-9892	32	15	,	,	PUNCT
aiua-9892	32	16	m1	m1	PROPN
aiua-9892	32	17	ab	ab	PROPN
aiua-9892	32	18	inition	inition	NOUN
aiua-9892	32	19	or	or	CCONJ
aiua-9892	32	20	progression	progression	NOUN
aiua-9892	32	21	after	after	ADP
aiua-9892	32	22	local	local	ADJ
aiua-9892	32	23	treatment	treatment	NOUN
aiua-9892	32	24	status	status	NOUN
aiua-9892	32	25	,	,	PUNCT
aiua-9892	32	26	previous	previous	ADJ
aiua-9892	32	27	period	period	NOUN
aiua-9892	32	28	of	of	ADP
aiua-9892	32	29	classical	classical	ADJ
aiua-9892	32	30	androgen	androgen	NOUN
aiua-9892	32	31	deprivation	deprivation	NOUN
aiua-9892	32	32	therapy	therapy	NOUN
aiua-9892	32	33	,	,	PUNCT
aiua-9892	32	34	psa	psa	NOUN
aiua-9892	32	35	level	level	NOUN
aiua-9892	32	36	,	,	PUNCT
aiua-9892	32	37	previous	previous	ADJ
aiua-9892	32	38	treatment	treatment	NOUN
aiua-9892	32	39	of	of	ADP
aiua-9892	32	40	taxane	taxane	NOUN
aiua-9892	32	41	-	-	PUNCT
aiua-9892	32	42	based	base	VERB
aiua-9892	32	43	chemotherapy	chemotherapy	NOUN
aiua-9892	32	44	and	and	CCONJ
aiua-9892	32	45	localization	localization	NOUN
aiua-9892	32	46	of	of	ADP
aiua-9892	32	47	metastasis	metastasis	NOUN
aiua-9892	32	48	)	)	PUNCT
aiua-9892	32	49	were	be	AUX
aiua-9892	32	50	registered	register	VERB
aiua-9892	32	51	at	at	ADP
aiua-9892	32	52	baseline	baseline	NOUN
aiua-9892	32	53	.	.	PUNCT
aiua-9892	33	1	data	datum	NOUN
aiua-9892	33	2	reported	report	VERB
aiua-9892	33	3	adverse	adverse	ADJ
aiua-9892	33	4	events	event	NOUN
aiua-9892	33	5	(	(	PUNCT
aiua-9892	33	6	aes	aes	NOUN
aiua-9892	33	7	)	)	PUNCT
aiua-9892	33	8	was	be	AUX
aiua-9892	33	9	also	also	ADV
aiua-9892	33	10	available	available	ADJ
aiua-9892	33	11	.	.	PUNCT
aiua-9892	34	1	per	per	ADP
aiua-9892	34	2	local	local	ADJ
aiua-9892	34	3	protocol	protocol	NOUN
aiua-9892	34	4	,	,	PUNCT
aiua-9892	34	5	stable	stable	ADJ
aiua-9892	34	6	patients	patient	NOUN
aiua-9892	34	7	with	with	ADP
aiua-9892	34	8	metastatic	metastatic	ADJ
aiua-9892	34	9	prostate	prostate	NOUN
aiua-9892	34	10	cancer	cancer	NOUN
aiua-9892	34	11	under	under	ADP
aiua-9892	34	12	novel	novel	ADJ
aiua-9892	34	13	hormonal	hormonal	ADJ
aiua-9892	34	14	agents	agent	NOUN
aiua-9892	34	15	are	be	AUX
aiua-9892	34	16	followed	follow	VERB
aiua-9892	34	17	with	with	ADP
aiua-9892	34	18	clinical	clinical	ADJ
aiua-9892	34	19	and	and	CCONJ
aiua-9892	34	20	analytical	analytical	ADJ
aiua-9892	34	21	evaluation	evaluation	NOUN
aiua-9892	34	22	including	include	VERB
aiua-9892	34	23	psa	psa	NOUN
aiua-9892	34	24	measurement	measurement	NOUN
aiua-9892	34	25	every	every	DET
aiua-9892	34	26	3	3	NUM
aiua-9892	34	27	months	month	NOUN
aiua-9892	34	28	by	by	ADP
aiua-9892	34	29	a	a	DET
aiua-9892	34	30	staff	staff	NOUN
aiua-9892	34	31	expert	expert	NOUN
aiua-9892	34	32	.	.	PUNCT
aiua-9892	35	1	occurrence	occurrence	NOUN
aiua-9892	35	2	of	of	ADP
aiua-9892	35	3	biochemical	biochemical	ADJ
aiua-9892	35	4	response	response	NOUN
aiua-9892	35	5	(	(	PUNCT
aiua-9892	35	6	defined	define	VERB
aiua-9892	35	7	as	as	ADP
aiua-9892	35	8	a	a	DET
aiua-9892	35	9	reduction	reduction	NOUN
aiua-9892	35	10	of	of	ADP
aiua-9892	35	11	≥	≥	NOUN
aiua-9892	35	12	50	50	NUM
aiua-9892	35	13	%	%	NOUN
aiua-9892	35	14	of	of	ADP
aiua-9892	35	15	pretreatment	pretreatment	NOUN
aiua-9892	35	16	psa	psa	NOUN
aiua-9892	35	17	level	level	NOUN
aiua-9892	35	18	after	after	ADP
aiua-9892	35	19	12	12	NUM
aiua-9892	35	20	weeks	week	NOUN
aiua-9892	35	21	of	of	ADP
aiua-9892	35	22	treatment	treatment	NOUN
aiua-9892	35	23	)	)	PUNCT
aiua-9892	35	24	,	,	PUNCT
aiua-9892	35	25	psa	psa	VERB
aiua-9892	35	26	progression	progression	NOUN
aiua-9892	35	27	(	(	PUNCT
aiua-9892	35	28	three	three	NUM
aiua-9892	35	29	consecutives	consecutive	NOUN
aiua-9892	35	30	rises	rise	VERB
aiua-9892	35	31	in	in	ADP
aiua-9892	35	32	psa	psa	NOUN
aiua-9892	35	33	at	at	ADV
aiua-9892	35	34	least	least	ADV
aiua-9892	35	35	one	one	NUM
aiua-9892	35	36	week	week	NOUN
aiua-9892	35	37	apart	apart	ADV
aiua-9892	35	38	resulting	result	VERB
aiua-9892	35	39	in	in	ADP
aiua-9892	35	40	two	two	NUM
aiua-9892	35	41	50	50	NUM
aiua-9892	35	42	%	%	NOUN
aiua-9892	35	43	increases	increase	NOUN
aiua-9892	35	44	over	over	ADP
aiua-9892	35	45	the	the	DET
aiua-9892	35	46	nadir	nadir	NOUN
aiua-9892	35	47	,	,	PUNCT
aiua-9892	35	48	and	and	CCONJ
aiua-9892	35	49	a	a	DET
aiua-9892	35	50	psa	psa	NOUN
aiua-9892	35	51	>	>	X
aiua-9892	35	52	2	2	NUM
aiua-9892	35	53	ng	ng	PROPN
aiua-9892	35	54	/	/	SYM
aiua-9892	35	55	ml	ml	NOUN
aiua-9892	35	56	)	)	PUNCT
aiua-9892	35	57	,	,	PUNCT
aiua-9892	35	58	radiological	radiological	ADJ
aiua-9892	35	59	progression	progression	NOUN
aiua-9892	35	60	(	(	PUNCT
aiua-9892	35	61	appearance	appearance	NOUN
aiua-9892	35	62	of	of	ADP
aiua-9892	35	63	new	new	ADJ
aiua-9892	35	64	lesions	lesion	NOUN
aiua-9892	35	65	:	:	PUNCT
aiua-9892	35	66	either	either	CCONJ
aiua-9892	35	67	two	two	NUM
aiua-9892	35	68	or	or	CCONJ
aiua-9892	35	69	more	more	ADJ
aiua-9892	35	70	new	new	ADJ
aiua-9892	35	71	bone	bone	NOUN
aiua-9892	35	72	lesions	lesion	NOUN
aiua-9892	35	73	or	or	CCONJ
aiua-9892	35	74	a	a	DET
aiua-9892	35	75	soft	soft	ADJ
aiua-9892	35	76	lesion	lesion	NOUN
aiua-9892	35	77	using	use	VERB
aiua-9892	35	78	recist	recist	NOUN
aiua-9892	35	79	)	)	PUNCT
aiua-9892	35	80	diagnosed	diagnose	VERB
aiua-9892	35	81	either	either	CCONJ
aiua-9892	35	82	by	by	ADP
aiua-9892	35	83	computed	compute	VERB
aiua-9892	35	84	tomography	tomography	NOUN
aiua-9892	35	85	(	(	PUNCT
aiua-9892	35	86	ct	ct	NOUN
aiua-9892	35	87	)	)	PUNCT
aiua-9892	35	88	scan	scan	NOUN
aiua-9892	35	89	,	,	PUNCT
aiua-9892	35	90	bone	bone	NOUN
aiua-9892	35	91	scintigraphy	scintigraphy	NOUN
aiua-9892	35	92	or	or	CCONJ
aiua-9892	35	93	g68	g68	VERB
aiua-9892	35	94	prostate	prostate	NOUN
aiua-9892	35	95	-	-	PUNCT
aiua-9892	35	96	specific	specific	ADJ
aiua-9892	35	97	membrane	membrane	NOUN
aiua-9892	35	98	antigen	antigen	NOUN
aiua-9892	35	99	(	(	PUNCT
aiua-9892	35	100	psma	psma	NOUN
aiua-9892	35	101	)	)	PUNCT
aiua-9892	35	102	positron	positron	NOUN
aiua-9892	35	103	emission	emission	NOUN
aiua-9892	35	104	tomography	tomography	NOUN
aiua-9892	35	105	(	(	PUNCT
aiua-9892	35	106	pet	pet	NOUN
aiua-9892	35	107	)	)	PUNCT
aiua-9892	35	108	,	,	PUNCT
aiua-9892	35	109	clinical	clinical	ADJ
aiua-9892	35	110	deterioration	deterioration	NOUN
aiua-9892	35	111	and/or	and/or	CCONJ
aiua-9892	35	112	death	death	NOUN
aiua-9892	35	113	and	and	CCONJ
aiua-9892	35	114	the	the	DET
aiua-9892	35	115	time	time	NOUN
aiua-9892	35	116	of	of	ADP
aiua-9892	35	117	their	their	PRON
aiua-9892	35	118	occurrence	occurrence	NOUN
aiua-9892	35	119	were	be	AUX
aiua-9892	35	120	available	available	ADJ
aiua-9892	35	121	.	.	PUNCT
aiua-9892	36	1	the	the	DET
aiua-9892	36	2	primary	primary	ADJ
aiua-9892	36	3	endpoints	endpoint	NOUN
aiua-9892	36	4	of	of	ADP
aiua-9892	36	5	this	this	DET
aiua-9892	36	6	study	study	NOUN
aiua-9892	36	7	were	be	AUX
aiua-9892	36	8	biochemical	biochemical	ADJ
aiua-9892	36	9	response	response	NOUN
aiua-9892	36	10	,	,	PUNCT
aiua-9892	36	11	biochemical	biochemical	ADJ
aiua-9892	36	12	progression	progression	NOUN
aiua-9892	36	13	,	,	PUNCT
aiua-9892	36	14	radiological	radiological	ADJ
aiua-9892	36	15	progression	progression	NOUN
aiua-9892	36	16	,	,	PUNCT
aiua-9892	36	17	clinical	clinical	ADJ
aiua-9892	36	18	deterioration	deterioration	NOUN
aiua-9892	36	19	(	(	PUNCT
aiua-9892	36	20	attributed	attribute	VERB
aiua-9892	36	21	to	to	ADP
aiua-9892	36	22	disease	disease	NOUN
aiua-9892	36	23	progression	progression	NOUN
aiua-9892	36	24	)	)	PUNCT
aiua-9892	36	25	and	and	CCONJ
aiua-9892	36	26	death	death	NOUN
aiua-9892	36	27	.	.	PUNCT
aiua-9892	37	1	safety	safety	NOUN
aiua-9892	37	2	was	be	AUX
aiua-9892	37	3	a	a	DET
aiua-9892	37	4	secondary	secondary	ADJ
aiua-9892	37	5	endpoint	endpoint	NOUN
aiua-9892	37	6	.	.	PUNCT
aiua-9892	38	1	follow	follow	VERB
aiua-9892	38	2	-	-	PUNCT
aiua-9892	38	3	up	up	NOUN
aiua-9892	38	4	was	be	AUX
aiua-9892	38	5	stopped	stop	VERB
aiua-9892	38	6	when	when	SCONJ
aiua-9892	38	7	the	the	DET
aiua-9892	38	8	drug	drug	NOUN
aiua-9892	38	9	was	be	AUX
aiua-9892	38	10	suspended	suspend	VERB
aiua-9892	38	11	due	due	ADP
aiua-9892	38	12	to	to	ADP
aiua-9892	38	13	adverse	adverse	ADJ
aiua-9892	38	14	reactions	reaction	NOUN
aiua-9892	38	15	or	or	CCONJ
aiua-9892	38	16	disease	disease	NOUN
aiua-9892	38	17	progression	progression	NOUN
aiua-9892	38	18	.	.	PUNCT
aiua-9892	39	1	there	there	PRON
aiua-9892	39	2	was	be	VERB
aiua-9892	39	3	no	no	DET
aiua-9892	39	4	crossover	crossover	NOUN
aiua-9892	39	5	.	.	PUNCT
aiua-9892	40	1	statistical	statistical	ADJ
aiua-9892	40	2	analysis	analysis	NOUN
aiua-9892	40	3	descriptive	descriptive	ADJ
aiua-9892	40	4	statistics	statistic	NOUN
aiua-9892	40	5	of	of	ADP
aiua-9892	40	6	patient	patient	ADJ
aiua-9892	40	7	and	and	CCONJ
aiua-9892	40	8	pathological	pathological	ADJ
aiua-9892	40	9	characteristic	characteristic	NOUN
aiua-9892	40	10	were	be	AUX
aiua-9892	40	11	calculated	calculate	VERB
aiua-9892	40	12	for	for	ADP
aiua-9892	40	13	all	all	DET
aiua-9892	40	14	patients	patient	NOUN
aiua-9892	40	15	included	include	VERB
aiua-9892	40	16	in	in	ADP
aiua-9892	40	17	the	the	DET
aiua-9892	40	18	present	present	ADJ
aiua-9892	40	19	study	study	NOUN
aiua-9892	40	20	,	,	PUNCT
aiua-9892	40	21	as	as	ADV
aiua-9892	40	22	well	well	ADV
aiua-9892	40	23	as	as	ADP
aiua-9892	40	24	by	by	ADP
aiua-9892	40	25	administered	administer	VERB
aiua-9892	40	26	agent	agent	NOUN
aiua-9892	40	27	.	.	PUNCT
aiua-9892	41	1	we	we	PRON
aiua-9892	41	2	used	use	VERB
aiua-9892	41	3	a	a	DET
aiua-9892	41	4	chi	chi	ADJ
aiua-9892	41	5	-	-	PUNCT
aiua-9892	41	6	square	square	ADJ
aiua-9892	41	7	univariate	univariate	ADJ
aiua-9892	41	8	analysis	analysis	NOUN
aiua-9892	41	9	to	to	PART
aiua-9892	41	10	assess	assess	VERB
aiua-9892	41	11	the	the	DET
aiua-9892	41	12	statistical	statistical	ADJ
aiua-9892	41	13	significance	significance	NOUN
aiua-9892	41	14	of	of	ADP
aiua-9892	41	15	the	the	DET
aiua-9892	41	16	difference	difference	NOUN
aiua-9892	41	17	between	between	ADP
aiua-9892	41	18	rate	rate	NOUN
aiua-9892	41	19	response	response	NOUN
aiua-9892	41	20	in	in	ADP
aiua-9892	41	21	the	the	DET
aiua-9892	41	22	abiraterone	abiraterone	NOUN
aiua-9892	41	23	and	and	CCONJ
aiua-9892	41	24	enzalutamide	enzalutamide	ADJ
aiua-9892	41	25	group	group	NOUN
aiua-9892	41	26	.	.	PUNCT
aiua-9892	42	1	further	far	ADV
aiua-9892	42	2	,	,	PUNCT
aiua-9892	42	3	we	we	PRON
aiua-9892	42	4	used	use	VERB
aiua-9892	42	5	a	a	DET
aiua-9892	42	6	binary	binary	ADJ
aiua-9892	42	7	logistic	logistic	ADJ
aiua-9892	42	8	regression	regression	NOUN
aiua-9892	42	9	,	,	PUNCT
aiua-9892	42	10	adjusted	adjust	VERB
aiua-9892	42	11	to	to	ADP
aiua-9892	42	12	clinicopathological	clinicopathological	ADJ
aiua-9892	42	13	features	feature	NOUN
aiua-9892	42	14	,	,	PUNCT
aiua-9892	42	15	to	to	PART
aiua-9892	42	16	quantify	quantify	VERB
aiua-9892	42	17	this	this	DET
aiua-9892	42	18	association	association	NOUN
aiua-9892	42	19	.	.	PUNCT
aiua-9892	43	1	a	a	DET
aiua-9892	43	2	cox	cox	PROPN
aiua-9892	43	3	-	-	PUNCT
aiua-9892	43	4	regression	regression	NOUN
aiua-9892	43	5	was	be	AUX
aiua-9892	43	6	performed	perform	VERB
aiua-9892	43	7	to	to	PART
aiua-9892	43	8	uncover	uncover	VERB
aiua-9892	43	9	predictive	predictive	ADJ
aiua-9892	43	10	co	co	NOUN
aiua-9892	43	11	-	-	NOUN
aiua-9892	43	12	variates	variate	NOUN
aiua-9892	43	13	of	of	ADP
aiua-9892	43	14	biochemical	biochemical	ADJ
aiua-9892	43	15	progression	progression	NOUN
aiua-9892	43	16	,	,	PUNCT
aiua-9892	43	17	radiological	radiological	ADJ
aiua-9892	43	18	progression	progression	NOUN
aiua-9892	43	19	and	and	CCONJ
aiua-9892	43	20	overall	overall	ADJ
aiua-9892	43	21	survival	survival	NOUN
aiua-9892	43	22	.	.	PUNCT
aiua-9892	44	1	a	a	DET
aiua-9892	44	2	survival	survival	NOUN
aiua-9892	44	3	analysis	analysis	NOUN
aiua-9892	44	4	using	use	VERB
aiua-9892	44	5	a	a	DET
aiua-9892	44	6	kaplan	kaplan	PROPN
aiua-9892	44	7	-	-	PUNCT
aiua-9892	44	8	meier	meier	PROPN
aiua-9892	44	9	method	method	NOUN
aiua-9892	44	10	was	be	AUX
aiua-9892	44	11	used	use	VERB
aiua-9892	44	12	to	to	PART
aiua-9892	44	13	evaluate	evaluate	VERB
aiua-9892	44	14	the	the	DET
aiua-9892	44	15	risk	risk	NOUN
aiua-9892	44	16	of	of	ADP
aiua-9892	44	17	biochemical	biochemical	ADJ
aiua-9892	44	18	progression	progression	NOUN
aiua-9892	44	19	,	,	PUNCT
aiua-9892	44	20	radiological	radiological	ADJ
aiua-9892	44	21	progression	progression	NOUN
aiua-9892	44	22	and	and	CCONJ
aiua-9892	44	23	overall	overall	ADJ
aiua-9892	44	24	survival	survival	NOUN
aiua-9892	44	25	and	and	CCONJ
aiua-9892	44	26	a	a	DET
aiua-9892	44	27	log	log	NOUN
aiua-9892	44	28	-	-	PUNCT
aiua-9892	44	29	rank	rank	NOUN
aiua-9892	44	30	test	test	NOUN
aiua-9892	44	31	applied	apply	VERB
aiua-9892	44	32	to	to	PART
aiua-9892	44	33	test	test	VERB
aiua-9892	44	34	for	for	ADP
aiua-9892	44	35	significant	significant	ADJ
aiua-9892	44	36	differences	difference	NOUN
aiua-9892	44	37	.	.	PUNCT
aiua-9892	45	1	all	all	DET
aiua-9892	45	2	analyses	analysis	NOUN
aiua-9892	45	3	were	be	AUX
aiua-9892	45	4	conducted	conduct	VERB
aiua-9892	45	5	using	use	VERB
aiua-9892	45	6	ibm	ibm	PROPN
aiua-9892	45	7	spss	spss	PROPN
aiua-9892	45	8	statistics	statistics	PROPN
aiua-9892	45	9	version	version	PROPN
aiua-9892	45	10	23	23	NUM
aiua-9892	45	11	.	.	PUNCT
aiua-9892	46	1	all	all	DET
aiua-9892	46	2	comparisons	comparison	NOUN
aiua-9892	46	3	were	be	AUX
aiua-9892	46	4	made	make	VERB
aiua-9892	46	5	using	use	VERB
aiua-9892	46	6	2	2	NUM
aiua-9892	46	7	-	-	PUNCT
aiua-9892	46	8	sided	sided	ADJ
aiua-9892	46	9	tests	test	NOUN
aiua-9892	46	10	,	,	PUNCT
aiua-9892	46	11	with	with	ADP
aiua-9892	46	12	p	p	X
aiua-9892	46	13	<	<	X
aiua-9892	46	14	0.05	0.05	NUM
aiua-9892	46	15	considered	consider	VERB
aiua-9892	46	16	statistically	statistically	ADV
aiua-9892	46	17	significant	significant	ADJ
aiua-9892	46	18	.	.	PUNCT
aiua-9892	47	1	results	result	VERB
aiua-9892	47	2	a	a	DET
aiua-9892	47	3	total	total	NOUN
aiua-9892	47	4	of	of	ADP
aiua-9892	47	5	91	91	NUM
aiua-9892	47	6	patients	patient	NOUN
aiua-9892	47	7	who	who	PRON
aiua-9892	47	8	initiated	initiate	VERB
aiua-9892	47	9	a	a	DET
aiua-9892	47	10	novel	novel	ADJ
aiua-9892	47	11	hormonal	hormonal	ADJ
aiua-9892	47	12	agent	agent	NOUN
aiua-9892	47	13	,	,	PUNCT
aiua-9892	47	14	either	either	CCONJ
aiua-9892	47	15	abiraterone	abiraterone	NOUN
aiua-9892	47	16	or	or	CCONJ
aiua-9892	47	17	enzalutamide	enzalutamide	NOUN
aiua-9892	47	18	,	,	PUNCT
aiua-9892	47	19	between	between	ADP
aiua-9892	47	20	january	january	PROPN
aiua-9892	47	21	2016	2016	NUM
aiua-9892	47	22	and	and	CCONJ
aiua-9892	47	23	december	december	PROPN
aiua-9892	47	24	2019	2019	NUM
aiua-9892	47	25	were	be	AUX
aiua-9892	47	26	included	include	VERB
aiua-9892	47	27	in	in	ADP
aiua-9892	47	28	the	the	DET
aiua-9892	47	29	study	study	NOUN
aiua-9892	47	30	.	.	PUNCT
aiua-9892	48	1	56	56	NUM
aiua-9892	48	2	(	(	PUNCT
aiua-9892	48	3	61.5	61.5	NUM
aiua-9892	48	4	%	%	NOUN
aiua-9892	48	5	)	)	PUNCT
aiua-9892	48	6	patients	patient	NOUN
aiua-9892	48	7	were	be	AUX
aiua-9892	48	8	treated	treat	VERB
aiua-9892	48	9	with	with	ADP
aiua-9892	48	10	abiraterone	abiraterone	NOUN
aiua-9892	48	11	and	and	CCONJ
aiua-9892	48	12	the	the	DET
aiua-9892	48	13	remaining	remain	VERB
aiua-9892	48	14	35	35	NUM
aiua-9892	48	15	(	(	PUNCT
aiua-9892	48	16	38.5	38.5	NUM
aiua-9892	48	17	%	%	NOUN
aiua-9892	48	18	)	)	PUNCT
aiua-9892	48	19	with	with	ADP
aiua-9892	48	20	enzalutamide	enzalutamide	NOUN
aiua-9892	48	21	.	.	PUNCT
aiua-9892	49	1	45	45	NUM
aiua-9892	49	2	(	(	PUNCT
aiua-9892	49	3	49.5	49.5	NUM
aiua-9892	49	4	%	%	NOUN
aiua-9892	49	5	)	)	PUNCT
aiua-9892	50	1	patients	patient	NOUN
aiua-9892	50	2	were	be	AUX
aiua-9892	50	3	diagnosed	diagnose	VERB
aiua-9892	50	4	with	with	ADP
aiua-9892	50	5	metastatic	metastatic	ADJ
aiua-9892	50	6	prostate	prostate	NOUN
aiua-9892	50	7	cancer	cancer	NOUN
aiua-9892	50	8	ab	ab	PROPN
aiua-9892	50	9	inition	inition	NOUN
aiua-9892	50	10	.	.	PUNCT
aiua-9892	51	1	74.7	74.7	NUM
aiua-9892	51	2	%	%	NOUN
aiua-9892	51	3	,	,	PUNCT
aiua-9892	51	4	53.8	53.8	NUM
aiua-9892	51	5	%	%	NOUN
aiua-9892	51	6	and	and	CCONJ
aiua-9892	51	7	6.6	6.6	NUM
aiua-9892	51	8	%	%	NOUN
aiua-9892	51	9	had	have	VERB
aiua-9892	51	10	bone	bone	NOUN
aiua-9892	51	11	,	,	PUNCT
aiua-9892	51	12	lymphatic	lymphatic	ADJ
aiua-9892	51	13	,	,	PUNCT
aiua-9892	51	14	and	and	CCONJ
aiua-9892	51	15	visceral	visceral	ADJ
aiua-9892	51	16	metastasis	metastasis	NOUN
aiua-9892	51	17	,	,	PUNCT
aiua-9892	51	18	respectively	respectively	ADV
aiua-9892	51	19	.	.	PUNCT
aiua-9892	52	1	almost	almost	ADV
aiua-9892	52	2	30	30	NUM
aiua-9892	52	3	%	%	NOUN
aiua-9892	52	4	of	of	ADP
aiua-9892	52	5	patients	patient	NOUN
aiua-9892	52	6	had	have	AUX
aiua-9892	52	7	been	be	AUX
aiua-9892	52	8	previously	previously	ADV
aiua-9892	52	9	submitted	submit	VERB
aiua-9892	52	10	to	to	ADP
aiua-9892	52	11	taxane	taxane	NOUN
aiua-9892	52	12	-	-	PUNCT
aiua-9892	52	13	based	base	VERB
aiua-9892	52	14	chemotherapy	chemotherapy	NOUN
aiua-9892	52	15	.	.	PUNCT
aiua-9892	53	1	mean	mean	ADJ
aiua-9892	53	2	age	age	NOUN
aiua-9892	53	3	of	of	ADP
aiua-9892	53	4	the	the	DET
aiua-9892	53	5	cohort	cohort	NOUN
aiua-9892	53	6	was	be	AUX
aiua-9892	53	7	74.4	74.4	NUM
aiua-9892	53	8	(	(	PUNCT
aiua-9892	53	9	±	±	NOUN
aiua-9892	53	10	8.26	8.26	NUM
aiua-9892	53	11	)	)	PUNCT
aiua-9892	53	12	years	year	NOUN
aiua-9892	53	13	,	,	PUNCT
aiua-9892	53	14	while	while	SCONJ
aiua-9892	53	15	the	the	DET
aiua-9892	53	16	mean	mean	ADJ
aiua-9892	53	17	pretreatment	pretreatment	NOUN
aiua-9892	53	18	psa	psa	NOUN
aiua-9892	53	19	level	level	NOUN
aiua-9892	53	20	was	be	AUX
aiua-9892	53	21	231.51	231.51	NUM
aiua-9892	53	22	(	(	PUNCT
aiua-9892	53	23	±	±	NUM
aiua-9892	53	24	380.15	380.15	NUM
aiua-9892	53	25	)	)	PUNCT
aiua-9892	53	26	ng	ng	PROPN
aiua-9892	53	27	/	/	SYM
aiua-9892	53	28	ml	ml	PROPN
aiua-9892	53	29	and	and	CCONJ
aiua-9892	53	30	previous	previous	ADJ
aiua-9892	53	31	classical	classical	ADJ
aiua-9892	53	32	androgen	androgen	NOUN
aiua-9892	53	33	deprivation	deprivation	NOUN
aiua-9892	53	34	therapy	therapy	NOUN
aiua-9892	53	35	duration	duration	NOUN
aiua-9892	53	36	was	be	AUX
aiua-9892	53	37	74.13	74.13	NUM
aiua-9892	53	38	(	(	PUNCT
aiua-9892	53	39	±	±	NUM
aiua-9892	53	40	54.87	54.87	NUM
aiua-9892	53	41	)	)	PUNCT
aiua-9892	53	42	months	month	NOUN
aiua-9892	53	43	.	.	PUNCT
aiua-9892	54	1	median	median	ADJ
aiua-9892	54	2	follow	follow	VERB
aiua-9892	54	3	-	-	PUNCT
aiua-9892	54	4	up	up	NOUN
aiua-9892	54	5	time	time	NOUN
aiua-9892	54	6	was	be	AUX
aiua-9892	54	7	18.34	18.34	NUM
aiua-9892	54	8	months	month	NOUN
aiua-9892	54	9	.	.	PUNCT
aiua-9892	55	1	all	all	DET
aiua-9892	55	2	covariates	covariate	VERB
aiua-9892	55	3	,	,	PUNCT
aiua-9892	55	4	as	as	ADP
aiua-9892	55	5	age	age	NOUN
aiua-9892	55	6	,	,	PUNCT
aiua-9892	55	7	pretreatment	pretreatment	NOUN
aiua-9892	55	8	psa	psa	NOUN
aiua-9892	55	9	level	level	NOUN
aiua-9892	55	10	,	,	PUNCT
aiua-9892	55	11	isup	isup	ADJ
aiua-9892	55	12	score	score	NOUN
aiua-9892	55	13	,	,	PUNCT
aiua-9892	55	14	m1	m1	PROPN
aiua-9892	55	15	ab	ab	PROPN
aiua-9892	55	16	inition	inition	NOUN
aiua-9892	55	17	or	or	CCONJ
aiua-9892	55	18	progression	progression	NOUN
aiua-9892	55	19	after	after	ADP
aiua-9892	55	20	local	local	ADJ
aiua-9892	55	21	treatment	treatment	NOUN
aiua-9892	55	22	status	status	NOUN
aiua-9892	55	23	,	,	PUNCT
aiua-9892	55	24	previous	previous	ADJ
aiua-9892	55	25	period	period	NOUN
aiua-9892	55	26	of	of	ADP
aiua-9892	55	27	classical	classical	ADJ
aiua-9892	55	28	androgen	androgen	NOUN
aiua-9892	55	29	deprivation	deprivation	NOUN
aiua-9892	55	30	therapy	therapy	NOUN
aiua-9892	55	31	,	,	PUNCT
aiua-9892	55	32	previous	previous	ADJ
aiua-9892	55	33	treatment	treatment	NOUN
aiua-9892	55	34	of	of	ADP
aiua-9892	55	35	taxane	taxane	NOUN
aiua-9892	55	36	-	-	PUNCT
aiua-9892	55	37	based	base	VERB
aiua-9892	55	38	chemotherapy	chemotherapy	NOUN
aiua-9892	55	39	and	and	CCONJ
aiua-9892	55	40	localization	localization	NOUN
aiua-9892	55	41	of	of	ADP
aiua-9892	55	42	metastasis	metastasis	NOUN
aiua-9892	55	43	were	be	AUX
aiua-9892	55	44	similar	similar	ADJ
aiua-9892	55	45	between	between	ADP
aiua-9892	55	46	the	the	DET
aiua-9892	55	47	groups	group	NOUN
aiua-9892	55	48	.	.	PUNCT
aiua-9892	56	1	baseline	baseline	VERB
aiua-9892	56	2	demographic	demographic	ADJ
aiua-9892	56	3	and	and	CCONJ
aiua-9892	56	4	clinicopathological	clinicopathological	ADJ
aiua-9892	56	5	features	feature	NOUN
aiua-9892	56	6	are	be	AUX
aiua-9892	56	7	shown	show	VERB
aiua-9892	56	8	in	in	ADP
aiua-9892	56	9	table	table	NOUN
aiua-9892	56	10	1	1	NUM
aiua-9892	56	11	.	.	PUNCT
aiua-9892	57	1	biochemical	biochemical	ADJ
aiua-9892	57	2	response	response	NOUN
aiua-9892	57	3	overall	overall	ADJ
aiua-9892	57	4	,	,	PUNCT
aiua-9892	57	5	rate	rate	NOUN
aiua-9892	57	6	of	of	ADP
aiua-9892	57	7	biochemical	biochemical	ADJ
aiua-9892	57	8	response	response	NOUN
aiua-9892	57	9	was	be	AUX
aiua-9892	57	10	61.5	61.5	NUM
aiua-9892	57	11	%	%	NOUN
aiua-9892	57	12	in	in	ADP
aiua-9892	57	13	mcrpc	mcrpc	NOUN
aiua-9892	57	14	patients	patient	NOUN
aiua-9892	57	15	.	.	PUNCT
aiua-9892	58	1	it	it	PRON
aiua-9892	58	2	was	be	AUX
aiua-9892	58	3	found	find	VERB
aiua-9892	58	4	to	to	PART
aiua-9892	58	5	be	be	AUX
aiua-9892	58	6	significantly	significantly	ADV
aiua-9892	58	7	higher	high	ADJ
aiua-9892	58	8	in	in	ADP
aiua-9892	58	9	the	the	DET
aiua-9892	58	10	enzalutamide	enzalutamide	ADJ
aiua-9892	58	11	group	group	NOUN
aiua-9892	58	12	than	than	ADP
aiua-9892	58	13	in	in	ADP
aiua-9892	58	14	the	the	DET
aiua-9892	58	15	abiraterone	abiraterone	NOUN
aiua-9892	58	16	group	group	NOUN
aiua-9892	58	17	,	,	PUNCT
aiua-9892	58	18	with	with	ADP
aiua-9892	58	19	a	a	DET
aiua-9892	58	20	rate	rate	NOUN
aiua-9892	58	21	response	response	NOUN
aiua-9892	58	22	of	of	ADP
aiua-9892	58	23	77.1	77.1	NUM
aiua-9892	58	24	%	%	NOUN
aiua-9892	58	25	and	and	CCONJ
aiua-9892	58	26	58.1	58.1	NUM
aiua-9892	58	27	%	%	NOUN
aiua-9892	58	28	,	,	PUNCT
aiua-9892	58	29	respectively	respectively	ADV
aiua-9892	58	30	(	(	PUNCT
aiua-9892	58	31	p	p	X
aiua-9892	58	32	=	=	NOUN
aiua-9892	58	33	0.016	0.016	NUM
aiua-9892	58	34	)	)	PUNCT
aiua-9892	58	35	.	.	PUNCT
aiua-9892	59	1	in	in	ADP
aiua-9892	59	2	binary	binary	PROPN
aiua-9892	59	3	logistic	logistic	ADJ
aiua-9892	59	4	regression	regression	NOUN
aiua-9892	59	5	adjusted	adjust	VERB
aiua-9892	59	6	to	to	ADP
aiua-9892	59	7	clinicopathological	clinicopathological	ADJ
aiua-9892	59	8	features	feature	NOUN
aiua-9892	59	9	,	,	PUNCT
aiua-9892	59	10	enzalutamide	enzalutamide	ADV
aiua-9892	59	11	was	be	AUX
aiua-9892	59	12	associated	associate	VERB
aiua-9892	59	13	with	with	ADP
aiua-9892	59	14	a	a	DET
aiua-9892	59	15	higher	high	ADJ
aiua-9892	59	16	probatable	probatable	ADJ
aiua-9892	59	17	1	1	NUM
aiua-9892	59	18	.	.	PUNCT
aiua-9892	59	19	baseline	baseline	VERB
aiua-9892	59	20	demographic	demographic	ADJ
aiua-9892	59	21	and	and	CCONJ
aiua-9892	59	22	clinicopathological	clinicopathological	ADJ
aiua-9892	59	23	characteristics	characteristic	NOUN
aiua-9892	59	24	by	by	ADP
aiua-9892	59	25	drug	drug	NOUN
aiua-9892	59	26	of	of	ADP
aiua-9892	59	27	mcrpc	mcrpc	NOUN
aiua-9892	59	28	patients	patient	NOUN
aiua-9892	59	29	.	.	PUNCT
aiua-9892	60	1	demographic	demographic	ADJ
aiua-9892	60	2	and	and	CCONJ
aiua-9892	60	3	pathological	pathological	ADJ
aiua-9892	60	4	features	feature	NOUN
aiua-9892	60	5	total	total	VERB
aiua-9892	60	6	abiraterone	abiraterone	NOUN
aiua-9892	60	7	enzalutamide	enzalutamide	ADV
aiua-9892	60	8	p	p	PROPN
aiua-9892	60	9	(	(	PUNCT
aiua-9892	60	10	n	n	NOUN
aiua-9892	60	11	=	=	SYM
aiua-9892	60	12	91	91	NUM
aiua-9892	60	13	)	)	PUNCT
aiua-9892	60	14	(	(	PUNCT
aiua-9892	60	15	n	n	NOUN
aiua-9892	60	16	=	=	SYM
aiua-9892	60	17	56	56	NUM
aiua-9892	60	18	)	)	PUNCT
aiua-9892	60	19	(	(	PUNCT
aiua-9892	60	20	n	n	NOUN
aiua-9892	60	21	=	=	SYM
aiua-9892	60	22	35	35	NUM
aiua-9892	60	23	)	)	PUNCT
aiua-9892	60	24	age	age	NOUN
aiua-9892	60	25	(	(	PUNCT
aiua-9892	60	26	years	year	NOUN
aiua-9892	60	27	)	)	PUNCT
aiua-9892	60	28	74.44	74.44	NUM
aiua-9892	60	29	±	±	NUM
aiua-9892	60	30	8.26	8.26	NUM
aiua-9892	60	31	75.00	75.00	NUM
aiua-9892	60	32	±	±	NUM
aiua-9892	60	33	7.01	7.01	NUM
aiua-9892	60	34	73.54	73.54	NUM
aiua-9892	60	35	±	±	NUM
aiua-9892	60	36	9.980	9.980	NUM
aiua-9892	60	37	0.416	0.416	NUM
aiua-9892	60	38	pretreatment	pretreatment	NOUN
aiua-9892	60	39	psa	psa	NOUN
aiua-9892	60	40	level	level	NOUN
aiua-9892	60	41	(	(	PUNCT
aiua-9892	60	42	ng	ng	NOUN
aiua-9892	60	43	/	/	SYM
aiua-9892	60	44	ml	ml	NOUN
aiua-9892	60	45	)	)	PUNCT
aiua-9892	60	46	231.51	231.51	NUM
aiua-9892	60	47	±	±	NUM
aiua-9892	60	48	380.16	380.16	NUM
aiua-9892	60	49	215.40	215.40	NUM
aiua-9892	60	50	±	±	NUM
aiua-9892	60	51	372.82	372.82	NUM
aiua-9892	60	52	257.94	257.94	NUM
aiua-9892	60	53	±	±	NOUN
aiua-9892	60	54	401.65	401.65	NUM
aiua-9892	60	55	0.717	0.717	NUM
aiua-9892	60	56	previous	previous	ADJ
aiua-9892	60	57	adt	adt	NOUN
aiua-9892	60	58	(	(	PUNCT
aiua-9892	60	59	months	month	NOUN
aiua-9892	60	60	)	)	PUNCT
aiua-9892	60	61	74.13	74.13	NUM
aiua-9892	60	62	±	±	NUM
aiua-9892	61	1	54.87	54.87	NUM
aiua-9892	61	2	77.53	77.53	NUM
aiua-9892	61	3	±	±	NUM
aiua-9892	61	4	61.66	61.66	NUM
aiua-9892	61	5	68.82	68.82	NUM
aiua-9892	61	6	±	±	NUM
aiua-9892	61	7	42.50	42.50	NUM
aiua-9892	61	8	0.882	0.882	NUM
aiua-9892	61	9	follow	follow	VERB
aiua-9892	61	10	-	-	PUNCT
aiua-9892	61	11	up	up	NOUN
aiua-9892	61	12	(	(	PUNCT
aiua-9892	61	13	months	month	NOUN
aiua-9892	61	14	)	)	PUNCT
aiua-9892	61	15	18.34	18.34	NUM
aiua-9892	61	16	±	±	NUM
aiua-9892	61	17	9.81	9.81	NUM
aiua-9892	61	18	17.16	17.16	NUM
aiua-9892	61	19	±	±	NUM
aiua-9892	61	20	8.71	8.71	NUM
aiua-9892	61	21	20.68	20.68	NUM
aiua-9892	61	22	±	±	NUM
aiua-9892	61	23	11.20	11.20	NUM
aiua-9892	61	24	0.276	0.276	NUM
aiua-9892	61	25	isup	isup	NOUN
aiua-9892	61	26	0.612	0.612	NUM
aiua-9892	61	27	1	1	NUM
aiua-9892	61	28	9	9	NUM
aiua-9892	61	29	(	(	PUNCT
aiua-9892	61	30	10	10	NUM
aiua-9892	61	31	%	%	NOUN
aiua-9892	61	32	)	)	PUNCT
aiua-9892	61	33	4	4	NUM
aiua-9892	61	34	(	(	PUNCT
aiua-9892	61	35	7.3	7.3	NUM
aiua-9892	61	36	%	%	NOUN
aiua-9892	61	37	)	)	PUNCT
aiua-9892	61	38	5	5	NUM
aiua-9892	61	39	(	(	PUNCT
aiua-9892	61	40	14.3	14.3	NUM
aiua-9892	61	41	%	%	NOUN
aiua-9892	61	42	)	)	PUNCT
aiua-9892	61	43	2	2	NUM
aiua-9892	61	44	18	18	NUM
aiua-9892	61	45	(	(	PUNCT
aiua-9892	61	46	20	20	NUM
aiua-9892	61	47	%	%	NOUN
aiua-9892	61	48	)	)	PUNCT
aiua-9892	61	49	13	13	NUM
aiua-9892	61	50	(	(	PUNCT
aiua-9892	61	51	23.6	23.6	NUM
aiua-9892	61	52	%	%	NOUN
aiua-9892	61	53	)	)	PUNCT
aiua-9892	61	54	5	5	NUM
aiua-9892	61	55	(	(	PUNCT
aiua-9892	61	56	14.3	14.3	NUM
aiua-9892	61	57	%	%	NOUN
aiua-9892	61	58	)	)	PUNCT
aiua-9892	61	59	3	3	NUM
aiua-9892	61	60	25	25	NUM
aiua-9892	61	61	(	(	PUNCT
aiua-9892	61	62	27.8	27.8	NUM
aiua-9892	61	63	%	%	NOUN
aiua-9892	61	64	)	)	PUNCT
aiua-9892	61	65	16	16	NUM
aiua-9892	61	66	(	(	PUNCT
aiua-9892	61	67	29.1	29.1	NUM
aiua-9892	61	68	%	%	NOUN
aiua-9892	61	69	)	)	PUNCT
aiua-9892	61	70	9	9	NUM
aiua-9892	61	71	(	(	PUNCT
aiua-9892	61	72	25.7	25.7	NUM
aiua-9892	61	73	%	%	NOUN
aiua-9892	61	74	)	)	PUNCT
aiua-9892	61	75	≥	≥	NOUN
aiua-9892	61	76	4	4	NUM
aiua-9892	61	77	19	19	NUM
aiua-9892	61	78	(	(	PUNCT
aiua-9892	61	79	21.1	21.1	NUM
aiua-9892	61	80	%	%	NOUN
aiua-9892	61	81	)	)	PUNCT
aiua-9892	61	82	12	12	NUM
aiua-9892	61	83	(	(	PUNCT
aiua-9892	61	84	21.8	21.8	NUM
aiua-9892	61	85	%	%	NOUN
aiua-9892	61	86	)	)	PUNCT
aiua-9892	61	87	7	7	NUM
aiua-9892	61	88	(	(	PUNCT
aiua-9892	61	89	20	20	NUM
aiua-9892	61	90	%	%	NOUN
aiua-9892	61	91	)	)	PUNCT
aiua-9892	61	92	n	n	CCONJ
aiua-9892	61	93	/	/	SYM
aiua-9892	61	94	a	a	DET
aiua-9892	61	95	19	19	NUM
aiua-9892	61	96	(	(	PUNCT
aiua-9892	61	97	21.1	21.1	NUM
aiua-9892	61	98	%	%	NOUN
aiua-9892	61	99	)	)	PUNCT
aiua-9892	61	100	10	10	NUM
aiua-9892	61	101	(	(	PUNCT
aiua-9892	61	102	18.2	18.2	NUM
aiua-9892	61	103	%	%	NOUN
aiua-9892	61	104	)	)	PUNCT
aiua-9892	61	105	9	9	NUM
aiua-9892	61	106	(	(	PUNCT
aiua-9892	61	107	25.7	25.7	NUM
aiua-9892	61	108	%	%	NOUN
aiua-9892	61	109	)	)	PUNCT
aiua-9892	61	110	status	status	NOUN
aiua-9892	61	111	0.934	0.934	NUM
aiua-9892	61	112	m1	m1	PROPN
aiua-9892	61	113	ab	ab	PROPN
aiua-9892	61	114	inition	inition	NOUN
aiua-9892	61	115	45	45	NUM
aiua-9892	61	116	(	(	PUNCT
aiua-9892	61	117	50.6	50.6	NUM
aiua-9892	61	118	%	%	NOUN
aiua-9892	61	119	)	)	PUNCT
aiua-9892	61	120	28	28	NUM
aiua-9892	61	121	(	(	PUNCT
aiua-9892	61	122	50.9	50.9	NUM
aiua-9892	61	123	%	%	NOUN
aiua-9892	61	124	)	)	PUNCT
aiua-9892	61	125	17	17	NUM
aiua-9892	61	126	(	(	PUNCT
aiua-9892	61	127	50	50	NUM
aiua-9892	61	128	%	%	NOUN
aiua-9892	61	129	)	)	PUNCT
aiua-9892	61	130	post	post	VERB
aiua-9892	61	131	local	local	ADJ
aiua-9892	61	132	treatment	treatment	NOUN
aiua-9892	61	133	44	44	NUM
aiua-9892	61	134	(	(	PUNCT
aiua-9892	61	135	49.4	49.4	NUM
aiua-9892	61	136	%	%	NOUN
aiua-9892	61	137	)	)	PUNCT
aiua-9892	61	138	27	27	NUM
aiua-9892	61	139	(	(	PUNCT
aiua-9892	61	140	49.1	49.1	NUM
aiua-9892	61	141	%	%	NOUN
aiua-9892	61	142	)	)	PUNCT
aiua-9892	61	143	17	17	NUM
aiua-9892	61	144	(	(	PUNCT
aiua-9892	61	145	50	50	NUM
aiua-9892	61	146	%	%	NOUN
aiua-9892	61	147	)	)	PUNCT
aiua-9892	61	148	metastasis	metastasis	NOUN
aiua-9892	61	149	bone	bone	NOUN
aiua-9892	61	150	68	68	NUM
aiua-9892	61	151	(	(	PUNCT
aiua-9892	61	152	74.7	74.7	NUM
aiua-9892	61	153	%	%	NOUN
aiua-9892	61	154	)	)	PUNCT
aiua-9892	61	155	39	39	NUM
aiua-9892	61	156	(	(	PUNCT
aiua-9892	61	157	69.6	69.6	NUM
aiua-9892	61	158	%	%	NOUN
aiua-9892	61	159	)	)	PUNCT
aiua-9892	61	160	29	29	NUM
aiua-9892	61	161	(	(	PUNCT
aiua-9892	61	162	82.9	82.9	NUM
aiua-9892	61	163	%	%	NOUN
aiua-9892	61	164	)	)	PUNCT
aiua-9892	61	165	0.158	0.158	NUM
aiua-9892	61	166	ganglionar	ganglionar	VERB
aiua-9892	61	167	49	49	NUM
aiua-9892	61	168	(	(	PUNCT
aiua-9892	61	169	53.8	53.8	NUM
aiua-9892	61	170	%	%	NOUN
aiua-9892	61	171	)	)	PUNCT
aiua-9892	61	172	30	30	NUM
aiua-9892	61	173	(	(	PUNCT
aiua-9892	61	174	53.6	53.6	NUM
aiua-9892	61	175	%	%	NOUN
aiua-9892	61	176	)	)	PUNCT
aiua-9892	61	177	19	19	NUM
aiua-9892	61	178	(	(	PUNCT
aiua-9892	61	179	54.3	54.3	NUM
aiua-9892	61	180	%	%	NOUN
aiua-9892	61	181	)	)	PUNCT
aiua-9892	61	182	0.947	0.947	NUM
aiua-9892	61	183	visceral	visceral	ADJ
aiua-9892	61	184	6	6	NUM
aiua-9892	61	185	(	(	PUNCT
aiua-9892	61	186	6.2	6.2	NUM
aiua-9892	61	187	%	%	NOUN
aiua-9892	61	188	)	)	PUNCT
aiua-9892	61	189	4	4	NUM
aiua-9892	61	190	(	(	PUNCT
aiua-9892	61	191	6.5	6.5	NUM
aiua-9892	61	192	%	%	NOUN
aiua-9892	61	193	)	)	PUNCT
aiua-9892	61	194	2	2	NUM
aiua-9892	61	195	(	(	PUNCT
aiua-9892	61	196	5.7	5.7	NUM
aiua-9892	61	197	%	%	NOUN
aiua-9892	61	198	)	)	PUNCT
aiua-9892	61	199	0.788	0.788	NUM
aiua-9892	61	200	post	post	NOUN
aiua-9892	61	201	docetaxel	docetaxel	NOUN
aiua-9892	61	202	27	27	NUM
aiua-9892	61	203	(	(	PUNCT
aiua-9892	61	204	29.7	29.7	NUM
aiua-9892	61	205	%	%	NOUN
aiua-9892	61	206	)	)	PUNCT
aiua-9892	61	207	15	15	NUM
aiua-9892	61	208	(	(	PUNCT
aiua-9892	61	209	26.8	26.8	NUM
aiua-9892	61	210	%	%	NOUN
aiua-9892	61	211	)	)	PUNCT
aiua-9892	61	212	12	12	NUM
aiua-9892	61	213	(	(	PUNCT
aiua-9892	61	214	34.3	34.3	NUM
aiua-9892	61	215	%	%	NOUN
aiua-9892	61	216	)	)	PUNCT
aiua-9892	61	217	0.446	0.446	NUM
aiua-9892	61	218	adt	adt	NOUN
aiua-9892	61	219	:	:	PUNCT
aiua-9892	61	220	androgen	androgen	NOUN
aiua-9892	61	221	deprivation	deprivation	NOUN
aiua-9892	61	222	therapy	therapy	NOUN
aiua-9892	61	223	;	;	PUNCT
aiua-9892	61	224	psa	psa	VERB
aiua-9892	61	225	:	:	PUNCT
aiua-9892	61	226	prostate	prostate	NOUN
aiua-9892	61	227	-	-	PUNCT
aiua-9892	61	228	specific	specific	ADJ
aiua-9892	61	229	antigen	antigen	NOUN
aiua-9892	61	230	;	;	PUNCT
aiua-9892	61	231	n	n	CCONJ
aiua-9892	61	232	/	/	SYM
aiua-9892	61	233	a	a	PRON
aiua-9892	61	234	:	:	PUNCT
aiua-9892	61	235	not	not	PART
aiua-9892	61	236	admitted	admit	VERB
aiua-9892	61	237	.	.	PUNCT
aiua-9892	62	1	395archivio	395archivio	PROPN
aiua-9892	62	2	italiano	italiano	NOUN
aiua-9892	62	3	di	di	X
aiua-9892	62	4	urologia	urologia	PROPN
aiua-9892	62	5	e	e	PROPN
aiua-9892	62	6	andrologia	andrologia	NOUN
aiua-9892	62	7	2021	2021	NUM
aiua-9892	62	8	;	;	PUNCT
aiua-9892	62	9	93	93	NUM
aiua-9892	62	10	,	,	PUNCT
aiua-9892	62	11	4	4	NUM
aiua-9892	62	12	novel	novel	ADJ
aiua-9892	62	13	hormonal	hormonal	ADJ
aiua-9892	62	14	agents	agent	NOUN
aiua-9892	62	15	for	for	ADP
aiua-9892	62	16	metastatic	metastatic	ADJ
aiua-9892	62	17	castration	castration	NOUN
aiua-9892	62	18	-	-	PUNCT
aiua-9892	62	19	resistant	resistant	ADJ
aiua-9892	62	20	prostate	prostate	NOUN
aiua-9892	62	21	cancer	cancer	NOUN
aiua-9892	62	22	:	:	PUNCT
aiua-9892	62	23	comparing	compare	VERB
aiua-9892	62	24	outcomes	outcome	NOUN
aiua-9892	62	25	bility	bility	NOUN
aiua-9892	62	26	of	of	ADP
aiua-9892	62	27	biochemical	biochemical	ADJ
aiua-9892	62	28	response	response	NOUN
aiua-9892	62	29	(	(	PUNCT
aiua-9892	62	30	or	or	CCONJ
aiua-9892	62	31	:	:	PUNCT
aiua-9892	62	32	3.485	3.485	NUM
aiua-9892	62	33	,	,	PUNCT
aiua-9892	62	34	p	p	X
aiua-9892	62	35	=	=	PROPN
aiua-9892	62	36	0.021	0.021	NUM
aiua-9892	62	37	)	)	PUNCT
aiua-9892	62	38	.	.	PUNCT
aiua-9892	63	1	biochemical	biochemical	ADJ
aiua-9892	63	2	response	response	NOUN
aiua-9892	63	3	was	be	AUX
aiua-9892	63	4	associated	associate	VERB
aiua-9892	63	5	with	with	ADP
aiua-9892	63	6	lower	low	ADJ
aiua-9892	63	7	probability	probability	NOUN
aiua-9892	63	8	of	of	ADP
aiua-9892	63	9	biochemical	biochemical	ADJ
aiua-9892	63	10	progression	progression	NOUN
aiua-9892	63	11	(	(	PUNCT
aiua-9892	63	12	or	or	CCONJ
aiua-9892	63	13	:	:	PUNCT
aiua-9892	63	14	0.248	0.248	NUM
aiua-9892	63	15	,	,	PUNCT
aiua-9892	63	16	p	p	X
aiua-9892	63	17	=	=	NOUN
aiua-9892	63	18	0.017	0.017	NUM
aiua-9892	63	19	)	)	PUNCT
aiua-9892	63	20	and	and	CCONJ
aiua-9892	63	21	death	death	NOUN
aiua-9892	63	22	(	(	PUNCT
aiua-9892	63	23	or	or	CCONJ
aiua-9892	63	24	:	:	PUNCT
aiua-9892	63	25	0.302	0.302	NUM
aiua-9892	63	26	,	,	PUNCT
aiua-9892	63	27	p	p	X
aiua-9892	63	28	=	=	NOUN
aiua-9892	63	29	0.038	0.038	NUM
aiua-9892	63	30	)	)	PUNCT
aiua-9892	63	31	,	,	PUNCT
aiua-9892	63	32	adjusted	adjust	VERB
aiua-9892	63	33	to	to	ADP
aiua-9892	63	34	clinicopathological	clinicopathological	ADJ
aiua-9892	63	35	features	feature	NOUN
aiua-9892	63	36	.	.	PUNCT
aiua-9892	64	1	subgroup	subgroup	NOUN
aiua-9892	64	2	analyses	analysis	NOUN
aiua-9892	64	3	showed	show	VERB
aiua-9892	64	4	no	no	DET
aiua-9892	64	5	statistically	statistically	ADV
aiua-9892	64	6	significant	significant	ADJ
aiua-9892	64	7	difference	difference	NOUN
aiua-9892	64	8	between	between	ADP
aiua-9892	64	9	biochemical	biochemical	ADJ
aiua-9892	64	10	responses	response	NOUN
aiua-9892	64	11	in	in	ADP
aiua-9892	64	12	the	the	DET
aiua-9892	64	13	docetaxelnaïve	docetaxelnaïve	ADJ
aiua-9892	64	14	patients	patient	NOUN
aiua-9892	64	15	between	between	ADP
aiua-9892	64	16	abiraterone	abiraterone	NOUN
aiua-9892	64	17	and	and	CCONJ
aiua-9892	64	18	enzalutamide	enzalutamide	ADV
aiua-9892	64	19	(	(	PUNCT
aiua-9892	64	20	56.1	56.1	NUM
aiua-9892	64	21	%	%	NOUN
aiua-9892	64	22	vs	vs	ADP
aiua-9892	64	23	73.9	73.9	NUM
aiua-9892	64	24	%	%	NOUN
aiua-9892	64	25	,	,	PUNCT
aiua-9892	64	26	p	p	X
aiua-9892	64	27	=	=	NOUN
aiua-9892	64	28	0.158	0.158	NUM
aiua-9892	64	29	)	)	PUNCT
aiua-9892	64	30	,	,	PUNCT
aiua-9892	64	31	but	but	CCONJ
aiua-9892	64	32	enzalutamide	enzalutamide	ADV
aiua-9892	64	33	had	have	VERB
aiua-9892	64	34	a	a	DET
aiua-9892	64	35	higher	high	ADJ
aiua-9892	64	36	response	response	NOUN
aiua-9892	64	37	rate	rate	NOUN
aiua-9892	64	38	than	than	ADP
aiua-9892	64	39	abiraterone	abiraterone	NOUN
aiua-9892	64	40	in	in	ADP
aiua-9892	64	41	patients	patient	NOUN
aiua-9892	64	42	previously	previously	ADV
aiua-9892	64	43	submitted	submit	VERB
aiua-9892	64	44	to	to	ADP
aiua-9892	64	45	docetaxel	docetaxel	PROPN
aiua-9892	64	46	(	(	PUNCT
aiua-9892	64	47	83.3	83.3	NUM
aiua-9892	64	48	%	%	NOUN
aiua-9892	64	49	vs	vs	ADP
aiua-9892	64	50	40	40	NUM
aiua-9892	64	51	%	%	NOUN
aiua-9892	64	52	,	,	PUNCT
aiua-9892	64	53	p	p	X
aiua-9892	64	54	=	=	NOUN
aiua-9892	64	55	0.019	0.019	NUM
aiua-9892	64	56	)	)	PUNCT
aiua-9892	64	57	.	.	PUNCT
aiua-9892	65	1	in	in	ADP
aiua-9892	65	2	the	the	DET
aiua-9892	65	3	subgroup	subgroup	NOUN
aiua-9892	65	4	of	of	ADP
aiua-9892	65	5	patients	patient	NOUN
aiua-9892	65	6	with	with	ADP
aiua-9892	65	7	metastatic	metastatic	ADJ
aiua-9892	65	8	prostate	prostate	NOUN
aiua-9892	65	9	cancer	cancer	NOUN
aiua-9892	65	10	ab	ab	PROPN
aiua-9892	65	11	inition	inition	NOUN
aiua-9892	65	12	,	,	PUNCT
aiua-9892	65	13	that	that	PRON
aiua-9892	65	14	progressed	progress	VERB
aiua-9892	65	15	to	to	ADP
aiua-9892	65	16	mcrpc	mcrpc	PROPN
aiua-9892	65	17	and	and	CCONJ
aiua-9892	65	18	were	be	AUX
aiua-9892	65	19	docetaxel	docetaxel	NOUN
aiua-9892	65	20	-	-	PUNCT
aiua-9892	65	21	naïve	naïve	PROPN
aiua-9892	65	22	,	,	PUNCT
aiua-9892	65	23	the	the	DET
aiua-9892	65	24	period	period	NOUN
aiua-9892	65	25	of	of	ADP
aiua-9892	65	26	previous	previous	ADJ
aiua-9892	65	27	classical	classical	ADJ
aiua-9892	65	28	hormonal	hormonal	ADJ
aiua-9892	65	29	therapy	therapy	NOUN
aiua-9892	65	30	was	be	AUX
aiua-9892	65	31	inversely	inversely	ADV
aiua-9892	65	32	associated	associate	VERB
aiua-9892	65	33	with	with	ADP
aiua-9892	65	34	biochemical	biochemical	ADJ
aiua-9892	65	35	response	response	NOUN
aiua-9892	65	36	(	(	PUNCT
aiua-9892	65	37	or	or	CCONJ
aiua-9892	65	38	:	:	PUNCT
aiua-9892	65	39	0.928	0.928	NUM
aiua-9892	65	40	,	,	PUNCT
aiua-9892	65	41	p	p	NOUN
aiua-9892	65	42	=	=	NOUN
aiua-9892	65	43	0.035	0.035	NUM
aiua-9892	65	44	)	)	PUNCT
aiua-9892	65	45	.	.	PUNCT
aiua-9892	66	1	biochemical	biochemical	ADJ
aiua-9892	66	2	progression	progression	NOUN
aiua-9892	66	3	mcrpc	mcrpc	NOUN
aiua-9892	66	4	patients	patient	NOUN
aiua-9892	66	5	submitted	submit	VERB
aiua-9892	66	6	to	to	ADP
aiua-9892	66	7	treatment	treatment	NOUN
aiua-9892	66	8	with	with	ADP
aiua-9892	66	9	enzalutamide	enzalutamide	NOUN
aiua-9892	66	10	and	and	CCONJ
aiua-9892	66	11	abiraterone	abiraterone	NOUN
aiua-9892	66	12	had	have	VERB
aiua-9892	66	13	a	a	DET
aiua-9892	66	14	biochemical	biochemical	ADJ
aiua-9892	66	15	progressionfree	progressionfree	NOUN
aiua-9892	66	16	survival	survival	NOUN
aiua-9892	66	17	(	(	PUNCT
aiua-9892	66	18	bpfs	bpfs	PROPN
aiua-9892	66	19	)	)	PUNCT
aiua-9892	66	20	of	of	ADP
aiua-9892	66	21	19.2	19.2	NUM
aiua-9892	66	22	and	and	CCONJ
aiua-9892	66	23	30.2	30.2	NUM
aiua-9892	66	24	months	month	NOUN
aiua-9892	66	25	,	,	PUNCT
aiua-9892	66	26	respectively	respectively	ADV
aiua-9892	66	27	.	.	PUNCT
aiua-9892	67	1	the	the	DET
aiua-9892	67	2	difference	difference	NOUN
aiua-9892	67	3	failed	fail	VERB
aiua-9892	67	4	to	to	PART
aiua-9892	67	5	achieve	achieve	VERB
aiua-9892	67	6	statistical	statistical	ADJ
aiua-9892	67	7	significance	significance	NOUN
aiua-9892	67	8	(	(	PUNCT
aiua-9892	67	9	p	p	NOUN
aiua-9892	67	10	=	=	NOUN
aiua-9892	67	11	0.284	0.284	NUM
aiua-9892	67	12	)	)	PUNCT
aiua-9892	67	13	.	.	PUNCT
aiua-9892	68	1	the	the	DET
aiua-9892	68	2	kaplan	kaplan	PROPN
aiua-9892	68	3	-	-	PUNCT
aiua-9892	68	4	meier	meier	PROPN
aiua-9892	68	5	curves	curve	NOUN
aiua-9892	68	6	for	for	ADP
aiua-9892	68	7	bpfs	bpf	NOUN
aiua-9892	68	8	are	be	AUX
aiua-9892	68	9	showed	show	VERB
aiua-9892	68	10	in	in	ADP
aiua-9892	68	11	the	the	DET
aiua-9892	68	12	figure	figure	NOUN
aiua-9892	68	13	1	1	NUM
aiua-9892	68	14	.	.	PUNCT
aiua-9892	69	1	in	in	ADP
aiua-9892	69	2	patients	patient	NOUN
aiua-9892	69	3	who	who	PRON
aiua-9892	69	4	achieved	achieve	VERB
aiua-9892	69	5	a	a	DET
aiua-9892	69	6	biochemical	biochemical	ADJ
aiua-9892	69	7	response	response	NOUN
aiua-9892	69	8	,	,	PUNCT
aiua-9892	69	9	the	the	DET
aiua-9892	69	10	bpfs	bpf	NOUN
aiua-9892	69	11	was	be	AUX
aiua-9892	69	12	similar	similar	ADJ
aiua-9892	69	13	in	in	ADP
aiua-9892	69	14	both	both	CCONJ
aiua-9892	69	15	enzalutamide	enzalutamide	ADJ
aiua-9892	69	16	group	group	NOUN
aiua-9892	69	17	and	and	CCONJ
aiua-9892	69	18	abiraterone	abiraterone	NOUN
aiua-9892	69	19	group	group	NOUN
aiua-9892	69	20	(	(	PUNCT
aiua-9892	69	21	24.0	24.0	NUM
aiua-9892	69	22	vs	vs	ADP
aiua-9892	69	23	24.3	24.3	NUM
aiua-9892	69	24	months	month	NOUN
aiua-9892	69	25	,	,	PUNCT
aiua-9892	69	26	p	p	NOUN
aiua-9892	69	27	=	=	NOUN
aiua-9892	69	28	0.651	0.651	NUM
aiua-9892	69	29	)	)	PUNCT
aiua-9892	69	30	.	.	PUNCT
aiua-9892	70	1	no	no	DET
aiua-9892	70	2	covariate	covariate	ADJ
aiua-9892	70	3	factor	factor	NOUN
aiua-9892	70	4	was	be	AUX
aiua-9892	70	5	identified	identify	VERB
aiua-9892	70	6	as	as	ADP
aiua-9892	70	7	predictor	predictor	NOUN
aiua-9892	70	8	of	of	ADP
aiua-9892	70	9	bpfs	bpf	NOUN
aiua-9892	70	10	in	in	ADP
aiua-9892	70	11	multivariate	multivariate	NOUN
aiua-9892	70	12	analysis	analysis	NOUN
aiua-9892	70	13	.	.	PUNCT
aiua-9892	71	1	figure	figure	NOUN
aiua-9892	71	2	1	1	NUM
aiua-9892	71	3	.	.	PUNCT
aiua-9892	72	1	biochemical	biochemical	ADJ
aiua-9892	72	2	progression	progression	NOUN
aiua-9892	72	3	based	base	VERB
aiua-9892	72	4	on	on	ADP
aiua-9892	72	5	administered	administer	VERB
aiua-9892	72	6	drug	drug	NOUN
aiua-9892	72	7	.	.	PUNCT
aiua-9892	73	1	figure	figure	NOUN
aiua-9892	73	2	2	2	NUM
aiua-9892	73	3	.	.	PUNCT
aiua-9892	73	4	radiological	radiological	ADJ
aiua-9892	73	5	progression	progression	NOUN
aiua-9892	73	6	based	base	VERB
aiua-9892	73	7	on	on	ADP
aiua-9892	73	8	administered	administer	VERB
aiua-9892	73	9	drug	drug	NOUN
aiua-9892	73	10	.	.	PUNCT
aiua-9892	74	1	archivio	archivio	NOUN
aiua-9892	74	2	italiano	italiano	PROPN
aiua-9892	74	3	di	di	X
aiua-9892	74	4	urologia	urologia	PROPN
aiua-9892	74	5	e	e	PROPN
aiua-9892	74	6	andrologia	andrologia	NOUN
aiua-9892	74	7	2021	2021	NUM
aiua-9892	74	8	;	;	PUNCT
aiua-9892	74	9	93	93	NUM
aiua-9892	74	10	,	,	PUNCT
aiua-9892	74	11	4	4	NUM
aiua-9892	74	12	r.	r.	NOUN
aiua-9892	74	13	saldanha	saldanha	NOUN
aiua-9892	74	14	jarimba	jarimba	NOUN
aiua-9892	74	15	,	,	PUNCT
aiua-9892	74	16	m.	m.	NOUN
aiua-9892	74	17	nobre	nobre	PROPN
aiua-9892	74	18	eliseu	eliseu	PROPN
aiua-9892	74	19	,	,	PUNCT
aiua-9892	74	20	j.	j.	PROPN
aiua-9892	74	21	pedroso	pedroso	PROPN
aiua-9892	74	22	lima	lima	PROPN
aiua-9892	74	23	,	,	PUNCT
aiua-9892	74	24	et	et	PROPN
aiua-9892	74	25	al	al	PROPN
aiua-9892	74	26	.	.	PROPN
aiua-9892	74	27	396	396	NUM
aiua-9892	74	28	radiological	radiological	ADJ
aiua-9892	74	29	progression	progression	NOUN
aiua-9892	74	30	overall	overall	ADJ
aiua-9892	74	31	,	,	PUNCT
aiua-9892	74	32	in	in	ADP
aiua-9892	74	33	the	the	DET
aiua-9892	74	34	mcrpc	mcrpc	PROPN
aiua-9892	74	35	group	group	NOUN
aiua-9892	74	36	the	the	DET
aiua-9892	74	37	rpfs	rpf	NOUN
aiua-9892	74	38	in	in	ADP
aiua-9892	74	39	patients	patient	NOUN
aiua-9892	74	40	submitted	submit	VERB
aiua-9892	74	41	to	to	AUX
aiua-9892	74	42	enzalutamide	enzalutamide	VERB
aiua-9892	74	43	was	be	AUX
aiua-9892	74	44	41.2	41.2	NUM
aiua-9892	74	45	months	month	NOUN
aiua-9892	74	46	vs	vs	ADP
aiua-9892	74	47	28.57	28.57	NUM
aiua-9892	74	48	months	month	NOUN
aiua-9892	74	49	in	in	ADP
aiua-9892	74	50	the	the	DET
aiua-9892	74	51	abiraterone	abiraterone	NOUN
aiua-9892	74	52	group	group	NOUN
aiua-9892	74	53	,	,	PUNCT
aiua-9892	74	54	but	but	CCONJ
aiua-9892	74	55	with	with	ADP
aiua-9892	74	56	no	no	DET
aiua-9892	74	57	statistical	statistical	ADJ
aiua-9892	74	58	significance	significance	NOUN
aiua-9892	74	59	(	(	PUNCT
aiua-9892	74	60	p	p	X
aiua-9892	74	61	=	=	NOUN
aiua-9892	74	62	0.363	0.363	NUM
aiua-9892	74	63	)	)	PUNCT
aiua-9892	74	64	.	.	PUNCT
aiua-9892	75	1	the	the	DET
aiua-9892	75	2	kaplan	kaplan	PROPN
aiua-9892	75	3	-	-	PUNCT
aiua-9892	75	4	meier	meier	PROPN
aiua-9892	75	5	curves	curve	NOUN
aiua-9892	75	6	for	for	ADP
aiua-9892	75	7	rpfs	rpf	NOUN
aiua-9892	75	8	are	be	AUX
aiua-9892	75	9	showed	show	VERB
aiua-9892	75	10	in	in	ADP
aiua-9892	75	11	the	the	DET
aiua-9892	75	12	figure	figure	NOUN
aiua-9892	75	13	2	2	NUM
aiua-9892	75	14	.	.	PUNCT
aiua-9892	76	1	among	among	ADP
aiua-9892	76	2	biochemical	biochemical	ADJ
aiua-9892	76	3	responders	responder	NOUN
aiua-9892	76	4	,	,	PUNCT
aiua-9892	76	5	patients	patient	NOUN
aiua-9892	76	6	submitted	submit	VERB
aiua-9892	76	7	to	to	ADP
aiua-9892	76	8	abiraterone	abiraterone	NOUN
aiua-9892	76	9	had	have	VERB
aiua-9892	76	10	a	a	DET
aiua-9892	76	11	rpfs	rpf	NOUN
aiua-9892	76	12	of	of	ADP
aiua-9892	76	13	32.2	32.2	NUM
aiua-9892	76	14	months	month	NOUN
aiua-9892	76	15	and	and	CCONJ
aiua-9892	76	16	patients	patient	NOUN
aiua-9892	76	17	treated	treat	VERB
aiua-9892	76	18	with	with	ADP
aiua-9892	76	19	enzalutamide	enzalutamide	NOUN
aiua-9892	76	20	had	have	VERB
aiua-9892	76	21	a	a	DET
aiua-9892	76	22	rpfs	rpf	NOUN
aiua-9892	76	23	of	of	ADP
aiua-9892	76	24	29.34	29.34	NUM
aiua-9892	76	25	months	month	NOUN
aiua-9892	76	26	.	.	PUNCT
aiua-9892	77	1	no	no	DET
aiua-9892	77	2	statistically	statistically	ADV
aiua-9892	77	3	significant	significant	ADJ
aiua-9892	77	4	differences	difference	NOUN
aiua-9892	77	5	was	be	AUX
aiua-9892	77	6	achieved	achieve	VERB
aiua-9892	77	7	(	(	PUNCT
aiua-9892	77	8	p	p	X
aiua-9892	77	9	=	=	NOUN
aiua-9892	77	10	0.791	0.791	NUM
aiua-9892	77	11	)	)	PUNCT
aiua-9892	77	12	.	.	PUNCT
aiua-9892	78	1	no	no	DET
aiua-9892	78	2	covariate	covariate	ADJ
aiua-9892	78	3	factor	factor	NOUN
aiua-9892	78	4	was	be	AUX
aiua-9892	78	5	identified	identify	VERB
aiua-9892	78	6	as	as	ADP
aiua-9892	78	7	predictor	predictor	NOUN
aiua-9892	78	8	of	of	ADP
aiua-9892	78	9	rpfs	rpf	NOUN
aiua-9892	78	10	in	in	ADP
aiua-9892	78	11	multivariate	multivariate	NOUN
aiua-9892	78	12	analysis	analysis	NOUN
aiua-9892	78	13	.	.	PUNCT
aiua-9892	79	1	overall	overall	ADJ
aiua-9892	79	2	survival	survival	NOUN
aiua-9892	79	3	all	all	PRON
aiua-9892	79	4	cause	cause	VERB
aiua-9892	79	5	time	time	NOUN
aiua-9892	79	6	-	-	PUNCT
aiua-9892	79	7	to	to	ADP
aiua-9892	79	8	-	-	PUNCT
aiua-9892	79	9	death	death	NOUN
aiua-9892	79	10	,	,	PUNCT
aiua-9892	79	11	in	in	ADP
aiua-9892	79	12	mcrpc	mcrpc	NOUN
aiua-9892	79	13	patients	patient	NOUN
aiua-9892	79	14	,	,	PUNCT
aiua-9892	79	15	was	be	AUX
aiua-9892	79	16	37.5	37.5	NUM
aiua-9892	79	17	months	month	NOUN
aiua-9892	79	18	in	in	ADP
aiua-9892	79	19	enzalutamide	enzalutamide	ADJ
aiua-9892	79	20	group	group	NOUN
aiua-9892	79	21	and	and	CCONJ
aiua-9892	79	22	26	26	NUM
aiua-9892	79	23	months	month	NOUN
aiua-9892	79	24	in	in	ADP
aiua-9892	79	25	abiraterone	abiraterone	NOUN
aiua-9892	79	26	group	group	NOUN
aiua-9892	79	27	,	,	PUNCT
aiua-9892	79	28	without	without	ADP
aiua-9892	79	29	achieving	achieve	VERB
aiua-9892	79	30	a	a	DET
aiua-9892	79	31	statistically	statistically	ADV
aiua-9892	79	32	significant	significant	ADJ
aiua-9892	79	33	difference	difference	NOUN
aiua-9892	79	34	(	(	PUNCT
aiua-9892	79	35	p	p	NOUN
aiua-9892	79	36	=	=	NOUN
aiua-9892	79	37	0.277	0.277	NUM
aiua-9892	79	38	)	)	PUNCT
aiua-9892	79	39	.	.	PUNCT
aiua-9892	80	1	the	the	DET
aiua-9892	80	2	kaplan	kaplan	PROPN
aiua-9892	80	3	-	-	PUNCT
aiua-9892	80	4	meier	meier	PROPN
aiua-9892	80	5	curves	curve	NOUN
aiua-9892	80	6	for	for	ADP
aiua-9892	80	7	overall	overall	ADJ
aiua-9892	80	8	survival	survival	NOUN
aiua-9892	80	9	(	(	PUNCT
aiua-9892	80	10	os	os	NOUN
aiua-9892	80	11	)	)	PUNCT
aiua-9892	80	12	are	be	AUX
aiua-9892	80	13	showed	show	VERB
aiua-9892	80	14	in	in	ADP
aiua-9892	80	15	the	the	DET
aiua-9892	80	16	figure	figure	NOUN
aiua-9892	80	17	3	3	X
aiua-9892	80	18	.	.	PUNCT
aiua-9892	81	1	in	in	ADP
aiua-9892	81	2	patients	patient	NOUN
aiua-9892	81	3	in	in	ADP
aiua-9892	81	4	whom	whom	PRON
aiua-9892	81	5	biochemical	biochemical	ADJ
aiua-9892	81	6	response	response	NOUN
aiua-9892	81	7	was	be	AUX
aiua-9892	81	8	achieved	achieve	VERB
aiua-9892	81	9	,	,	PUNCT
aiua-9892	81	10	the	the	DET
aiua-9892	81	11	abiraterone	abiraterone	NOUN
aiua-9892	81	12	group	group	NOUN
aiua-9892	81	13	had	have	VERB
aiua-9892	81	14	a	a	DET
aiua-9892	81	15	os	os	NOUN
aiua-9892	81	16	of	of	ADP
aiua-9892	81	17	31.27	31.27	NUM
aiua-9892	81	18	months	month	NOUN
aiua-9892	81	19	vs	vs	ADP
aiua-9892	81	20	27.30	27.30	NUM
aiua-9892	81	21	months	month	NOUN
aiua-9892	81	22	in	in	ADP
aiua-9892	81	23	the	the	DET
aiua-9892	81	24	enzalutamide	enzalutamide	ADJ
aiua-9892	81	25	group	group	NOUN
aiua-9892	81	26	,	,	PUNCT
aiua-9892	81	27	but	but	CCONJ
aiua-9892	81	28	without	without	ADP
aiua-9892	81	29	statistically	statistically	ADV
aiua-9892	81	30	significant	significant	ADJ
aiua-9892	81	31	difference	difference	NOUN
aiua-9892	81	32	(	(	PUNCT
aiua-9892	81	33	p	p	NOUN
aiua-9892	81	34	=	=	NOUN
aiua-9892	81	35	0.994	0.994	NUM
aiua-9892	81	36	)	)	PUNCT
aiua-9892	81	37	.	.	PUNCT
aiua-9892	82	1	in	in	ADP
aiua-9892	82	2	patients	patient	NOUN
aiua-9892	82	3	that	that	PRON
aiua-9892	82	4	failed	fail	VERB
aiua-9892	82	5	to	to	PART
aiua-9892	82	6	meet	meet	VERB
aiua-9892	82	7	biochemical	biochemical	ADJ
aiua-9892	82	8	response	response	NOUN
aiua-9892	82	9	criteria	criterion	NOUN
aiua-9892	82	10	,	,	PUNCT
aiua-9892	82	11	os	os	PROPN
aiua-9892	82	12	was	be	AUX
aiua-9892	82	13	31.15	31.15	NUM
aiua-9892	82	14	months	month	NOUN
aiua-9892	82	15	and	and	CCONJ
aiua-9892	82	16	17.58	17.58	NUM
aiua-9892	82	17	months	month	NOUN
aiua-9892	82	18	in	in	ADP
aiua-9892	82	19	enzalutamide	enzalutamide	NOUN
aiua-9892	82	20	and	and	CCONJ
aiua-9892	82	21	abiraterone	abiraterone	NOUN
aiua-9892	82	22	group	group	NOUN
aiua-9892	82	23	,	,	PUNCT
aiua-9892	82	24	respectively	respectively	ADV
aiua-9892	82	25	.	.	PUNCT
aiua-9892	83	1	a	a	DET
aiua-9892	83	2	statistically	statistically	ADV
aiua-9892	83	3	significant	significant	ADJ
aiua-9892	83	4	difference	difference	NOUN
aiua-9892	83	5	was	be	AUX
aiua-9892	83	6	not	not	PART
aiua-9892	83	7	achieved	achieve	VERB
aiua-9892	83	8	(	(	PUNCT
aiua-9892	83	9	31.18	31.18	NUM
aiua-9892	83	10	vs	vs	ADP
aiua-9892	83	11	17.58	17.58	NUM
aiua-9892	83	12	,	,	PUNCT
aiua-9892	83	13	p	p	X
aiua-9892	83	14	=	=	NOUN
aiua-9892	83	15	0.121	0.121	NUM
aiua-9892	83	16	)	)	PUNCT
aiua-9892	83	17	.	.	PUNCT
aiua-9892	84	1	no	no	DET
aiua-9892	84	2	covariate	covariate	ADJ
aiua-9892	84	3	factor	factor	NOUN
aiua-9892	84	4	was	be	AUX
aiua-9892	84	5	identified	identify	VERB
aiua-9892	84	6	as	as	ADP
aiua-9892	84	7	predictor	predictor	NOUN
aiua-9892	84	8	of	of	ADP
aiua-9892	84	9	os	os	NOUN
aiua-9892	84	10	in	in	ADP
aiua-9892	84	11	multivariate	multivariate	NOUN
aiua-9892	84	12	analysis	analysis	NOUN
aiua-9892	84	13	.	.	PUNCT
aiua-9892	85	1	aes	aes	PROPN
aiua-9892	85	2	associated	associate	VERB
aiua-9892	85	3	with	with	ADP
aiua-9892	85	4	treatment	treatment	NOUN
aiua-9892	85	5	with	with	ADP
aiua-9892	85	6	abiraterone	abiraterone	NOUN
aiua-9892	85	7	or	or	CCONJ
aiua-9892	85	8	enzalutamide	enzalutamide	NOUN
aiua-9892	85	9	overall	overall	ADJ
aiua-9892	85	10	,	,	PUNCT
aiua-9892	85	11	14	14	NUM
aiua-9892	85	12	patients	patient	NOUN
aiua-9892	85	13	(	(	PUNCT
aiua-9892	85	14	14.4	14.4	NUM
aiua-9892	85	15	%	%	NOUN
aiua-9892	85	16	)	)	PUNCT
aiua-9892	85	17	experienced	experience	VERB
aiua-9892	85	18	drug	drug	NOUN
aiua-9892	85	19	-	-	PUNCT
aiua-9892	85	20	related	relate	VERB
aiua-9892	85	21	adverse	adverse	ADJ
aiua-9892	85	22	events	event	NOUN
aiua-9892	85	23	(	(	PUNCT
aiua-9892	85	24	aes	aes	NOUN
aiua-9892	85	25	)	)	PUNCT
aiua-9892	85	26	,	,	PUNCT
aiua-9892	85	27	10	10	NUM
aiua-9892	85	28	(	(	PUNCT
aiua-9892	85	29	16.1	16.1	NUM
aiua-9892	85	30	%	%	NOUN
aiua-9892	85	31	)	)	PUNCT
aiua-9892	85	32	in	in	ADP
aiua-9892	85	33	abiraterone	abiraterone	NOUN
aiua-9892	85	34	group	group	NOUN
aiua-9892	85	35	and	and	CCONJ
aiua-9892	85	36	4	4	NUM
aiua-9892	85	37	(	(	PUNCT
aiua-9892	85	38	11.4	11.4	NUM
aiua-9892	85	39	%	%	NOUN
aiua-9892	85	40	)	)	PUNCT
aiua-9892	85	41	in	in	ADP
aiua-9892	85	42	enzalutamide	enzalutamide	ADJ
aiua-9892	85	43	group	group	NOUN
aiua-9892	85	44	.	.	PUNCT
aiua-9892	86	1	the	the	DET
aiua-9892	86	2	common	common	ADJ
aiua-9892	86	3	aes	aes	PROPN
aiua-9892	86	4	that	that	PRON
aiua-9892	86	5	occurred	occur	VERB
aiua-9892	86	6	in	in	ADP
aiua-9892	86	7	this	this	DET
aiua-9892	86	8	series	series	NOUN
aiua-9892	86	9	were	be	AUX
aiua-9892	86	10	as	as	SCONJ
aiua-9892	86	11	follows	follow	VERB
aiua-9892	86	12	:	:	PUNCT
aiua-9892	86	13	fatigue	fatigue	NOUN
aiua-9892	86	14	(	(	PUNCT
aiua-9892	86	15	60	60	NUM
aiua-9892	86	16	%	%	NOUN
aiua-9892	86	17	)	)	PUNCT
aiua-9892	86	18	and	and	CCONJ
aiua-9892	86	19	diarrhea	diarrhea	NOUN
aiua-9892	86	20	(	(	PUNCT
aiua-9892	86	21	20	20	NUM
aiua-9892	86	22	%	%	NOUN
aiua-9892	86	23	)	)	PUNCT
aiua-9892	86	24	in	in	ADP
aiua-9892	86	25	abiraterone	abiraterone	NOUN
aiua-9892	86	26	group	group	NOUN
aiua-9892	86	27	and	and	CCONJ
aiua-9892	86	28	fatigue	fatigue	NOUN
aiua-9892	86	29	(	(	PUNCT
aiua-9892	86	30	100	100	NUM
aiua-9892	86	31	%	%	NOUN
aiua-9892	86	32	)	)	PUNCT
aiua-9892	86	33	in	in	ADP
aiua-9892	86	34	enzalutamide	enzalutamide	ADJ
aiua-9892	86	35	group	group	NOUN
aiua-9892	86	36	.	.	PUNCT
aiua-9892	87	1	only	only	ADV
aiua-9892	87	2	2	2	NUM
aiua-9892	87	3	aes	aes	PROPN
aiua-9892	87	4	≥	≥	NOUN
aiua-9892	87	5	grade	grade	NOUN
aiua-9892	87	6	3	3	NUM
aiua-9892	87	7	were	be	AUX
aiua-9892	87	8	registered	register	VERB
aiua-9892	87	9	,	,	PUNCT
aiua-9892	87	10	1	1	NUM
aiua-9892	87	11	in	in	ADP
aiua-9892	87	12	each	each	DET
aiua-9892	87	13	group	group	NOUN
aiua-9892	87	14	,	,	PUNCT
aiua-9892	87	15	causing	cause	VERB
aiua-9892	87	16	the	the	DET
aiua-9892	87	17	suspension	suspension	NOUN
aiua-9892	87	18	of	of	ADP
aiua-9892	87	19	the	the	DET
aiua-9892	87	20	drug	drug	NOUN
aiua-9892	87	21	.	.	PUNCT
aiua-9892	88	1	discussion	discussion	NOUN
aiua-9892	88	2	novel	novel	NOUN
aiua-9892	88	3	hormonal	hormonal	ADJ
aiua-9892	88	4	agents	agent	NOUN
aiua-9892	88	5	are	be	AUX
aiua-9892	88	6	now	now	ADV
aiua-9892	88	7	a	a	DET
aiua-9892	88	8	cornerstone	cornerstone	NOUN
aiua-9892	88	9	in	in	ADP
aiua-9892	88	10	the	the	DET
aiua-9892	88	11	treatment	treatment	NOUN
aiua-9892	88	12	of	of	ADP
aiua-9892	88	13	castration	castration	NOUN
aiua-9892	88	14	-	-	PUNCT
aiua-9892	88	15	resistant	resistant	ADJ
aiua-9892	88	16	prostate	prostate	NOUN
aiua-9892	88	17	cancer	cancer	NOUN
aiua-9892	88	18	.	.	PUNCT
aiua-9892	89	1	both	both	PRON
aiua-9892	89	2	enzalutamide	enzalutamide	ADV
aiua-9892	89	3	and	and	CCONJ
aiua-9892	89	4	abiraterone	abiraterone	NOUN
aiua-9892	89	5	with	with	ADP
aiua-9892	89	6	prednisolone	prednisolone	PROPN
aiua-9892	89	7	are	be	AUX
aiua-9892	89	8	approved	approve	VERB
aiua-9892	89	9	therapies	therapy	NOUN
aiua-9892	89	10	for	for	ADP
aiua-9892	89	11	men	man	NOUN
aiua-9892	89	12	with	with	ADP
aiua-9892	89	13	mcrpc	mcrpc	NOUN
aiua-9892	89	14	.	.	PUNCT
aiua-9892	90	1	these	these	DET
aiua-9892	90	2	two	two	NUM
aiua-9892	90	3	drugs	drug	NOUN
aiua-9892	90	4	have	have	AUX
aiua-9892	90	5	shown	show	VERB
aiua-9892	90	6	clinical	clinical	ADJ
aiua-9892	90	7	efficacy	efficacy	NOUN
aiua-9892	90	8	in	in	ADP
aiua-9892	90	9	multicenter	multicenter	ADJ
aiua-9892	90	10	phase	phase	NOUN
aiua-9892	90	11	iii	iii	NUM
aiua-9892	90	12	rcts	rct	NOUN
aiua-9892	90	13	(	(	PUNCT
aiua-9892	90	14	1	1	NUM
aiua-9892	90	15	-	-	SYM
aiua-9892	90	16	4	4	NUM
aiua-9892	90	17	)	)	PUNCT
aiua-9892	90	18	,	,	PUNCT
aiua-9892	90	19	yet	yet	CCONJ
aiua-9892	90	20	there	there	PRON
aiua-9892	90	21	is	be	VERB
aiua-9892	90	22	a	a	DET
aiua-9892	90	23	lack	lack	NOUN
aiua-9892	90	24	of	of	ADP
aiua-9892	90	25	evidence	evidence	NOUN
aiua-9892	90	26	regarding	regard	VERB
aiua-9892	90	27	comparative	comparative	ADJ
aiua-9892	90	28	outcomes	outcome	NOUN
aiua-9892	90	29	of	of	ADP
aiua-9892	90	30	men	man	NOUN
aiua-9892	90	31	submitted	submit	VERB
aiua-9892	90	32	to	to	ADP
aiua-9892	90	33	treatment	treatment	NOUN
aiua-9892	90	34	with	with	ADP
aiua-9892	90	35	either	either	PRON
aiua-9892	90	36	of	of	ADP
aiua-9892	90	37	the	the	DET
aiua-9892	90	38	two	two	NUM
aiua-9892	90	39	drugs	drug	NOUN
aiua-9892	90	40	.	.	PUNCT
aiua-9892	91	1	findings	finding	NOUN
aiua-9892	91	2	from	from	ADP
aiua-9892	91	3	previous	previous	ADJ
aiua-9892	91	4	retrospective	retrospective	ADJ
aiua-9892	91	5	studies	study	NOUN
aiua-9892	91	6	suggest	suggest	VERB
aiua-9892	91	7	survival	survival	NOUN
aiua-9892	91	8	advantages	advantage	NOUN
aiua-9892	91	9	toward	toward	ADP
aiua-9892	91	10	enzalutamide	enzalutamide	ADV
aiua-9892	91	11	compared	compare	VERB
aiua-9892	91	12	with	with	ADP
aiua-9892	91	13	abiraterone	abiraterone	NOUN
aiua-9892	91	14	and	and	CCONJ
aiua-9892	91	15	prednisolone	prednisolone	NOUN
aiua-9892	91	16	in	in	ADP
aiua-9892	91	17	the	the	DET
aiua-9892	91	18	treatment	treatment	NOUN
aiua-9892	91	19	of	of	ADP
aiua-9892	91	20	men	man	NOUN
aiua-9892	91	21	with	with	ADP
aiua-9892	91	22	mcrpc	mcrpc	NOUN
aiua-9892	91	23	(	(	PUNCT
aiua-9892	91	24	5	5	NUM
aiua-9892	91	25	)	)	PUNCT
aiua-9892	91	26	,	,	PUNCT
aiua-9892	91	27	although	although	SCONJ
aiua-9892	91	28	both	both	DET
aiua-9892	91	29	drugs	drug	NOUN
aiua-9892	91	30	were	be	AUX
aiua-9892	91	31	effective	effective	ADJ
aiua-9892	91	32	,	,	PUNCT
aiua-9892	91	33	with	with	ADP
aiua-9892	91	34	psa	psa	NOUN
aiua-9892	91	35	rate	rate	NOUN
aiua-9892	91	36	response	response	NOUN
aiua-9892	91	37	over	over	ADP
aiua-9892	91	38	50	50	NUM
aiua-9892	91	39	%	%	NOUN
aiua-9892	91	40	.	.	PUNCT
aiua-9892	92	1	our	our	PRON
aiua-9892	92	2	analysis	analysis	NOUN
aiua-9892	92	3	is	be	AUX
aiua-9892	92	4	consistent	consistent	ADJ
aiua-9892	92	5	with	with	ADP
aiua-9892	92	6	prior	prior	ADJ
aiua-9892	92	7	data	datum	NOUN
aiua-9892	92	8	for	for	ADP
aiua-9892	92	9	better	well	ADJ
aiua-9892	92	10	biochemical	biochemical	ADJ
aiua-9892	92	11	response	response	NOUN
aiua-9892	92	12	with	with	ADP
aiua-9892	92	13	enzalutamide	enzalutamide	NOUN
aiua-9892	92	14	in	in	ADP
aiua-9892	92	15	men	man	NOUN
aiua-9892	92	16	with	with	ADP
aiua-9892	92	17	mcrpc	mcrpc	NOUN
aiua-9892	92	18	.	.	PUNCT
aiua-9892	93	1	we	we	PRON
aiua-9892	93	2	found	find	VERB
aiua-9892	93	3	that	that	SCONJ
aiua-9892	93	4	patients	patient	NOUN
aiua-9892	93	5	in	in	ADP
aiua-9892	93	6	the	the	DET
aiua-9892	93	7	enzalutamide	enzalutamide	ADJ
aiua-9892	93	8	group	group	NOUN
aiua-9892	93	9	had	have	VERB
aiua-9892	93	10	a	a	DET
aiua-9892	93	11	significantly	significantly	ADV
aiua-9892	93	12	higher	high	ADJ
aiua-9892	93	13	biochemical	biochemical	ADJ
aiua-9892	93	14	response	response	NOUN
aiua-9892	93	15	than	than	ADP
aiua-9892	93	16	the	the	DET
aiua-9892	93	17	abiraterone	abiraterone	NOUN
aiua-9892	93	18	group	group	NOUN
aiua-9892	93	19	,	,	PUNCT
aiua-9892	93	20	with	with	ADP
aiua-9892	93	21	a	a	DET
aiua-9892	93	22	rate	rate	NOUN
aiua-9892	93	23	response	response	NOUN
aiua-9892	93	24	of	of	ADP
aiua-9892	93	25	51.8	51.8	NUM
aiua-9892	93	26	%	%	NOUN
aiua-9892	93	27	and	and	CCONJ
aiua-9892	93	28	77.1	77.1	NUM
aiua-9892	93	29	%	%	NOUN
aiua-9892	93	30	,	,	PUNCT
aiua-9892	93	31	respectively	respectively	ADV
aiua-9892	93	32	(	(	PUNCT
aiua-9892	93	33	p	p	X
aiua-9892	93	34	=	=	NOUN
aiua-9892	93	35	0.016	0.016	NUM
aiua-9892	93	36	)	)	PUNCT
aiua-9892	93	37	.	.	PUNCT
aiua-9892	94	1	this	this	PRON
aiua-9892	94	2	seems	seem	VERB
aiua-9892	94	3	particularly	particularly	ADV
aiua-9892	94	4	relevant	relevant	ADJ
aiua-9892	94	5	in	in	ADP
aiua-9892	94	6	patients	patient	NOUN
aiua-9892	94	7	previously	previously	ADV
aiua-9892	94	8	submitted	submit	VERB
aiua-9892	94	9	to	to	ADP
aiua-9892	94	10	taxane	taxane	NOUN
aiua-9892	94	11	-	-	PUNCT
aiua-9892	94	12	based	base	VERB
aiua-9892	94	13	chemotherapy	chemotherapy	NOUN
aiua-9892	94	14	.	.	PUNCT
aiua-9892	95	1	in	in	ADP
aiua-9892	95	2	a	a	DET
aiua-9892	95	3	multivariate	multivariate	NOUN
aiua-9892	95	4	analysis	analysis	NOUN
aiua-9892	95	5	,	,	PUNCT
aiua-9892	95	6	enzalutamide	enzalutamide	ADV
aiua-9892	95	7	was	be	AUX
aiua-9892	95	8	associated	associate	VERB
aiua-9892	95	9	with	with	ADP
aiua-9892	95	10	a	a	DET
aiua-9892	95	11	higher	high	ADJ
aiua-9892	95	12	probability	probability	NOUN
aiua-9892	95	13	of	of	ADP
aiua-9892	95	14	rate	rate	NOUN
aiua-9892	95	15	response	response	NOUN
aiua-9892	95	16	compared	compare	VERB
aiua-9892	95	17	with	with	ADP
aiua-9892	95	18	abiraterone	abiraterone	NOUN
aiua-9892	95	19	(	(	PUNCT
aiua-9892	95	20	or	or	CCONJ
aiua-9892	95	21	:	:	PUNCT
aiua-9892	95	22	3.485	3.485	NUM
aiua-9892	95	23	,	,	PUNCT
aiua-9892	95	24	p	p	X
aiua-9892	95	25	=	=	PROPN
aiua-9892	95	26	0.021	0.021	NUM
aiua-9892	95	27	)	)	PUNCT
aiua-9892	95	28	.	.	PUNCT
aiua-9892	96	1	biochemical	biochemical	ADJ
aiua-9892	96	2	response	response	NOUN
aiua-9892	96	3	was	be	AUX
aiua-9892	96	4	associated	associate	VERB
aiua-9892	96	5	with	with	ADP
aiua-9892	96	6	a	a	DET
aiua-9892	96	7	lower	low	ADJ
aiua-9892	96	8	probability	probability	NOUN
aiua-9892	96	9	of	of	ADP
aiua-9892	96	10	biochemical	biochemical	ADJ
aiua-9892	96	11	progression	progression	NOUN
aiua-9892	96	12	(	(	PUNCT
aiua-9892	96	13	or	or	CCONJ
aiua-9892	96	14	:	:	PUNCT
aiua-9892	96	15	0.248	0.248	NUM
aiua-9892	96	16	,	,	PUNCT
aiua-9892	96	17	p	p	X
aiua-9892	96	18	=	=	NOUN
aiua-9892	96	19	0.017	0.017	NUM
aiua-9892	96	20	)	)	PUNCT
aiua-9892	96	21	and	and	CCONJ
aiua-9892	96	22	death	death	NOUN
aiua-9892	96	23	(	(	PUNCT
aiua-9892	96	24	or	or	CCONJ
aiua-9892	96	25	:	:	PUNCT
aiua-9892	96	26	0.302	0.302	NUM
aiua-9892	96	27	,	,	PUNCT
aiua-9892	96	28	p	p	X
aiua-9892	96	29	=	=	NOUN
aiua-9892	96	30	0.038	0.038	NUM
aiua-9892	96	31	)	)	PUNCT
aiua-9892	96	32	.	.	PUNCT
aiua-9892	97	1	this	this	DET
aiua-9892	97	2	data	data	NOUN
aiua-9892	97	3	suggests	suggest	VERB
aiua-9892	97	4	that	that	SCONJ
aiua-9892	97	5	the	the	DET
aiua-9892	97	6	higher	high	ADJ
aiua-9892	97	7	rate	rate	NOUN
aiua-9892	97	8	of	of	ADP
aiua-9892	97	9	biochemical	biochemical	ADJ
aiua-9892	97	10	response	response	NOUN
aiua-9892	97	11	of	of	ADP
aiua-9892	97	12	enzalutamide	enzalutamide	NOUN
aiua-9892	97	13	is	be	AUX
aiua-9892	97	14	associated	associate	VERB
aiua-9892	97	15	with	with	ADP
aiua-9892	97	16	better	well	ADJ
aiua-9892	97	17	outcomes	outcome	NOUN
aiua-9892	97	18	.	.	PUNCT
aiua-9892	98	1	respective	respective	ADJ
aiua-9892	98	2	to	to	ADP
aiua-9892	98	3	other	other	ADJ
aiua-9892	98	4	endpoints	endpoint	NOUN
aiua-9892	98	5	(	(	PUNCT
aiua-9892	98	6	biochemical	biochemical	ADJ
aiua-9892	98	7	progression	progression	NOUN
aiua-9892	98	8	,	,	PUNCT
aiua-9892	98	9	radiological	radiological	ADJ
aiua-9892	98	10	progression	progression	NOUN
aiua-9892	98	11	,	,	PUNCT
aiua-9892	98	12	and	and	CCONJ
aiua-9892	98	13	overall	overall	ADJ
aiua-9892	98	14	survival	survival	NOUN
aiua-9892	98	15	)	)	PUNCT
aiua-9892	98	16	,	,	PUNCT
aiua-9892	98	17	there	there	PRON
aiua-9892	98	18	was	be	VERB
aiua-9892	98	19	a	a	DET
aiua-9892	98	20	trend	trend	NOUN
aiua-9892	98	21	toward	toward	ADP
aiua-9892	98	22	advantage	advantage	NOUN
aiua-9892	98	23	of	of	ADP
aiua-9892	98	24	enzalutamide	enzalutamide	NOUN
aiua-9892	98	25	over	over	ADP
aiua-9892	98	26	abiraterone	abiraterone	NOUN
aiua-9892	98	27	with	with	ADP
aiua-9892	98	28	no	no	DET
aiua-9892	98	29	statistical	statistical	ADJ
aiua-9892	98	30	significance	significance	NOUN
aiua-9892	98	31	.	.	PUNCT
aiua-9892	99	1	data	datum	NOUN
aiua-9892	99	2	showed	show	VERB
aiua-9892	99	3	that	that	SCONJ
aiua-9892	99	4	in	in	ADP
aiua-9892	99	5	patients	patient	NOUN
aiua-9892	99	6	who	who	PRON
aiua-9892	99	7	achieved	achieve	VERB
aiua-9892	99	8	biochemical	biochemical	ADJ
aiua-9892	99	9	response	response	NOUN
aiua-9892	99	10	,	,	PUNCT
aiua-9892	99	11	the	the	DET
aiua-9892	99	12	apparent	apparent	ADJ
aiua-9892	99	13	advantage	advantage	NOUN
aiua-9892	99	14	of	of	ADP
aiua-9892	99	15	enzalutamide	enzalutamide	NOUN
aiua-9892	99	16	over	over	ADP
aiua-9892	99	17	abiraterone	abiraterone	NOUN
aiua-9892	99	18	disappears	disappear	VERB
aiua-9892	99	19	.	.	PUNCT
aiua-9892	100	1	patients	patient	NOUN
aiua-9892	100	2	who	who	PRON
aiua-9892	100	3	did	do	AUX
aiua-9892	100	4	not	not	PART
aiua-9892	100	5	achieve	achieve	VERB
aiua-9892	100	6	a	a	DET
aiua-9892	100	7	biochemical	biochemical	ADJ
aiua-9892	100	8	response	response	NOUN
aiua-9892	100	9	had	have	VERB
aiua-9892	100	10	a	a	DET
aiua-9892	100	11	trend	trend	NOUN
aiua-9892	100	12	to	to	ADP
aiua-9892	100	13	longer	long	ADJ
aiua-9892	100	14	survival	survival	VERB
aiua-9892	100	15	when	when	SCONJ
aiua-9892	100	16	treated	treat	VERB
aiua-9892	100	17	to	to	PART
aiua-9892	100	18	enzalutamide	enzalutamide	ADP
aiua-9892	100	19	vs	vs	ADP
aiua-9892	100	20	abiraterone	abiraterone	NOUN
aiua-9892	100	21	,	,	PUNCT
aiua-9892	100	22	albeit	albeit	SCONJ
aiua-9892	100	23	not	not	PART
aiua-9892	100	24	statistically	statistically	ADV
aiua-9892	100	25	different	different	ADJ
aiua-9892	100	26	.	.	PUNCT
aiua-9892	101	1	as	as	SCONJ
aiua-9892	101	2	suggested	suggest	VERB
aiua-9892	101	3	in	in	ADP
aiua-9892	101	4	previous	previous	ADJ
aiua-9892	101	5	studies	study	NOUN
aiua-9892	101	6	(	(	PUNCT
aiua-9892	101	7	6	6	NUM
aiua-9892	101	8	,	,	PUNCT
aiua-9892	101	9	7	7	NUM
aiua-9892	101	10	)	)	PUNCT
aiua-9892	101	11	,	,	PUNCT
aiua-9892	101	12	this	this	PRON
aiua-9892	101	13	may	may	AUX
aiua-9892	101	14	support	support	VERB
aiua-9892	101	15	an	an	DET
aiua-9892	101	16	early	early	ADJ
aiua-9892	101	17	change	change	NOUN
aiua-9892	101	18	of	of	ADP
aiua-9892	101	19	therapeutical	therapeutical	ADJ
aiua-9892	101	20	strategy	strategy	NOUN
aiua-9892	101	21	when	when	SCONJ
aiua-9892	101	22	biochemical	biochemical	ADJ
aiua-9892	101	23	response	response	NOUN
aiua-9892	101	24	is	be	AUX
aiua-9892	101	25	not	not	PART
aiua-9892	101	26	achieved	achieve	VERB
aiua-9892	101	27	with	with	ADP
aiua-9892	101	28	abiraterone	abiraterone	NOUN
aiua-9892	101	29	.	.	PUNCT
aiua-9892	102	1	figure	figure	NOUN
aiua-9892	102	2	3	3	NUM
aiua-9892	102	3	.	.	PUNCT
aiua-9892	102	4	overall	overall	ADJ
aiua-9892	102	5	survival	survival	NOUN
aiua-9892	102	6	based	base	VERB
aiua-9892	102	7	on	on	ADP
aiua-9892	102	8	administered	administer	VERB
aiua-9892	102	9	drug	drug	NOUN
aiua-9892	102	10	.	.	PUNCT
aiua-9892	103	1	397archivio	397archivio	PROPN
aiua-9892	103	2	italiano	italiano	NOUN
aiua-9892	103	3	di	di	NOUN
aiua-9892	103	4	urologia	urologia	PROPN
aiua-9892	103	5	e	e	PROPN
aiua-9892	103	6	andrologia	andrologia	NOUN
aiua-9892	103	7	2021	2021	NUM
aiua-9892	103	8	;	;	PUNCT
aiua-9892	103	9	93	93	NUM
aiua-9892	103	10	,	,	PUNCT
aiua-9892	103	11	4	4	NUM
aiua-9892	103	12	novel	novel	ADJ
aiua-9892	103	13	hormonal	hormonal	ADJ
aiua-9892	103	14	agents	agent	NOUN
aiua-9892	103	15	for	for	ADP
aiua-9892	103	16	metastatic	metastatic	ADJ
aiua-9892	103	17	castration	castration	NOUN
aiua-9892	103	18	-	-	PUNCT
aiua-9892	103	19	resistant	resistant	ADJ
aiua-9892	103	20	prostate	prostate	NOUN
aiua-9892	103	21	cancer	cancer	NOUN
aiua-9892	103	22	:	:	PUNCT
aiua-9892	103	23	comparing	compare	VERB
aiua-9892	103	24	outcomes	outcome	NOUN
aiua-9892	103	25	miyake	miyake	PROPN
aiua-9892	103	26	et	et	PROPN
aiua-9892	103	27	al	al	PROPN
aiua-9892	103	28	.	.	PROPN
aiua-9892	103	29	,	,	PUNCT
aiua-9892	103	30	retrospectively	retrospectively	ADV
aiua-9892	103	31	reviewed	review	VERB
aiua-9892	103	32	280	280	NUM
aiua-9892	103	33	docetaxelnaïve	docetaxelnaïve	ADJ
aiua-9892	103	34	mcrpc	mcrpc	NOUN
aiua-9892	103	35	patients	patient	NOUN
aiua-9892	103	36	.	.	PUNCT
aiua-9892	104	1	a	a	DET
aiua-9892	104	2	higher	high	ADJ
aiua-9892	104	3	psa	psa	NOUN
aiua-9892	104	4	response	response	NOUN
aiua-9892	104	5	rate	rate	NOUN
aiua-9892	104	6	for	for	ADP
aiua-9892	104	7	patients	patient	NOUN
aiua-9892	104	8	treated	treat	VERB
aiua-9892	104	9	with	with	ADP
aiua-9892	104	10	enzalutamide	enzalutamide	NOUN
aiua-9892	104	11	when	when	SCONJ
aiua-9892	104	12	compared	compare	VERB
aiua-9892	104	13	with	with	ADP
aiua-9892	104	14	abiraterone	abiraterone	NOUN
aiua-9892	104	15	(	(	PUNCT
aiua-9892	104	16	70.7	70.7	NUM
aiua-9892	104	17	%	%	NOUN
aiua-9892	104	18	vs	vs	ADP
aiua-9892	104	19	53.1	53.1	NUM
aiua-9892	104	20	%	%	NOUN
aiua-9892	104	21	)	)	PUNCT
aiua-9892	104	22	was	be	AUX
aiua-9892	104	23	found	find	VERB
aiua-9892	104	24	,	,	PUNCT
aiua-9892	104	25	in	in	ADP
aiua-9892	104	26	line	line	NOUN
aiua-9892	104	27	with	with	ADP
aiua-9892	104	28	our	our	PRON
aiua-9892	104	29	results	result	NOUN
aiua-9892	104	30	.	.	PUNCT
aiua-9892	105	1	on	on	ADP
aiua-9892	105	2	the	the	DET
aiua-9892	105	3	other	other	ADJ
aiua-9892	105	4	hand	hand	NOUN
aiua-9892	105	5	,	,	PUNCT
aiua-9892	105	6	a	a	DET
aiua-9892	105	7	better	well	ADJ
aiua-9892	105	8	bpfs	bpf	NOUN
aiua-9892	105	9	in	in	ADP
aiua-9892	105	10	enzalutamide	enzalutamide	ADJ
aiua-9892	105	11	group	group	NOUN
aiua-9892	105	12	was	be	AUX
aiua-9892	105	13	also	also	ADV
aiua-9892	105	14	found	find	VERB
aiua-9892	105	15	,	,	PUNCT
aiua-9892	105	16	which	which	PRON
aiua-9892	105	17	our	our	PRON
aiua-9892	105	18	study	study	NOUN
aiua-9892	105	19	failed	fail	VERB
aiua-9892	105	20	to	to	PART
aiua-9892	105	21	find	find	VERB
aiua-9892	105	22	.	.	PUNCT
aiua-9892	106	1	in	in	ADP
aiua-9892	106	2	this	this	DET
aiua-9892	106	3	study	study	NOUN
aiua-9892	106	4	,	,	PUNCT
aiua-9892	106	5	because	because	SCONJ
aiua-9892	106	6	of	of	ADP
aiua-9892	106	7	the	the	DET
aiua-9892	106	8	drug	drug	NOUN
aiua-9892	106	9	choice	choice	NOUN
aiua-9892	106	10	was	be	AUX
aiua-9892	106	11	at	at	ADP
aiua-9892	106	12	physician	physician	NOUN
aiua-9892	106	13	discretion	discretion	NOUN
aiua-9892	106	14	,	,	PUNCT
aiua-9892	106	15	there	there	PRON
aiua-9892	106	16	was	be	VERB
aiua-9892	106	17	a	a	DET
aiua-9892	106	18	preference	preference	NOUN
aiua-9892	106	19	of	of	ADP
aiua-9892	106	20	abiraterone	abiraterone	NOUN
aiua-9892	106	21	over	over	ADP
aiua-9892	106	22	enzalutamide	enzalutamide	ADV
aiua-9892	106	23	in	in	ADP
aiua-9892	106	24	patients	patient	NOUN
aiua-9892	106	25	with	with	ADP
aiua-9892	106	26	less	less	ADV
aiua-9892	106	27	favorable	favorable	ADJ
aiua-9892	106	28	clinicopathological	clinicopathological	ADJ
aiua-9892	106	29	features	feature	NOUN
aiua-9892	106	30	based	base	VERB
aiua-9892	106	31	in	in	ADP
aiua-9892	106	32	the	the	DET
aiua-9892	106	33	results	result	NOUN
aiua-9892	106	34	of	of	ADP
aiua-9892	106	35	cou	cou	NOUN
aiua-9892	106	36	-	-	PUNCT
aiua-9892	106	37	aa-302	aa-302	PROPN
aiua-9892	106	38	and	and	CCONJ
aiua-9892	106	39	prevail	prevail	VERB
aiua-9892	106	40	trials	trial	NOUN
aiua-9892	106	41	,	,	PUNCT
aiua-9892	106	42	respectively	respectively	ADV
aiua-9892	106	43	(	(	PUNCT
aiua-9892	106	44	8)	8)	NUM
aiua-9892	106	45	.	.	PUNCT
aiua-9892	107	1	heo	heo	PROPN
aiua-9892	107	2	et	et	PROPN
aiua-9892	107	3	al	al	PROPN
aiua-9892	107	4	.	.	PROPN
aiua-9892	107	5	performed	perform	VERB
aiua-9892	107	6	a	a	DET
aiua-9892	107	7	retrospective	retrospective	ADJ
aiua-9892	107	8	study	study	NOUN
aiua-9892	107	9	that	that	PRON
aiua-9892	107	10	evaluated	evaluate	VERB
aiua-9892	107	11	the	the	DET
aiua-9892	107	12	outcomes	outcome	NOUN
aiua-9892	107	13	of	of	ADP
aiua-9892	107	14	patients	patient	NOUN
aiua-9892	107	15	diagnosed	diagnose	VERB
aiua-9892	107	16	with	with	ADP
aiua-9892	107	17	mcrpc	mcrpc	NOUN
aiua-9892	107	18	treated	treat	VERB
aiua-9892	107	19	with	with	ADP
aiua-9892	107	20	abiraterone	abiraterone	NOUN
aiua-9892	107	21	and	and	CCONJ
aiua-9892	107	22	enzalutamide	enzalutamide	ADV
aiua-9892	107	23	in	in	ADP
aiua-9892	107	24	post	post	ADJ
aiua-9892	107	25	-	-	ADJ
aiua-9892	107	26	docetaxel	docetaxel	ADJ
aiua-9892	107	27	setting	setting	NOUN
aiua-9892	107	28	.	.	PUNCT
aiua-9892	108	1	54	54	NUM
aiua-9892	108	2	patients	patient	NOUN
aiua-9892	108	3	were	be	AUX
aiua-9892	108	4	evaluated	evaluate	VERB
aiua-9892	108	5	(	(	PUNCT
aiua-9892	108	6	25	25	NUM
aiua-9892	108	7	in	in	ADP
aiua-9892	108	8	abiraterone	abiraterone	NOUN
aiua-9892	108	9	group	group	NOUN
aiua-9892	108	10	and	and	CCONJ
aiua-9892	108	11	29	29	NUM
aiua-9892	108	12	in	in	ADP
aiua-9892	108	13	enzalutamide	enzalutamide	ADJ
aiua-9892	108	14	group	group	NOUN
aiua-9892	108	15	)	)	PUNCT
aiua-9892	108	16	and	and	CCONJ
aiua-9892	108	17	a	a	DET
aiua-9892	108	18	psa	psa	NOUN
aiua-9892	108	19	rate	rate	NOUN
aiua-9892	108	20	response	response	NOUN
aiua-9892	108	21	was	be	AUX
aiua-9892	108	22	seen	see	VERB
aiua-9892	108	23	36	36	NUM
aiua-9892	108	24	%	%	NOUN
aiua-9892	108	25	and	and	CCONJ
aiua-9892	108	26	52	52	NUM
aiua-9892	108	27	%	%	NOUN
aiua-9892	108	28	for	for	ADP
aiua-9892	108	29	abiraterone	abiraterone	NOUN
aiua-9892	108	30	and	and	CCONJ
aiua-9892	108	31	enzalutamide	enzalutamide	ADV
aiua-9892	108	32	,	,	PUNCT
aiua-9892	108	33	respectively	respectively	ADV
aiua-9892	108	34	.	.	PUNCT
aiua-9892	109	1	in	in	ADP
aiua-9892	109	2	our	our	PRON
aiua-9892	109	3	cohort	cohort	NOUN
aiua-9892	109	4	the	the	DET
aiua-9892	109	5	psa	psa	NOUN
aiua-9892	109	6	rate	rate	NOUN
aiua-9892	109	7	response	response	NOUN
aiua-9892	109	8	was	be	AUX
aiua-9892	109	9	similar	similar	ADJ
aiua-9892	109	10	for	for	ADP
aiua-9892	109	11	abiraterone	abiraterone	NOUN
aiua-9892	109	12	(	(	PUNCT
aiua-9892	109	13	40	40	NUM
aiua-9892	109	14	%	%	NOUN
aiua-9892	109	15	)	)	PUNCT
aiua-9892	109	16	,	,	PUNCT
aiua-9892	109	17	but	but	CCONJ
aiua-9892	109	18	enzalutamide	enzalutamide	ADV
aiua-9892	109	19	had	have	VERB
aiua-9892	109	20	a	a	DET
aiua-9892	109	21	higher	high	ADJ
aiua-9892	109	22	response	response	NOUN
aiua-9892	109	23	rate	rate	NOUN
aiua-9892	109	24	than	than	SCONJ
aiua-9892	109	25	reported	report	VERB
aiua-9892	109	26	in	in	ADP
aiua-9892	109	27	this	this	DET
aiua-9892	109	28	study	study	NOUN
aiua-9892	109	29	(	(	PUNCT
aiua-9892	109	30	83.3	83.3	NUM
aiua-9892	109	31	%	%	NOUN
aiua-9892	109	32	)	)	PUNCT
aiua-9892	109	33	in	in	ADP
aiua-9892	109	34	this	this	DET
aiua-9892	109	35	subset	subset	NOUN
aiua-9892	109	36	of	of	ADP
aiua-9892	109	37	patients	patient	NOUN
aiua-9892	109	38	(	(	PUNCT
aiua-9892	109	39	9	9	NUM
aiua-9892	109	40	)	)	PUNCT
aiua-9892	109	41	.	.	PUNCT
aiua-9892	110	1	both	both	DET
aiua-9892	110	2	drugs	drug	NOUN
aiua-9892	110	3	were	be	AUX
aiua-9892	110	4	well	well	ADV
aiua-9892	110	5	tolerated	tolerate	VERB
aiua-9892	110	6	,	,	PUNCT
aiua-9892	110	7	with	with	ADP
aiua-9892	110	8	low	low	ADJ
aiua-9892	110	9	incidence	incidence	NOUN
aiua-9892	110	10	of	of	ADP
aiua-9892	110	11	drug	drug	NOUN
aiua-9892	110	12	-	-	PUNCT
aiua-9892	110	13	related	relate	VERB
aiua-9892	110	14	grade	grade	NOUN
aiua-9892	110	15	≥	≥	NOUN
aiua-9892	110	16	3	3	NUM
aiua-9892	110	17	events	event	NOUN
aiua-9892	110	18	.	.	PUNCT
aiua-9892	111	1	only	only	ADV
aiua-9892	111	2	two	two	NUM
aiua-9892	111	3	patients	patient	NOUN
aiua-9892	111	4	had	have	VERB
aiua-9892	111	5	their	their	PRON
aiua-9892	111	6	treatment	treatment	NOUN
aiua-9892	111	7	suspended	suspend	VERB
aiua-9892	111	8	.	.	PUNCT
aiua-9892	112	1	the	the	DET
aiua-9892	112	2	type	type	NOUN
aiua-9892	112	3	of	of	ADP
aiua-9892	112	4	aes	aes	PROPN
aiua-9892	112	5	registered	register	VERB
aiua-9892	112	6	were	be	AUX
aiua-9892	112	7	in	in	ADP
aiua-9892	112	8	line	line	NOUN
aiua-9892	112	9	with	with	ADP
aiua-9892	112	10	ones	one	NOUN
aiua-9892	112	11	reported	report	VERB
aiua-9892	112	12	in	in	ADP
aiua-9892	112	13	cou	cou	PROPN
aiua-9892	112	14	-	-	PUNCT
aiua-9892	112	15	aa-302	aa-302	PROPN
aiua-9892	112	16	and	and	CCONJ
aiua-9892	112	17	prevail	prevail	VERB
aiua-9892	112	18	trials	trial	NOUN
aiua-9892	112	19	.	.	PUNCT
aiua-9892	113	1	norris	norris	PROPN
aiua-9892	113	2	et	et	PROPN
aiua-9892	113	3	al	al	PROPN
aiua-9892	113	4	.	.	PROPN
aiua-9892	113	5	retrospectively	retrospectively	ADV
aiua-9892	113	6	studied	study	VERB
aiua-9892	113	7	198	198	NUM
aiua-9892	113	8	mcrpc	mcrpc	NOUN
aiua-9892	113	9	patients	patient	NOUN
aiua-9892	113	10	submitted	submit	VERB
aiua-9892	113	11	to	to	ADP
aiua-9892	113	12	treatment	treatment	NOUN
aiua-9892	113	13	with	with	ADP
aiua-9892	113	14	abiraterone	abiraterone	NOUN
aiua-9892	113	15	and	and	CCONJ
aiua-9892	113	16	enzalutamide	enzalutamide	NOUN
aiua-9892	113	17	.	.	PUNCT
aiua-9892	114	1	significantly	significantly	ADV
aiua-9892	114	2	higher	high	ADJ
aiua-9892	114	3	psa	psa	NOUN
aiua-9892	114	4	response	response	NOUN
aiua-9892	114	5	rates	rate	NOUN
aiua-9892	114	6	were	be	AUX
aiua-9892	114	7	observed	observe	VERB
aiua-9892	114	8	in	in	ADP
aiua-9892	114	9	the	the	DET
aiua-9892	114	10	enzalutamide	enzalutamide	NOUN
aiua-9892	114	11	(	(	PUNCT
aiua-9892	114	12	51	51	NUM
aiua-9892	114	13	%	%	NOUN
aiua-9892	114	14	)	)	PUNCT
aiua-9892	114	15	than	than	ADP
aiua-9892	114	16	abiraterone	abiraterone	NOUN
aiua-9892	114	17	(	(	PUNCT
aiua-9892	114	18	36	36	NUM
aiua-9892	114	19	%	%	NOUN
aiua-9892	114	20	)	)	PUNCT
aiua-9892	114	21	.	.	PUNCT
aiua-9892	115	1	in	in	ADP
aiua-9892	115	2	our	our	PRON
aiua-9892	115	3	cohort	cohort	NOUN
aiua-9892	115	4	the	the	DET
aiua-9892	115	5	overall	overall	ADJ
aiua-9892	115	6	psa	psa	NOUN
aiua-9892	115	7	response	response	NOUN
aiua-9892	115	8	rate	rate	NOUN
aiua-9892	115	9	were	be	AUX
aiua-9892	115	10	higher	high	ADJ
aiua-9892	115	11	,	,	PUNCT
aiua-9892	115	12	51.8	51.8	NUM
aiua-9892	115	13	%	%	NOUN
aiua-9892	115	14	and	and	CCONJ
aiua-9892	115	15	77.1	77.1	NUM
aiua-9892	115	16	%	%	NOUN
aiua-9892	115	17	in	in	ADP
aiua-9892	115	18	abiraterone	abiraterone	NOUN
aiua-9892	115	19	and	and	CCONJ
aiua-9892	115	20	enzalutamide	enzalutamide	ADV
aiua-9892	115	21	,	,	PUNCT
aiua-9892	115	22	respectively	respectively	ADV
aiua-9892	115	23	.	.	PUNCT
aiua-9892	116	1	there	there	PRON
aiua-9892	116	2	was	be	VERB
aiua-9892	116	3	no	no	DET
aiua-9892	116	4	significant	significant	ADJ
aiua-9892	116	5	difference	difference	NOUN
aiua-9892	116	6	in	in	ADP
aiua-9892	116	7	os	os	NOUN
aiua-9892	116	8	between	between	ADP
aiua-9892	116	9	the	the	DET
aiua-9892	116	10	groups	group	NOUN
aiua-9892	116	11	with	with	ADP
aiua-9892	116	12	median	median	PROPN
aiua-9892	116	13	os	os	NOUN
aiua-9892	116	14	of	of	ADP
aiua-9892	116	15	15.3	15.3	NUM
aiua-9892	116	16	months	month	NOUN
aiua-9892	116	17	in	in	ADP
aiua-9892	116	18	abiraterone	abiraterone	NOUN
aiua-9892	116	19	group	group	NOUN
aiua-9892	116	20	versus	versus	ADP
aiua-9892	116	21	22.2	22.2	NUM
aiua-9892	116	22	months	month	NOUN
aiua-9892	116	23	in	in	ADP
aiua-9892	116	24	the	the	DET
aiua-9892	116	25	enzalutamide	enzalutamide	ADJ
aiua-9892	116	26	group	group	NOUN
aiua-9892	116	27	.	.	PUNCT
aiua-9892	117	1	the	the	DET
aiua-9892	117	2	os	os	PROPN
aiua-9892	117	3	survival	survival	NOUN
aiua-9892	117	4	in	in	ADP
aiua-9892	117	5	our	our	PRON
aiua-9892	117	6	study	study	NOUN
aiua-9892	117	7	was	be	AUX
aiua-9892	117	8	also	also	ADV
aiua-9892	117	9	higher	high	ADJ
aiua-9892	117	10	for	for	ADP
aiua-9892	117	11	enzalutamide	enzalutamide	NOUN
aiua-9892	117	12	(	(	PUNCT
aiua-9892	117	13	37.5	37.5	NUM
aiua-9892	117	14	months	month	NOUN
aiua-9892	117	15	for	for	ADP
aiua-9892	117	16	enzalutamide	enzalutamide	NOUN
aiua-9892	117	17	and	and	CCONJ
aiua-9892	117	18	27.30	27.30	NUM
aiua-9892	117	19	months	month	NOUN
aiua-9892	117	20	for	for	ADP
aiua-9892	117	21	abiraterone	abiraterone	NOUN
aiua-9892	117	22	)	)	PUNCT
aiua-9892	117	23	.	.	PUNCT
aiua-9892	118	1	these	these	DET
aiua-9892	118	2	differences	difference	NOUN
aiua-9892	118	3	can	can	AUX
aiua-9892	118	4	be	be	AUX
aiua-9892	118	5	partially	partially	ADV
aiua-9892	118	6	explained	explain	VERB
aiua-9892	118	7	by	by	ADP
aiua-9892	118	8	the	the	DET
aiua-9892	118	9	proportion	proportion	NOUN
aiua-9892	118	10	of	of	ADP
aiua-9892	118	11	patients	patient	NOUN
aiua-9892	118	12	that	that	PRON
aiua-9892	118	13	were	be	AUX
aiua-9892	118	14	treated	treat	VERB
aiua-9892	118	15	in	in	ADP
aiua-9892	118	16	post	post	ADJ
aiua-9892	118	17	-	-	ADJ
aiua-9892	118	18	docetaxel	docetaxel	NOUN
aiua-9892	118	19	setting	setting	NOUN
aiua-9892	118	20	in	in	ADP
aiua-9892	118	21	each	each	DET
aiua-9892	118	22	study	study	NOUN
aiua-9892	118	23	,	,	PUNCT
aiua-9892	118	24	being	be	AUX
aiua-9892	118	25	the	the	DET
aiua-9892	118	26	majority	majority	NOUN
aiua-9892	118	27	of	of	ADP
aiua-9892	118	28	patients	patient	NOUN
aiua-9892	118	29	in	in	ADP
aiua-9892	118	30	norris	norris	PROPN
aiua-9892	118	31	et	et	PROPN
aiua-9892	118	32	al	al	PROPN
aiua-9892	118	33	.	.	PROPN
aiua-9892	118	34	cohort	cohort	PROPN
aiua-9892	118	35	and	and	CCONJ
aiua-9892	118	36	only	only	ADV
aiua-9892	118	37	30	30	NUM
aiua-9892	118	38	%	%	NOUN
aiua-9892	118	39	in	in	ADP
aiua-9892	118	40	ours	ours	PRON
aiua-9892	118	41	.	.	PUNCT
aiua-9892	119	1	as	as	SCONJ
aiua-9892	119	2	seen	see	VERB
aiua-9892	119	3	in	in	ADP
aiua-9892	119	4	our	our	PRON
aiua-9892	119	5	cohort	cohort	NOUN
aiua-9892	119	6	,	,	PUNCT
aiua-9892	119	7	higher	high	ADJ
aiua-9892	119	8	psa	psa	NOUN
aiua-9892	119	9	response	response	NOUN
aiua-9892	119	10	rates	rate	NOUN
aiua-9892	119	11	were	be	AUX
aiua-9892	119	12	seen	see	VERB
aiua-9892	119	13	in	in	ADP
aiua-9892	119	14	the	the	DET
aiua-9892	119	15	pre	pre	ADJ
aiua-9892	119	16	-	-	ADJ
aiua-9892	119	17	docetaxel	docetaxel	ADJ
aiua-9892	119	18	group	group	NOUN
aiua-9892	119	19	compared	compare	VERB
aiua-9892	119	20	to	to	ADP
aiua-9892	119	21	the	the	DET
aiua-9892	119	22	post	post	NOUN
aiua-9892	119	23	-	-	NOUN
aiua-9892	119	24	docetaxel	docetaxel	ADJ
aiua-9892	119	25	(	(	PUNCT
aiua-9892	119	26	10	10	NUM
aiua-9892	119	27	)	)	PUNCT
aiua-9892	119	28	.	.	PUNCT
aiua-9892	120	1	garcia	garcia	PROPN
aiua-9892	120	2	et	et	PROPN
aiua-9892	120	3	al	al	PROPN
aiua-9892	120	4	.	.	PROPN
aiua-9892	120	5	performed	perform	VERB
aiua-9892	120	6	a	a	DET
aiua-9892	120	7	retrospective	retrospective	ADJ
aiua-9892	120	8	observational	observational	ADJ
aiua-9892	120	9	study	study	NOUN
aiua-9892	120	10	reviewing	review	VERB
aiua-9892	120	11	48	48	NUM
aiua-9892	120	12	patients	patient	NOUN
aiua-9892	120	13	with	with	ADP
aiua-9892	120	14	mcrpc	mcrpc	PROPN
aiua-9892	120	15	(	(	PUNCT
aiua-9892	120	16	26	26	NUM
aiua-9892	120	17	in	in	ADP
aiua-9892	120	18	abiraterone	abiraterone	NOUN
aiua-9892	120	19	group	group	NOUN
aiua-9892	120	20	and	and	CCONJ
aiua-9892	120	21	22	22	NUM
aiua-9892	120	22	in	in	ADP
aiua-9892	120	23	enzalutamide	enzalutamide	NOUN
aiua-9892	120	24	)	)	PUNCT
aiua-9892	120	25	.	.	PUNCT
aiua-9892	121	1	most	most	ADJ
aiua-9892	121	2	patients	patient	NOUN
aiua-9892	121	3	had	have	AUX
aiua-9892	121	4	been	be	AUX
aiua-9892	121	5	submitted	submit	VERB
aiua-9892	121	6	to	to	ADP
aiua-9892	121	7	docetaxel	docetaxel	PROPN
aiua-9892	121	8	.	.	PUNCT
aiua-9892	122	1	the	the	DET
aiua-9892	122	2	primary	primary	ADJ
aiua-9892	122	3	endpoint	endpoint	NOUN
aiua-9892	122	4	was	be	AUX
aiua-9892	122	5	biochemical	biochemical	ADJ
aiua-9892	122	6	response	response	NOUN
aiua-9892	122	7	.	.	PUNCT
aiua-9892	123	1	unlike	unlike	ADP
aiua-9892	123	2	our	our	PRON
aiua-9892	123	3	study	study	NOUN
aiua-9892	123	4	,	,	PUNCT
aiua-9892	123	5	no	no	DET
aiua-9892	123	6	statistically	statistically	ADJ
aiua-9892	123	7	difference	difference	NOUN
aiua-9892	123	8	in	in	ADP
aiua-9892	123	9	biochemical	biochemical	ADJ
aiua-9892	123	10	response	response	NOUN
aiua-9892	123	11	between	between	ADP
aiua-9892	123	12	abiraterone	abiraterone	NOUN
aiua-9892	123	13	and	and	CCONJ
aiua-9892	123	14	enzalutamide	enzalutamide	NOUN
aiua-9892	123	15	was	be	AUX
aiua-9892	123	16	observed	observe	VERB
aiua-9892	123	17	(	(	PUNCT
aiua-9892	123	18	53.85	53.85	NUM
aiua-9892	123	19	%	%	NOUN
aiua-9892	123	20	and	and	CCONJ
aiua-9892	123	21	58.85	58.85	NUM
aiua-9892	123	22	%	%	NOUN
aiua-9892	123	23	for	for	ADP
aiua-9892	123	24	abiraterone	abiraterone	NOUN
aiua-9892	123	25	and	and	CCONJ
aiua-9892	123	26	enzalutamide	enzalutamide	ADJ
aiua-9892	123	27	groups	group	NOUN
aiua-9892	123	28	,	,	PUNCT
aiua-9892	123	29	respectively	respectively	ADV
aiua-9892	123	30	)	)	PUNCT
aiua-9892	123	31	.	.	PUNCT
aiua-9892	124	1	a	a	DET
aiua-9892	124	2	low	low	ADJ
aiua-9892	124	3	number	number	NOUN
aiua-9892	124	4	of	of	ADP
aiua-9892	124	5	patients	patient	NOUN
aiua-9892	124	6	treated	treat	VERB
aiua-9892	124	7	can	can	AUX
aiua-9892	124	8	impair	impair	VERB
aiua-9892	124	9	the	the	DET
aiua-9892	124	10	statistical	statistical	ADJ
aiua-9892	124	11	power	power	NOUN
aiua-9892	124	12	of	of	ADP
aiua-9892	124	13	this	this	DET
aiua-9892	124	14	study	study	NOUN
aiua-9892	124	15	(	(	PUNCT
aiua-9892	124	16	11	11	NUM
aiua-9892	124	17	)	)	PUNCT
aiua-9892	124	18	.	.	PUNCT
aiua-9892	125	1	khalaf	khalaf	PROPN
aiua-9892	125	2	et	et	PROPN
aiua-9892	125	3	al	al	PROPN
aiua-9892	125	4	.	.	PROPN
aiua-9892	125	5	retrospectively	retrospectively	ADV
aiua-9892	125	6	analyzed	analyze	VERB
aiua-9892	125	7	210	210	NUM
aiua-9892	125	8	patients	patient	NOUN
aiua-9892	125	9	(	(	PUNCT
aiua-9892	125	10	106	106	NUM
aiua-9892	125	11	in	in	ADP
aiua-9892	125	12	abiraterone	abiraterone	NOUN
aiua-9892	125	13	and	and	CCONJ
aiua-9892	125	14	104	104	NUM
aiua-9892	125	15	in	in	ADP
aiua-9892	125	16	enzalutamide	enzalutamide	ADJ
aiua-9892	125	17	groups	group	NOUN
aiua-9892	125	18	)	)	PUNCT
aiua-9892	125	19	,	,	PUNCT
aiua-9892	125	20	older	old	ADJ
aiua-9892	125	21	than	than	ADP
aiua-9892	125	22	80	80	NUM
aiua-9892	125	23	years	year	NOUN
aiua-9892	125	24	who	who	PRON
aiua-9892	125	25	received	receive	VERB
aiua-9892	125	26	novel	novel	ADJ
aiua-9892	125	27	hormonal	hormonal	ADJ
aiua-9892	125	28	agents	agent	NOUN
aiua-9892	125	29	for	for	ADP
aiua-9892	125	30	firstline	firstline	ADJ
aiua-9892	125	31	treatment	treatment	NOUN
aiua-9892	125	32	of	of	ADP
aiua-9892	125	33	mcrpc	mcrpc	NOUN
aiua-9892	125	34	.	.	PUNCT
aiua-9892	126	1	as	as	ADP
aiua-9892	126	2	in	in	ADP
aiua-9892	126	3	our	our	PRON
aiua-9892	126	4	cohort	cohort	NOUN
aiua-9892	126	5	,	,	PUNCT
aiua-9892	126	6	the	the	DET
aiua-9892	126	7	biochemical	biochemical	ADJ
aiua-9892	126	8	response	response	NOUN
aiua-9892	126	9	was	be	AUX
aiua-9892	126	10	higher	high	ADJ
aiua-9892	126	11	in	in	ADP
aiua-9892	126	12	patients	patient	NOUN
aiua-9892	126	13	treated	treat	VERB
aiua-9892	126	14	with	with	ADP
aiua-9892	126	15	enzalutamide	enzalutamide	NOUN
aiua-9892	126	16	than	than	ADP
aiua-9892	126	17	abiraterone	abiraterone	NOUN
aiua-9892	126	18	(	(	PUNCT
aiua-9892	126	19	77.9	77.9	NUM
aiua-9892	126	20	%	%	NOUN
aiua-9892	126	21	vs	vs	ADP
aiua-9892	126	22	43.4	43.4	NUM
aiua-9892	126	23	%	%	NOUN
aiua-9892	126	24	)	)	PUNCT
aiua-9892	127	1	but	but	CCONJ
aiua-9892	127	2	no	no	DET
aiua-9892	127	3	os	os	NOUN
aiua-9892	127	4	advantage	advantage	NOUN
aiua-9892	127	5	was	be	AUX
aiua-9892	127	6	observed	observe	VERB
aiua-9892	127	7	.	.	PUNCT
aiua-9892	128	1	in	in	ADP
aiua-9892	128	2	our	our	PRON
aiua-9892	128	3	study	study	NOUN
aiua-9892	128	4	the	the	DET
aiua-9892	128	5	psa	psa	NOUN
aiua-9892	128	6	response	response	NOUN
aiua-9892	128	7	rates	rate	NOUN
aiua-9892	128	8	of	of	ADP
aiua-9892	128	9	docetaxel	docetaxel	NOUN
aiua-9892	128	10	-	-	PUNCT
aiua-9892	128	11	naïve	naïve	ADJ
aiua-9892	128	12	patients	patient	NOUN
aiua-9892	128	13	were	be	AUX
aiua-9892	128	14	similar	similar	ADJ
aiua-9892	128	15	with	with	ADP
aiua-9892	128	16	the	the	DET
aiua-9892	128	17	ones	one	NOUN
aiua-9892	128	18	reported	report	VERB
aiua-9892	128	19	in	in	ADP
aiua-9892	128	20	this	this	DET
aiua-9892	128	21	study	study	NOUN
aiua-9892	128	22	(	(	PUNCT
aiua-9892	128	23	56.1	56.1	NUM
aiua-9892	128	24	%	%	NOUN
aiua-9892	128	25	and	and	CCONJ
aiua-9892	128	26	73.9	73.9	NUM
aiua-9892	128	27	%	%	NOUN
aiua-9892	128	28	for	for	ADP
aiua-9892	128	29	abiraterone	abiraterone	NOUN
aiua-9892	128	30	and	and	CCONJ
aiua-9892	128	31	enzalutamide	enzalutamide	ADV
aiua-9892	128	32	,	,	PUNCT
aiua-9892	128	33	respectively	respectively	ADV
aiua-9892	128	34	)	)	PUNCT
aiua-9892	128	35	(	(	PUNCT
aiua-9892	128	36	12	12	NUM
aiua-9892	128	37	)	)	PUNCT
aiua-9892	128	38	.	.	PUNCT
aiua-9892	129	1	our	our	PRON
aiua-9892	129	2	study	study	NOUN
aiua-9892	129	3	has	have	VERB
aiua-9892	129	4	some	some	DET
aiua-9892	129	5	strengths	strength	NOUN
aiua-9892	129	6	:	:	PUNCT
aiua-9892	129	7	similar	similar	ADJ
aiua-9892	129	8	groups	group	NOUN
aiua-9892	129	9	regarding	regard	VERB
aiua-9892	129	10	clinicopathological	clinicopathological	ADJ
aiua-9892	129	11	characteristics	characteristic	NOUN
aiua-9892	129	12	and	and	CCONJ
aiua-9892	129	13	a	a	DET
aiua-9892	129	14	relatively	relatively	ADV
aiua-9892	129	15	uniform	uniform	ADJ
aiua-9892	129	16	distribution	distribution	NOUN
aiua-9892	129	17	between	between	ADP
aiua-9892	129	18	abiraterone	abiraterone	NOUN
aiua-9892	129	19	and	and	CCONJ
aiua-9892	129	20	enzalutamide	enzalutamide	ADJ
aiua-9892	129	21	groups	group	NOUN
aiua-9892	129	22	(	(	PUNCT
aiua-9892	129	23	61.5	61.5	NUM
aiua-9892	129	24	%	%	NOUN
aiua-9892	129	25	vs	vs	ADP
aiua-9892	129	26	38.5	38.5	NUM
aiua-9892	129	27	%	%	NOUN
aiua-9892	129	28	)	)	PUNCT
aiua-9892	129	29	.	.	PUNCT
aiua-9892	130	1	a	a	DET
aiua-9892	130	2	1:1	1:1	NUM
aiua-9892	130	3	proportion	proportion	NOUN
aiua-9892	130	4	between	between	ADP
aiua-9892	130	5	abiraterone	abiraterone	NOUN
aiua-9892	130	6	and	and	CCONJ
aiua-9892	130	7	enzalutamide	enzalutamide	NOUN
aiua-9892	130	8	was	be	AUX
aiua-9892	130	9	not	not	PART
aiua-9892	130	10	achieved	achieve	VERB
aiua-9892	130	11	due	due	ADP
aiua-9892	130	12	to	to	ADP
aiua-9892	130	13	the	the	DET
aiua-9892	130	14	numerous	numerous	ADJ
aiua-9892	130	15	contraindications	contraindication	NOUN
aiua-9892	130	16	to	to	PART
aiua-9892	130	17	enzalutamide	enzalutamide	VERB
aiua-9892	130	18	.	.	PUNCT
aiua-9892	131	1	the	the	DET
aiua-9892	131	2	approval	approval	NOUN
aiua-9892	131	3	of	of	ADP
aiua-9892	131	4	abiraterone	abiraterone	NOUN
aiua-9892	131	5	for	for	ADP
aiua-9892	131	6	treatment	treatment	NOUN
aiua-9892	131	7	of	of	ADP
aiua-9892	131	8	mcrpc	mcrpc	NOUN
aiua-9892	131	9	was	be	AUX
aiua-9892	131	10	conceded	concede	VERB
aiua-9892	131	11	before	before	ADP
aiua-9892	131	12	enzalutamide	enzalutamide	ADV
aiua-9892	131	13	by	by	ADP
aiua-9892	131	14	national	national	ADJ
aiua-9892	131	15	regulatory	regulatory	ADJ
aiua-9892	131	16	agency	agency	NOUN
aiua-9892	131	17	,	,	PUNCT
aiua-9892	131	18	contributing	contribute	VERB
aiua-9892	131	19	to	to	ADP
aiua-9892	131	20	the	the	DET
aiua-9892	131	21	discrepancy	discrepancy	NOUN
aiua-9892	131	22	in	in	ADP
aiua-9892	131	23	the	the	DET
aiua-9892	131	24	number	number	NOUN
aiua-9892	131	25	of	of	ADP
aiua-9892	131	26	patients	patient	NOUN
aiua-9892	131	27	in	in	ADP
aiua-9892	131	28	each	each	DET
aiua-9892	131	29	group	group	NOUN
aiua-9892	131	30	.	.	PUNCT
aiua-9892	132	1	some	some	DET
aiua-9892	132	2	limitations	limitation	NOUN
aiua-9892	132	3	of	of	ADP
aiua-9892	132	4	this	this	DET
aiua-9892	132	5	study	study	NOUN
aiua-9892	132	6	must	must	AUX
aiua-9892	132	7	however	however	ADV
aiua-9892	132	8	be	be	AUX
aiua-9892	132	9	noted	note	VERB
aiua-9892	132	10	.	.	PUNCT
aiua-9892	133	1	as	as	ADP
aiua-9892	133	2	a	a	DET
aiua-9892	133	3	real	real	ADJ
aiua-9892	133	4	-	-	PUNCT
aiua-9892	133	5	life	life	NOUN
aiua-9892	133	6	study	study	NOUN
aiua-9892	133	7	,	,	PUNCT
aiua-9892	133	8	the	the	DET
aiua-9892	133	9	results	result	NOUN
aiua-9892	133	10	can	can	AUX
aiua-9892	133	11	be	be	AUX
aiua-9892	133	12	biased	bias	VERB
aiua-9892	133	13	by	by	ADP
aiua-9892	133	14	not	not	PART
aiua-9892	133	15	randomized	randomize	VERB
aiua-9892	133	16	allocation	allocation	NOUN
aiua-9892	133	17	of	of	ADP
aiua-9892	133	18	patients	patient	NOUN
aiua-9892	133	19	to	to	ADP
aiua-9892	133	20	different	different	ADJ
aiua-9892	133	21	treatments	treatment	NOUN
aiua-9892	133	22	.	.	PUNCT
aiua-9892	134	1	adverse	adverse	ADJ
aiua-9892	134	2	events	event	NOUN
aiua-9892	134	3	were	be	AUX
aiua-9892	134	4	not	not	PART
aiua-9892	134	5	systematically	systematically	ADV
aiua-9892	134	6	evaluated	evaluate	VERB
aiua-9892	134	7	due	due	ADP
aiua-9892	134	8	to	to	ADP
aiua-9892	134	9	retrospective	retrospective	ADJ
aiua-9892	134	10	nature	nature	NOUN
aiua-9892	134	11	of	of	ADP
aiua-9892	134	12	this	this	DET
aiua-9892	134	13	study	study	NOUN
aiua-9892	134	14	,	,	PUNCT
aiua-9892	134	15	making	make	VERB
aiua-9892	134	16	security	security	NOUN
aiua-9892	134	17	performance	performance	NOUN
aiua-9892	134	18	assessment	assessment	NOUN
aiua-9892	134	19	inaccurate	inaccurate	ADJ
aiua-9892	134	20	.	.	PUNCT
aiua-9892	135	1	the	the	DET
aiua-9892	135	2	threshold	threshold	NOUN
aiua-9892	135	3	and	and	CCONJ
aiua-9892	135	4	image	image	NOUN
aiua-9892	135	5	modality	modality	NOUN
aiua-9892	135	6	(	(	PUNCT
aiua-9892	135	7	either	either	CCONJ
aiua-9892	135	8	ct	ct	PROPN
aiua-9892	135	9	and	and	CCONJ
aiua-9892	135	10	bone	bone	NOUN
aiua-9892	135	11	scintigraphy	scintigraphy	NOUN
aiua-9892	135	12	or	or	CCONJ
aiua-9892	135	13	ga68	ga68	PROPN
aiua-9892	135	14	petpsma	petpsma	NOUN
aiua-9892	135	15	)	)	PUNCT
aiua-9892	135	16	used	use	VERB
aiua-9892	135	17	for	for	ADP
aiua-9892	135	18	staging	stage	VERB
aiua-9892	135	19	patients	patient	NOUN
aiua-9892	135	20	in	in	ADP
aiua-9892	135	21	the	the	DET
aiua-9892	135	22	scenario	scenario	NOUN
aiua-9892	135	23	of	of	ADP
aiua-9892	135	24	biochemical	biochemical	ADJ
aiua-9892	135	25	progression	progression	NOUN
aiua-9892	135	26	was	be	AUX
aiua-9892	135	27	not	not	PART
aiua-9892	135	28	specified	specify	VERB
aiua-9892	135	29	,	,	PUNCT
aiua-9892	135	30	introducing	introduce	VERB
aiua-9892	135	31	some	some	DET
aiua-9892	135	32	bias	bias	NOUN
aiua-9892	135	33	in	in	ADP
aiua-9892	135	34	radiological	radiological	ADJ
aiua-9892	135	35	progression	progression	NOUN
aiua-9892	135	36	assessment	assessment	NOUN
aiua-9892	135	37	.	.	PUNCT
aiua-9892	136	1	mean	mean	ADJ
aiua-9892	136	2	followup	followup	NOUN
aiua-9892	136	3	period	period	NOUN
aiua-9892	136	4	was	be	AUX
aiua-9892	136	5	relatively	relatively	ADV
aiua-9892	136	6	short	short	ADJ
aiua-9892	136	7	.	.	PUNCT
aiua-9892	137	1	based	base	VERB
aiua-9892	137	2	on	on	ADP
aiua-9892	137	3	our	our	PRON
aiua-9892	137	4	results	result	NOUN
aiua-9892	137	5	,	,	PUNCT
aiua-9892	137	6	enzalutamide	enzalutamide	ADV
aiua-9892	137	7	conferred	confer	VERB
aiua-9892	137	8	higher	high	ADJ
aiua-9892	137	9	biochemical	biochemical	ADJ
aiua-9892	137	10	response	response	NOUN
aiua-9892	137	11	rate	rate	NOUN
aiua-9892	137	12	than	than	ADP
aiua-9892	137	13	abiraterone	abiraterone	NOUN
aiua-9892	137	14	in	in	ADP
aiua-9892	137	15	patients	patient	NOUN
aiua-9892	137	16	with	with	ADP
aiua-9892	137	17	mcrpc	mcrpc	NOUN
aiua-9892	137	18	.	.	PUNCT
aiua-9892	138	1	achieving	achieve	VERB
aiua-9892	138	2	a	a	DET
aiua-9892	138	3	biochemical	biochemical	ADJ
aiua-9892	138	4	response	response	NOUN
aiua-9892	138	5	was	be	AUX
aiua-9892	138	6	associated	associate	VERB
aiua-9892	138	7	with	with	ADP
aiua-9892	138	8	a	a	DET
aiua-9892	138	9	lower	low	ADJ
aiua-9892	138	10	risk	risk	NOUN
aiua-9892	138	11	of	of	ADP
aiua-9892	138	12	biochemical	biochemical	ADJ
aiua-9892	138	13	progression	progression	NOUN
aiua-9892	138	14	and	and	CCONJ
aiua-9892	138	15	death	death	NOUN
aiua-9892	138	16	.	.	PUNCT
aiua-9892	139	1	other	other	ADJ
aiua-9892	139	2	endpoints	endpoint	NOUN
aiua-9892	139	3	tended	tend	VERB
aiua-9892	139	4	to	to	PART
aiua-9892	139	5	improve	improve	VERB
aiua-9892	139	6	in	in	ADP
aiua-9892	139	7	the	the	DET
aiua-9892	139	8	enzalutamide	enzalutamide	ADJ
aiua-9892	139	9	group	group	NOUN
aiua-9892	139	10	although	although	SCONJ
aiua-9892	139	11	not	not	PART
aiua-9892	139	12	significantly	significantly	ADV
aiua-9892	139	13	.	.	PUNCT
aiua-9892	140	1	well	well	INTJ
aiua-9892	140	2	designed	design	VERB
aiua-9892	140	3	prospective	prospective	ADJ
aiua-9892	140	4	studies	study	NOUN
aiua-9892	140	5	are	be	AUX
aiua-9892	140	6	needed	need	VERB
aiua-9892	140	7	to	to	PART
aiua-9892	140	8	elucidate	elucidate	VERB
aiua-9892	140	9	the	the	DET
aiua-9892	140	10	comparative	comparative	ADJ
aiua-9892	140	11	efficacies	efficacy	NOUN
aiua-9892	140	12	of	of	ADP
aiua-9892	140	13	these	these	DET
aiua-9892	140	14	agents	agent	NOUN
aiua-9892	140	15	.	.	PUNCT
aiua-9892	141	1	references	reference	NOUN
aiua-9892	141	2	1	1	NUM
aiua-9892	141	3	.	.	PUNCT
aiua-9892	141	4	fizazi	fizazi	PROPN
aiua-9892	141	5	k	k	PROPN
aiua-9892	141	6	,	,	PUNCT
aiua-9892	141	7	scher	scher	PROPN
aiua-9892	141	8	hi	hi	PROPN
aiua-9892	141	9	,	,	PUNCT
aiua-9892	141	10	molina	molina	PROPN
aiua-9892	141	11	a	a	PROPN
aiua-9892	141	12	,	,	PUNCT
aiua-9892	141	13	et	et	PROPN
aiua-9892	141	14	al	al	PROPN
aiua-9892	141	15	.	.	PUNCT
aiua-9892	142	1	abiraterone	abiraterone	NOUN
aiua-9892	142	2	acetate	acetate	NOUN
aiua-9892	142	3	for	for	ADP
aiua-9892	142	4	treatment	treatment	NOUN
aiua-9892	142	5	of	of	ADP
aiua-9892	142	6	metastatic	metastatic	ADJ
aiua-9892	142	7	castration	castration	NOUN
aiua-9892	142	8	-	-	PUNCT
aiua-9892	142	9	resistant	resistant	ADJ
aiua-9892	142	10	prostate	prostate	NOUN
aiua-9892	142	11	cancer	cancer	NOUN
aiua-9892	142	12	:	:	PUNCT
aiua-9892	142	13	final	final	ADJ
aiua-9892	142	14	overall	overall	ADJ
aiua-9892	142	15	survival	survival	NOUN
aiua-9892	142	16	analysis	analysis	NOUN
aiua-9892	142	17	of	of	ADP
aiua-9892	142	18	the	the	DET
aiua-9892	142	19	cou	cou	PROPN
aiua-9892	142	20	-	-	PUNCT
aiua-9892	142	21	aa-301	aa-301	PRON
aiua-9892	142	22	randomised	randomise	VERB
aiua-9892	142	23	,	,	PUNCT
aiua-9892	142	24	double	double	ADJ
aiua-9892	142	25	-	-	PUNCT
aiua-9892	142	26	blind	blind	ADJ
aiua-9892	142	27	,	,	PUNCT
aiua-9892	142	28	placebo	placebo	NOUN
aiua-9892	142	29	-	-	PUNCT
aiua-9892	142	30	controlled	control	VERB
aiua-9892	142	31	phase	phase	NOUN
aiua-9892	142	32	3	3	NUM
aiua-9892	142	33	study	study	NOUN
aiua-9892	142	34	.	.	PUNCT
aiua-9892	143	1	lancet	lancet	PROPN
aiua-9892	143	2	oncol	oncol	PROPN
aiua-9892	143	3	.	.	PUNCT
aiua-9892	144	1	2012	2012	NUM
aiua-9892	144	2	;	;	PUNCT
aiua-9892	144	3	13:983	13:983	NUM
aiua-9892	144	4	-	-	SYM
aiua-9892	144	5	92	92	NUM
aiua-9892	144	6	.	.	PUNCT
aiua-9892	145	1	2	2	X
aiua-9892	145	2	.	.	X
aiua-9892	145	3	beer	beer	PROPN
aiua-9892	145	4	tm	tm	PROPN
aiua-9892	145	5	,	,	PUNCT
aiua-9892	145	6	armstrong	armstrong	PROPN
aiua-9892	145	7	aj	aj	PROPN
aiua-9892	145	8	,	,	PUNCT
aiua-9892	145	9	rathkopf	rathkopf	VERB
aiua-9892	145	10	de	de	PROPN
aiua-9892	145	11	,	,	PUNCT
aiua-9892	145	12	et	et	PROPN
aiua-9892	145	13	al	al	PROPN
aiua-9892	146	1	.	.	PROPN
aiua-9892	146	2	enzalutamide	enzalutamide	PROPN
aiua-9892	146	3	in	in	ADP
aiua-9892	146	4	metastatic	metastatic	ADJ
aiua-9892	146	5	prostate	prostate	NOUN
aiua-9892	146	6	cancer	cancer	NOUN
aiua-9892	146	7	before	before	ADP
aiua-9892	146	8	chemotherapy	chemotherapy	NOUN
aiua-9892	146	9	.	.	PUNCT
aiua-9892	147	1	n	n	PROPN
aiua-9892	147	2	engl	engl	PROPN
aiua-9892	147	3	j	j	PROPN
aiua-9892	147	4	med	med	PROPN
aiua-9892	147	5	.	.	PUNCT
aiua-9892	147	6	2014	2014	NUM
aiua-9892	147	7	;	;	PUNCT
aiua-9892	147	8	371:424	371:424	NUM
aiua-9892	147	9	-	-	SYM
aiua-9892	147	10	33	33	NUM
aiua-9892	147	11	.	.	PUNCT
aiua-9892	148	1	3	3	X
aiua-9892	148	2	.	.	X
aiua-9892	148	3	scher	scher	PROPN
aiua-9892	148	4	hi	hi	PROPN
aiua-9892	148	5	,	,	PUNCT
aiua-9892	148	6	fizazi	fizazi	PROPN
aiua-9892	148	7	k	k	PROPN
aiua-9892	148	8	,	,	PUNCT
aiua-9892	148	9	saad	saad	PROPN
aiua-9892	148	10	f	f	PROPN
aiua-9892	148	11	,	,	PUNCT
aiua-9892	148	12	et	et	PROPN
aiua-9892	148	13	al	al	PROPN
aiua-9892	148	14	.	.	PROPN
aiua-9892	148	15	increased	increase	VERB
aiua-9892	148	16	survival	survival	NOUN
aiua-9892	148	17	with	with	ADP
aiua-9892	148	18	enzalutamide	enzalutamide	NOUN
aiua-9892	148	19	in	in	ADP
aiua-9892	148	20	prostate	prostate	NOUN
aiua-9892	148	21	cancer	cancer	NOUN
aiua-9892	148	22	after	after	ADP
aiua-9892	148	23	chemotherapy	chemotherapy	NOUN
aiua-9892	148	24	.	.	PUNCT
aiua-9892	149	1	n	n	PROPN
aiua-9892	149	2	engl	engl	PROPN
aiua-9892	149	3	j	j	PROPN
aiua-9892	149	4	med	med	PROPN
aiua-9892	149	5	.	.	PROPN
aiua-9892	149	6	2012	2012	NUM
aiua-9892	149	7	;	;	PUNCT
aiua-9892	149	8	367:1187	367:1187	NUM
aiua-9892	149	9	-	-	SYM
aiua-9892	149	10	97	97	NUM
aiua-9892	149	11	.	.	NOUN
aiua-9892	150	1	4	4	NUM
aiua-9892	150	2	.	.	X
aiua-9892	150	3	ryan	ryan	PROPN
aiua-9892	150	4	cj	cj	PROPN
aiua-9892	150	5	,	,	PUNCT
aiua-9892	150	6	smith	smith	PROPN
aiua-9892	150	7	mr	mr	PROPN
aiua-9892	150	8	,	,	PUNCT
aiua-9892	150	9	fizazi	fizazi	PROPN
aiua-9892	150	10	k	k	PROPN
aiua-9892	150	11	,	,	PUNCT
aiua-9892	150	12	et	et	PROPN
aiua-9892	150	13	al	al	PROPN
aiua-9892	150	14	.	.	PUNCT
aiua-9892	151	1	abiraterone	abiraterone	NOUN
aiua-9892	151	2	acetate	acetate	NOUN
aiua-9892	151	3	plus	plus	CCONJ
aiua-9892	151	4	prednisone	prednisone	NOUN
aiua-9892	151	5	versus	versus	ADP
aiua-9892	151	6	placebo	placebo	NOUN
aiua-9892	151	7	plus	plus	CCONJ
aiua-9892	151	8	prednisone	prednisone	NOUN
aiua-9892	151	9	in	in	ADP
aiua-9892	151	10	chemotherapy	chemotherapy	NOUN
aiua-9892	151	11	-	-	ADJ
aiua-9892	151	12	naive	naive	ADJ
aiua-9892	151	13	men	man	NOUN
aiua-9892	151	14	with	with	ADP
aiua-9892	151	15	metastatic	metastatic	ADJ
aiua-9892	151	16	castration	castration	NOUN
aiua-9892	151	17	-	-	PUNCT
aiua-9892	151	18	resistant	resistant	ADJ
aiua-9892	151	19	prostate	prostate	NOUN
aiua-9892	151	20	cancer	cancer	NOUN
aiua-9892	151	21	(	(	PUNCT
aiua-9892	151	22	cou	cou	NOUN
aiua-9892	151	23	-	-	PUNCT
aiua-9892	151	24	aa-302	aa-302	PROPN
aiua-9892	151	25	):	):	PUNCT
aiua-9892	151	26	final	final	ADJ
aiua-9892	151	27	overall	overall	ADJ
aiua-9892	151	28	survival	survival	NOUN
aiua-9892	151	29	analysis	analysis	NOUN
aiua-9892	151	30	of	of	ADP
aiua-9892	151	31	a	a	DET
aiua-9892	151	32	randomised	randomised	ADJ
aiua-9892	151	33	,	,	PUNCT
aiua-9892	151	34	double	double	ADJ
aiua-9892	151	35	-	-	PUNCT
aiua-9892	151	36	blind	blind	ADJ
aiua-9892	151	37	,	,	PUNCT
aiua-9892	151	38	placebo	placebo	NOUN
aiua-9892	151	39	-	-	PUNCT
aiua-9892	151	40	controlled	control	VERB
aiua-9892	151	41	phase	phase	NOUN
aiua-9892	151	42	3	3	NUM
aiua-9892	151	43	study	study	NOUN
aiua-9892	151	44	.	.	PUNCT
aiua-9892	152	1	lancet	lancet	PROPN
aiua-9892	152	2	oncol	oncol	PROPN
aiua-9892	152	3	.	.	PUNCT
aiua-9892	153	1	2015	2015	NUM
aiua-9892	153	2	;	;	PUNCT
aiua-9892	153	3	16:152	16:152	NUM
aiua-9892	153	4	-	-	SYM
aiua-9892	153	5	60	60	NUM
aiua-9892	153	6	.	.	PUNCT
aiua-9892	154	1	5	5	NUM
aiua-9892	154	2	.	.	X
aiua-9892	155	1	wang	wang	PROPN
aiua-9892	155	2	x	x	PROPN
aiua-9892	155	3	,	,	PUNCT
aiua-9892	155	4	yang	yang	PROPN
aiua-9892	155	5	h	h	PROPN
aiua-9892	155	6	,	,	PUNCT
aiua-9892	155	7	hu	hu	PROPN
aiua-9892	155	8	x	x	PROPN
aiua-9892	155	9	,	,	PUNCT
aiua-9892	155	10	et	et	PROPN
aiua-9892	155	11	al	al	PROPN
aiua-9892	155	12	.	.	PROPN
aiua-9892	155	13	comparing	compare	VERB
aiua-9892	155	14	the	the	DET
aiua-9892	155	15	clinical	clinical	ADJ
aiua-9892	155	16	efficacy	efficacy	NOUN
aiua-9892	155	17	and	and	CCONJ
aiua-9892	155	18	safety	safety	NOUN
aiua-9892	155	19	of	of	ADP
aiua-9892	155	20	abiraterone	abiraterone	NOUN
aiua-9892	155	21	and	and	CCONJ
aiua-9892	155	22	enzalutamide	enzalutamide	ADV
aiua-9892	155	23	in	in	ADP
aiua-9892	155	24	metastatic	metastatic	ADJ
aiua-9892	155	25	castrationresistant	castrationresistant	NOUN
aiua-9892	155	26	prostate	prostate	NOUN
aiua-9892	155	27	cancer	cancer	NOUN
aiua-9892	155	28	:	:	PUNCT
aiua-9892	155	29	a	a	DET
aiua-9892	155	30	systematic	systematic	ADJ
aiua-9892	155	31	review	review	NOUN
aiua-9892	155	32	and	and	CCONJ
aiua-9892	155	33	meta	meta	ADJ
aiua-9892	155	34	-	-	PUNCT
aiua-9892	155	35	analysis	analysis	NOUN
aiua-9892	155	36	.	.	PUNCT
aiua-9892	156	1	j	j	PROPN
aiua-9892	156	2	oncol	oncol	ADJ
aiua-9892	156	3	pharm	pharm	PROPN
aiua-9892	156	4	pract	pract	PROPN
aiua-9892	156	5	.	.	PUNCT
aiua-9892	157	1	2021	2021	NUM
aiua-9892	157	2	;	;	PUNCT
aiua-9892	157	3	27:614	27:614	NUM
aiua-9892	157	4	-	-	SYM
aiua-9892	157	5	622	622	NUM
aiua-9892	157	6	.	.	PUNCT
aiua-9892	158	1	6	6	NUM
aiua-9892	158	2	.	.	PUNCT
aiua-9892	159	1	khalaf	khalaf	PROPN
aiua-9892	159	2	dj	dj	PROPN
aiua-9892	159	3	,	,	PUNCT
aiua-9892	159	4	annala	annala	PROPN
aiua-9892	159	5	m	m	PROPN
aiua-9892	159	6	,	,	PUNCT
aiua-9892	159	7	taavitsainen	taavitsainen	PROPN
aiua-9892	159	8	s	s	PROPN
aiua-9892	159	9	,	,	PUNCT
aiua-9892	159	10	et	et	PROPN
aiua-9892	159	11	al	al	PROPN
aiua-9892	159	12	.	.	PUNCT
aiua-9892	160	1	optimal	optimal	ADJ
aiua-9892	160	2	sequencing	sequencing	NOUN
aiua-9892	160	3	of	of	ADP
aiua-9892	160	4	enzalutamide	enzalutamide	NOUN
aiua-9892	160	5	and	and	CCONJ
aiua-9892	160	6	abiraterone	abiraterone	NOUN
aiua-9892	160	7	acetate	acetate	NOUN
aiua-9892	160	8	plus	plus	CCONJ
aiua-9892	160	9	prednisone	prednisone	NOUN
aiua-9892	160	10	in	in	ADP
aiua-9892	160	11	metastatic	metastatic	ADJ
aiua-9892	160	12	castration	castration	NOUN
aiua-9892	160	13	-	-	PUNCT
aiua-9892	160	14	resistant	resistant	ADJ
aiua-9892	160	15	prostate	prostate	NOUN
aiua-9892	160	16	cancer	cancer	NOUN
aiua-9892	160	17	:	:	PUNCT
aiua-9892	160	18	a	a	DET
aiua-9892	160	19	multicentre	multicentre	NOUN
aiua-9892	160	20	,	,	PUNCT
aiua-9892	160	21	randomised	randomise	VERB
aiua-9892	160	22	,	,	PUNCT
aiua-9892	160	23	open	open	ADJ
aiua-9892	160	24	-	-	PUNCT
aiua-9892	160	25	label	label	NOUN
aiua-9892	160	26	,	,	PUNCT
aiua-9892	160	27	phase	phase	NOUN
aiua-9892	160	28	2	2	NUM
aiua-9892	160	29	,	,	PUNCT
aiua-9892	160	30	crossover	crossover	VERB
aiua-9892	160	31	trial	trial	NOUN
aiua-9892	160	32	.	.	PUNCT
aiua-9892	161	1	lancet	lancet	PROPN
aiua-9892	161	2	oncol	oncol	PROPN
aiua-9892	161	3	.	.	PUNCT
aiua-9892	162	1	2019	2019	NUM
aiua-9892	162	2	;	;	PUNCT
aiua-9892	162	3	20:1730	20:1730	NUM
aiua-9892	162	4	-	-	SYM
aiua-9892	162	5	9	9	NUM
aiua-9892	162	6	.	.	NOUN
aiua-9892	162	7	7	7	NUM
aiua-9892	162	8	.	.	NUM
aiua-9892	162	9	hung	hung	PROPN
aiua-9892	162	10	sc	sc	PROPN
aiua-9892	162	11	,	,	PUNCT
aiua-9892	162	12	wang	wang	PROPN
aiua-9892	162	13	ss	ss	PROPN
aiua-9892	162	14	,	,	PUNCT
aiua-9892	162	15	li	li	PROPN
aiua-9892	162	16	jr	jr	PROPN
aiua-9892	162	17	,	,	PUNCT
aiua-9892	162	18	et	et	PROPN
aiua-9892	162	19	al	al	PROPN
aiua-9892	162	20	.	.	PROPN
aiua-9892	162	21	outcome	outcome	NOUN
aiua-9892	162	22	of	of	ADP
aiua-9892	162	23	patients	patient	NOUN
aiua-9892	162	24	with	with	ADP
aiua-9892	162	25	metastatic	metastatic	ADJ
aiua-9892	162	26	castration	castration	NOUN
aiua-9892	162	27	-	-	PUNCT
aiua-9892	162	28	resistant	resistant	ADJ
aiua-9892	162	29	prostate	prostate	NOUN
aiua-9892	162	30	cancer	cancer	NOUN
aiua-9892	162	31	after	after	SCONJ
aiua-9892	162	32	psa	psa	NOUN
aiua-9892	162	33	progression	progression	NOUN
aiua-9892	162	34	with	with	ADP
aiua-9892	162	35	abiraterone	abiraterone	NOUN
aiua-9892	162	36	acetate	acetate	NOUN
aiua-9892	162	37	.	.	PUNCT
aiua-9892	163	1	anticancer	anticancer	NOUN
aiua-9892	163	2	res	re	NOUN
aiua-9892	163	3	.	.	PROPN
aiua-9892	163	4	2018	2018	NUM
aiua-9892	163	5	;	;	PUNCT
aiua-9892	163	6	38:5429	38:5429	NUM
aiua-9892	163	7	-	-	SYM
aiua-9892	163	8	36	36	NUM
aiua-9892	163	9	.	.	PUNCT
aiua-9892	164	1	archivio	archivio	NOUN
aiua-9892	164	2	italiano	italiano	X
aiua-9892	164	3	di	di	X
aiua-9892	164	4	urologia	urologia	PROPN
aiua-9892	164	5	e	e	PROPN
aiua-9892	164	6	andrologia	andrologia	NOUN
aiua-9892	164	7	2021	2021	NUM
aiua-9892	164	8	;	;	PUNCT
aiua-9892	164	9	93	93	NUM
aiua-9892	164	10	,	,	PUNCT
aiua-9892	164	11	4	4	NUM
aiua-9892	164	12	r.	r.	NOUN
aiua-9892	164	13	saldanha	saldanha	NOUN
aiua-9892	164	14	jarimba	jarimba	NOUN
aiua-9892	164	15	,	,	PUNCT
aiua-9892	164	16	m.	m.	NOUN
aiua-9892	164	17	nobre	nobre	PROPN
aiua-9892	164	18	eliseu	eliseu	PROPN
aiua-9892	164	19	,	,	PUNCT
aiua-9892	164	20	j.	j.	PROPN
aiua-9892	164	21	pedroso	pedroso	PROPN
aiua-9892	164	22	lima	lima	PROPN
aiua-9892	164	23	,	,	PUNCT
aiua-9892	164	24	et	et	PROPN
aiua-9892	164	25	al	al	PROPN
aiua-9892	164	26	.	.	PROPN
aiua-9892	164	27	398	398	NUM
aiua-9892	164	28	8	8	NUM
aiua-9892	164	29	.	.	PUNCT
aiua-9892	165	1	miyake	miyake	PROPN
aiua-9892	165	2	h	h	PROPN
aiua-9892	165	3	,	,	PUNCT
aiua-9892	165	4	hara	hara	PROPN
aiua-9892	165	5	t	t	PROPN
aiua-9892	165	6	,	,	PUNCT
aiua-9892	165	7	terakawa	terakawa	PROPN
aiua-9892	165	8	t	t	PROPN
aiua-9892	165	9	,	,	PUNCT
aiua-9892	165	10	et	et	PROPN
aiua-9892	165	11	al	al	PROPN
aiua-9892	165	12	.	.	PROPN
aiua-9892	165	13	comparative	comparative	ADJ
aiua-9892	165	14	assessment	assessment	NOUN
aiua-9892	165	15	of	of	ADP
aiua-9892	165	16	clinical	clinical	ADJ
aiua-9892	165	17	outcomes	outcome	NOUN
aiua-9892	165	18	between	between	ADP
aiua-9892	165	19	abiraterone	abiraterone	NOUN
aiua-9892	165	20	acetate	acetate	NOUN
aiua-9892	165	21	and	and	CCONJ
aiua-9892	165	22	enzalutamide	enzalutamide	ADV
aiua-9892	165	23	in	in	ADP
aiua-9892	165	24	patients	patient	NOUN
aiua-9892	165	25	with	with	ADP
aiua-9892	165	26	docetaxel	docetaxel	NOUN
aiua-9892	165	27	-	-	PUNCT
aiua-9892	165	28	naive	naive	ADJ
aiua-9892	165	29	metastatic	metastatic	ADJ
aiua-9892	165	30	castration	castration	NOUN
aiua-9892	165	31	-	-	PUNCT
aiua-9892	165	32	resistant	resistant	ADJ
aiua-9892	165	33	prostate	prostate	NOUN
aiua-9892	165	34	cancer	cancer	NOUN
aiua-9892	165	35	:	:	PUNCT
aiua-9892	165	36	experience	experience	NOUN
aiua-9892	165	37	in	in	ADP
aiua-9892	165	38	real	real	ADJ
aiua-9892	165	39	-	-	PUNCT
aiua-9892	165	40	world	world	NOUN
aiua-9892	165	41	clinical	clinical	ADJ
aiua-9892	165	42	practice	practice	NOUN
aiua-9892	165	43	in	in	ADP
aiua-9892	165	44	japan	japan	PROPN
aiua-9892	165	45	.	.	PUNCT
aiua-9892	166	1	clin	clin	PROPN
aiua-9892	166	2	genitourin	genitourin	PROPN
aiua-9892	166	3	cancer	cancer	NOUN
aiua-9892	166	4	.	.	PUNCT
aiua-9892	167	1	2017	2017	NUM
aiua-9892	167	2	;	;	PUNCT
aiua-9892	167	3	15:313	15:313	NUM
aiua-9892	167	4	-	-	SYM
aiua-9892	167	5	9	9	NUM
aiua-9892	167	6	.	.	NOUN
aiua-9892	167	7	9	9	NUM
aiua-9892	167	8	.	.	PUNCT
aiua-9892	167	9	heo	heo	PROPN
aiua-9892	167	10	mh	mh	PROPN
aiua-9892	167	11	,	,	PUNCT
aiua-9892	167	12	park	park	PROPN
aiua-9892	167	13	sh	sh	PROPN
aiua-9892	167	14	,	,	PUNCT
aiua-9892	167	15	kim	kim	PROPN
aiua-9892	167	16	hk	hk	PROPN
aiua-9892	167	17	,	,	PUNCT
aiua-9892	167	18	et	et	PROPN
aiua-9892	167	19	al	al	PROPN
aiua-9892	167	20	.	.	PUNCT
aiua-9892	168	1	overall	overall	ADJ
aiua-9892	168	2	survival	survival	NOUN
aiua-9892	168	3	beyond	beyond	ADP
aiua-9892	168	4	firstline	firstline	NOUN
aiua-9892	168	5	docetaxel	docetaxel	NOUN
aiua-9892	168	6	in	in	ADP
aiua-9892	168	7	patients	patient	NOUN
aiua-9892	168	8	with	with	ADP
aiua-9892	168	9	metastatic	metastatic	ADJ
aiua-9892	168	10	castrate	castrate	NOUN
aiua-9892	168	11	-	-	PUNCT
aiua-9892	168	12	resistant	resistant	ADJ
aiua-9892	168	13	prostate	prostate	NOUN
aiua-9892	168	14	cancer	cancer	NOUN
aiua-9892	168	15	treated	treat	VERB
aiua-9892	168	16	with	with	ADP
aiua-9892	168	17	abiraterone	abiraterone	NOUN
aiua-9892	168	18	acetate	acetate	NOUN
aiua-9892	168	19	or	or	CCONJ
aiua-9892	168	20	enzalutamide	enzalutamide	NOUN
aiua-9892	168	21	.	.	PUNCT
aiua-9892	169	1	j	j	PROPN
aiua-9892	169	2	clin	clin	PROPN
aiua-9892	169	3	oncol	oncol	PROPN
aiua-9892	169	4	.	.	PUNCT
aiua-9892	170	1	2017	2017	NUM
aiua-9892	170	2	;	;	PUNCT
aiua-9892	170	3	35(6_suppl):e570	35(6_suppl):e570	NUM
aiua-9892	170	4	-	-	SYM
aiua-9892	170	5	e570	e570	PROPN
aiua-9892	170	6	.	.	PROPN
aiua-9892	171	1	10	10	NUM
aiua-9892	171	2	.	.	PUNCT
aiua-9892	171	3	norris	norris	PROPN
aiua-9892	171	4	t	t	PROPN
aiua-9892	171	5	,	,	PUNCT
aiua-9892	171	6	walter	walter	PROPN
aiua-9892	171	7	s	s	PROPN
aiua-9892	171	8	,	,	PUNCT
aiua-9892	171	9	williams	williams	PROPN
aiua-9892	171	10	a	a	PROPN
aiua-9892	171	11	,	,	PUNCT
aiua-9892	171	12	et	et	PROPN
aiua-9892	171	13	al	al	PROPN
aiua-9892	171	14	.	.	PROPN
aiua-9892	171	15	comparison	comparison	NOUN
aiua-9892	171	16	of	of	ADP
aiua-9892	171	17	toxicity	toxicity	NOUN
aiua-9892	171	18	and	and	CCONJ
aiua-9892	171	19	efficacy	efficacy	NOUN
aiua-9892	171	20	outcomes	outcome	NOUN
aiua-9892	171	21	of	of	ADP
aiua-9892	171	22	abiraterone	abiraterone	NOUN
aiua-9892	171	23	and	and	CCONJ
aiua-9892	171	24	enzalutamide	enzalutamide	ADP
aiua-9892	171	25	in	in	ADP
aiua-9892	171	26	198	198	NUM
aiua-9892	171	27	patients	patient	NOUN
aiua-9892	171	28	with	with	ADP
aiua-9892	171	29	metastatic	metastatic	ADJ
aiua-9892	171	30	castrate	castrate	VERB
aiua-9892	171	31	resistant	resistant	ADJ
aiua-9892	171	32	prostate	prostate	NOUN
aiua-9892	171	33	cancer	cancer	NOUN
aiua-9892	171	34	.	.	PUNCT
aiua-9892	172	1	clin	clin	PROPN
aiua-9892	172	2	oncol	oncol	PROPN
aiua-9892	172	3	.	.	PUNCT
aiua-9892	173	1	2017	2017	NUM
aiua-9892	173	2	;	;	PUNCT
aiua-9892	173	3	29	29	NUM
aiua-9892	173	4	:	:	PUNCT
aiua-9892	173	5	e87	e87	NOUN
aiua-9892	173	6	-	-	SYM
aiua-9892	173	7	8	8	NUM
aiua-9892	173	8	.	.	NOUN
aiua-9892	174	1	11	11	NUM
aiua-9892	174	2	.	.	PUNCT
aiua-9892	175	1	garcía	garcía	ADJ
aiua-9892	175	2	as	as	ADP
aiua-9892	175	3	,	,	PUNCT
aiua-9892	175	4	mateos	mateos	NOUN
aiua-9892	175	5	aa	aa	PROPN
aiua-9892	175	6	,	,	PUNCT
aiua-9892	175	7	esquerdo	esquerdo	PROPN
aiua-9892	175	8	ml	ml	PROPN
aiua-9892	175	9	,	,	PUNCT
aiua-9892	175	10	et	et	PROPN
aiua-9892	175	11	al	al	PROPN
aiua-9892	175	12	.	.	PROPN
aiua-9892	175	13	4cps-128	4cps-128	PROPN
aiua-9892	175	14	effectiveness	effectiveness	NOUN
aiua-9892	175	15	of	of	ADP
aiua-9892	175	16	abiraterone	abiraterone	NOUN
aiua-9892	175	17	acetate	acetate	NOUN
aiua-9892	175	18	and	and	CCONJ
aiua-9892	175	19	enzalutamide	enzalutamide	ADV
aiua-9892	175	20	in	in	ADP
aiua-9892	175	21	metastatic	metastatic	ADJ
aiua-9892	175	22	castration	castration	NOUN
aiua-9892	175	23	-	-	PUNCT
aiua-9892	175	24	resistant	resistant	ADJ
aiua-9892	175	25	prostate	prostate	NOUN
aiua-9892	175	26	cancer	cancer	NOUN
aiua-9892	175	27	.	.	PUNCT
aiua-9892	176	1	eur	eur	PROPN
aiua-9892	176	2	j	j	PROPN
aiua-9892	176	3	hosp	hosp	PROPN
aiua-9892	176	4	pharm	pharm	PROPN
aiua-9892	176	5	.	.	PUNCT
aiua-9892	177	1	2018	2018	NUM
aiua-9892	177	2	;	;	PUNCT
aiua-9892	177	3	25(suppl	25(suppl	NUM
aiua-9892	177	4	1):a101	1):a101	NUM
aiua-9892	177	5	-	-	PUNCT
aiua-9892	177	6	a101	a101	PROPN
aiua-9892	177	7	.	.	PUNCT
aiua-9892	178	1	12	12	NUM
aiua-9892	178	2	.	.	PUNCT
aiua-9892	179	1	khalaf	khalaf	PROPN
aiua-9892	179	2	d	d	PROPN
aiua-9892	179	3	,	,	PUNCT
aiua-9892	179	4	zou	zou	PROPN
aiua-9892	179	5	k	k	PROPN
aiua-9892	179	6	,	,	PUNCT
aiua-9892	179	7	struss	struss	PROPN
aiua-9892	179	8	wj	wj	PROPN
aiua-9892	179	9	,	,	PUNCT
aiua-9892	179	10	et	et	PROPN
aiua-9892	179	11	al	al	PROPN
aiua-9892	179	12	.	.	PROPN
aiua-9892	179	13	efficacy	efficacy	NOUN
aiua-9892	179	14	and	and	CCONJ
aiua-9892	179	15	tolerability	tolerability	NOUN
aiua-9892	179	16	of	of	ADP
aiua-9892	179	17	first	first	ADJ
aiua-9892	179	18	-	-	PUNCT
aiua-9892	179	19	line	line	NOUN
aiua-9892	179	20	abiraterone	abiraterone	NOUN
aiua-9892	179	21	+	+	CCONJ
aiua-9892	179	22	prednisone	prednisone	PROPN
aiua-9892	179	23	(	(	PUNCT
aiua-9892	179	24	abi	abi	PROPN
aiua-9892	179	25	)	)	PUNCT
aiua-9892	179	26	versus	versus	ADP
aiua-9892	179	27	enzalutamide	enzalutamide	X
aiua-9892	179	28	(	(	PUNCT
aiua-9892	179	29	enz	enz	PROPN
aiua-9892	179	30	)	)	PUNCT
aiua-9892	179	31	for	for	ADP
aiua-9892	179	32	metastatic	metastatic	ADJ
aiua-9892	179	33	castration	castration	NOUN
aiua-9892	179	34	-	-	PUNCT
aiua-9892	179	35	resistant	resistant	ADJ
aiua-9892	179	36	prostate	prostate	NOUN
aiua-9892	179	37	cancer	cancer	NOUN
aiua-9892	179	38	(	(	PUNCT
aiua-9892	179	39	mcrpc	mcrpc	NOUN
aiua-9892	179	40	)	)	PUNCT
aiua-9892	179	41	in	in	ADP
aiua-9892	179	42	men	man	NOUN
aiua-9892	179	43	≥	≥	VERB
aiua-9892	179	44	80	80	NUM
aiua-9892	179	45	years	year	NOUN
aiua-9892	179	46	:	:	PUNCT
aiua-9892	179	47	a	a	DET
aiua-9892	179	48	retrospective	retrospective	ADJ
aiua-9892	179	49	cohort	cohort	NOUN
aiua-9892	179	50	study	study	NOUN
aiua-9892	179	51	.	.	PUNCT
aiua-9892	180	1	j	j	PROPN
aiua-9892	180	2	clin	clin	PROPN
aiua-9892	180	3	oncol	oncol	PROPN
aiua-9892	180	4	.	.	PUNCT
aiua-9892	181	1	2018	2018	NUM
aiua-9892	181	2	;	;	PUNCT
aiua-9892	181	3	36(15_suppl):5051	36(15_suppl):5051	PROPN
aiua-9892	181	4	-	-	NOUN
aiua-9892	181	5	5051	5051	NUM
aiua-9892	181	6	.	.	PUNCT
aiua-9892	182	1	correspondence	correspondence	NOUN
aiua-9892	182	2	roberto	roberto	VERB
aiua-9892	182	3	saldanha	saldanha	NOUN
aiua-9892	182	4	jarimba	jarimba	PROPN
aiua-9892	182	5	robertojarimba@chuc.min-saude.pt	robertojarimba@chuc.min-saude.pt	NOUN
aiua-9892	182	6	serviço	serviço	NOUN
aiua-9892	182	7	de	de	X
aiua-9892	182	8	urologia	urologia	PROPN
aiua-9892	182	9	,	,	PUNCT
aiua-9892	182	10	centro	centro	PROPN
aiua-9892	182	11	hospitalar	hospitalar	PROPN
aiua-9892	182	12	e	e	PROPN
aiua-9892	182	13	universitário	universitário	PROPN
aiua-9892	182	14	de	de	PROPN
aiua-9892	182	15	coimbra	coimbra	PROPN
aiua-9892	182	16	rua	rua	PROPN
aiua-9892	182	17	professor	professor	PROPN
aiua-9892	182	18	mota	mota	PROPN
aiua-9892	182	19	pinto	pinto	PROPN
aiua-9892	182	20	3004	3004	NUM
aiua-9892	182	21	-	-	SYM
aiua-9892	182	22	561	561	NUM
aiua-9892	182	23	,	,	PUNCT
aiua-9892	182	24	coimbra	coimbra	PROPN
aiua-9892	182	25	(	(	PUNCT
aiua-9892	182	26	portugal	portugal	PROPN
aiua-9892	182	27	)	)	PUNCT
aiua-9892	182	28	miguel	miguel	PROPN
aiua-9892	182	29	nobre	nobre	PROPN
aiua-9892	182	30	eliseu	eliseu	PROPN
aiua-9892	182	31	,	,	PUNCT
aiua-9892	182	32	md	md	PROPN
aiua-9892	182	33	joão	joão	PROPN
aiua-9892	182	34	pedroso	pedroso	PROPN
aiua-9892	182	35	lima	lima	PROPN
aiua-9892	182	36	,	,	PUNCT
aiua-9892	182	37	md	md	PROPN
aiua-9892	182	38	vasco	vasco	PROPN
aiua-9892	182	39	quaresma	quaresma	PROPN
aiua-9892	182	40	,	,	PUNCT
aiua-9892	182	41	md	md	PROPN
aiua-9892	182	42	pedro	pedro	PROPN
aiua-9892	182	43	moreira	moreira	PROPN
aiua-9892	182	44	,	,	PUNCT
aiua-9892	182	45	md	md	PROPN
aiua-9892	182	46	urology	urology	NOUN
aiua-9892	182	47	and	and	CCONJ
aiua-9892	182	48	renal	renal	ADJ
aiua-9892	182	49	transplantation	transplantation	NOUN
aiua-9892	182	50	department	department	NOUN
aiua-9892	182	51	,	,	PUNCT
aiua-9892	182	52	centro	centro	PROPN
aiua-9892	182	53	hospitalar	hospitalar	PROPN
aiua-9892	182	54	e	e	PROPN
aiua-9892	182	55	universitário	universitário	PROPN
aiua-9892	182	56	de	de	X
aiua-9892	182	57	coimbra	coimbra	PROPN
aiua-9892	182	58	,	,	PUNCT
aiua-9892	182	59	coimbra	coimbra	PROPN
aiua-9892	182	60	(	(	PUNCT
aiua-9892	182	61	portugal	portugal	PROPN
aiua-9892	182	62	)	)	PUNCT
aiua-9892	182	63	pedro	pedro	PROPN
aiua-9892	182	64	coelho	coelho	PROPN
aiua-9892	182	65	nunes	nunes	PROPN
aiua-9892	182	66	,	,	PUNCT
aiua-9892	182	67	md	md	PROPN
aiua-9892	182	68	edgar	edgar	PROPN
aiua-9892	182	69	tavares	tavares	PROPN
aiua-9892	182	70	da	da	PROPN
aiua-9892	182	71	silva	silva	PROPN
aiua-9892	182	72	,	,	PUNCT
aiua-9892	182	73	md	md	PROPN
aiua-9892	182	74	arnaldo	arnaldo	PROPN
aiua-9892	182	75	josé	josé	PROPN
aiua-9892	182	76	figueiredo	figueiredo	PROPN
aiua-9892	182	77	,	,	PUNCT
aiua-9892	182	78	md	md	PROPN
aiua-9892	182	79	urology	urology	NOUN
aiua-9892	182	80	and	and	CCONJ
aiua-9892	182	81	renal	renal	ADJ
aiua-9892	182	82	transplantation	transplantation	NOUN
aiua-9892	182	83	department	department	NOUN
aiua-9892	182	84	,	,	PUNCT
aiua-9892	182	85	centro	centro	PROPN
aiua-9892	182	86	hospitalar	hospitalar	PROPN
aiua-9892	182	87	e	e	PROPN
aiua-9892	182	88	universitário	universitário	PROPN
aiua-9892	182	89	de	de	PROPN
aiua-9892	182	90	coimbra	coimbra	PROPN
aiua-9892	182	91	&	&	CCONJ
aiua-9892	182	92	faculty	faculty	NOUN
aiua-9892	182	93	of	of	ADP
aiua-9892	182	94	medicine	medicine	NOUN
aiua-9892	182	95	,	,	PUNCT
aiua-9892	182	96	university	university	NOUN
aiua-9892	182	97	of	of	ADP
aiua-9892	182	98	coimbra	coimbra	PROPN
aiua-9892	182	99	,	,	PUNCT
aiua-9892	182	100	coimbra	coimbra	PROPN
aiua-9892	182	101	(	(	PUNCT
aiua-9892	182	102	portugal	portugal	PROPN
aiua-9892	182	103	)	)	PUNCT